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THE WAR ON DRUGS V. THE WAR ON PAIN:
DO CONTROLLED PRESCRIBING LAWS
HAVE A ROLE?

Susanne F. Homant, D.P A .
Western Michigan University, 2006

The illegal use of prescription drugs and the under-treatment of chronic pain
are both considered serious public health issues in this country. Strong medicines
classified as controlled substances by the DEA are often used to treat chronic pain
conditions and are also known to be diverted to non-medical uses, thus a solution to
one problem may happen at the expense o f the other. Prescription Monitoring
Programs (PMPs) are public policies that are felt by many to address diversion of
controlled substances, and are generally welcomed by law enforcement as an
excellent tool in the war against drugs. A number of pain management advocates,
however, claim that the oversight included in PMPs discourages the prescribing of
controlled substances by physicians and thus reduces the quality of pain management.
This study reviewed the effect of PMPs on drug diversion—as a subcategory
of drug abuse—using a multiple regression analysis. Fifteen states were included in
the regression statistics, seven of which had PMPs in place and eight states that
operate without a PMP. The regression did not show a relationship between a change
in the amount o f drug diversion and the presence of a PMP.
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The research also included a case study consisting of 30 in-depth interviews of
physicians, pharmacists, and law enforcement officers, 15 in Michigan and 15 in
Florida. The interviews provided professional opinions on what affects pain
management and drug diversion, and the impact of PMPs on both issues. The case
study generally supported the conclusion o f the regression in relation to the effect o f a
PMP on drug diversion. It also provided additional insights into the best means of
addressing a reduction in drug diversion and improvements in pain management.
Education of clinicians and the general public was deemed critical by nearly every
interview subject, as was attention to better and more accessible treatment for
addictions. Physicians and pharmacists indicated they would welcome a prescription
database as a patient-care tool if it were not accessible to law enforcement. All
subjects seemed resigned to the presence o f drug abuse in our society, regardless of
the nature of public policy.
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CHAPTER I
INTRODUCTION
Overview
The national concern over abuse o f drugs and the consequences to individuals
and to society as a whole have long been a public issue and a public health issue. The
potential consequences o f drug abuse range from a person’s inability to function
normally with subsequent effects on personal, work, and family relationships, to
criminal activity that may include harm to others and self. People who continuously
abuse potent drugs, legal or illegal, will almost surely meet an early death, either from
drug-related medical problems or suicide. Illegal use of drugs takes many forms, one
of which is the diversion of legal prescription drugs to recreational use or use that is
otherwise significantly against medical advice or the intended prescribed purpose of
the medication. This research addresses public policy intended to help reduce illegal
drug use, and it focuses on the diversion of drugs that are classified as legal drugs in
the controlled substances schedules of the federal Controlled Substances Act. These
schedules include highly potent medications such as opioids and benzodiazepines.
The treatment of chronic pain conditions nearly always includes the
prescribing of drugs within the controlled substances schedules. Like drug abuse,
chronic pain is also considered by many to be a significant public health issue, with the
under-treatment of pain a factor in significant individual dysfunction. This includes
1
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consequences to the individual and family health, as well as drug-seeking behavior for
many if the condition is not managed. Drug-seeking behavior can include pursuit of
illegal drugs as well as prescription drugs and excessive use of over-the-counter drugs
such as alcohol. From the perspective of the diversion of controlled substances which
is the subject of this research, a logical tension exists between controlling diversion
and assuring access to the right pain medications. For decades, such concerns have
resulted in the implementation of public policies that hope to address the diversion of
legal drugs, while maintaining access to treatment for chronic pain conditions. One
such type of policy and the focus of this study is a prescription monitoring program,
or PMP. Those seeking more diversion control have encouraged the implementation
of PMPs on a national basis. According to the Alliance of States with Prescription
Monitoring Programs’ goals statement, PMPs are a very important tool in containing
diversion.
Diversion of controlled substances and other pharmaceuticals is generally
recognized as a serious problem throughout the United States. . . . States have
found that prescription monitoring programs are among the most effective
tools available to identify and prevent drug diversion at the prescriber,
pharmacy and patient levels. (Alliance of States with Prescription Monitoring
Programs, n.d.)
Those concerned over access to good pain management often feel such
policies create treatment barriers for physicians. Sandra Johnson. J.D., LL.M. of the
Saint Louis University School of Law and an active researcher on this topic stated:
In pain management, both real and perceived obstacles can have a powerful
negative effect. If physicians and health care institutions believe, even
wrongly, that they cannot do what needs to be done for their patients—for
example because the providers believe that they will be at risk for discipline or
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prosecution or because payment will be denied—it seriously decreases the
likelihood that patients will receive the care they need. (Johnson, 2003, p. 15)
Because a tension exists between the desire to control diversion while
allowing full medical access to drugs that are often diverted, this study was developed
to look at whether PMPs are an effective tool in the goal of decreasing diversion
while not limiting the quality of pain management. Such policies are now in place in
22 states with a national movement to encourage more states to enact such policies.
This research compares regulatory policies, specifically controlled substance
prescribing laws or PMPs in 15 selected states to determine the effect those laws, or
the absence of such laws, have on decreasing diversion. During the time frame of this
study, 7 of the states in the study operated under state-authorized controlled
substance prescribing restrictions, and 8 states did not. In addition to a quantitative
analysis using the 15-state sample, this research also includes a qualitative study. That
case study looks at the effect that laws such as PMPs may have on good pain
management practices in two selected states: Michigan (which had controlled
prescribing laws during the time period of the study) and Florida (which did not have
such laws during the study period). The qualitative research was developed to
determine if a balance between diversion control and pain management is possible, or
if the success o f one effort may only come at the expense of the other.
No specific study of the effectiveness of PMPs in states operating under
different controlled prescribing laws was found in an extensive literature search
incorporating journal articles and research reports, websites, books, and a variety of
media and other research resources over the past three years. Examples include Drug
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Enforcement Administration (DEA) reports and website, SAMHSA publications,
OIG reports, the Journal o f Law, Medicine, and Ethics, several pain and other
medical journals, the Hospice News Network, University of Wisconsin Pain Policy
website and reports, the National Association o f State Controlled Substance
Authorities, Google and other public search engines, the American Association of
Cancer Pain Initiatives, the National Institutes o f Health, and medlineplus, among
others.
Based on this search, it was thus assumed that no such study exists. However,
the results of such a study are likely to have significant impact on the identification of
effective means of controlling diversion while assuring that patient care is not
compromised in the process. Controlled prescribing laws may indeed be the best way
to manage diversion of controlled drugs. However, if such laws are not the answer
but are adopted by states, the perceived effectiveness of such laws has the potential to
create a barrier to the identification of other, better solutions to the reduction of
diversion activity while assuring the availability of drugs for medically recognized
purposes. Stated differently, government and the public may want to so strongly
believe that controlled prescribing laws are effective, that they may decrease efforts to
find a better means of addressing the drug diversion problem.
The following three stories illustrate some of the real and ongoing issues that
affect the public in relation to control of illegal use of legal drugs and the management
of chronic and terminal pain conditions. They are presented as real-life examples of
the dilemma that exists as government attempts to address the many problems
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surrounding the illegal use of legal drugs, and a desire to remove barriers to
appropriate pain management for those who suffer from chronic, terminal or other
pain conditions.
Mattie Howard, a 54-year-old high school teacher, was diagnosed with
breast cancer. After surgery, she remained in remission fo r a year and a h a lf
before the cancer reappeared in bone metastases. The disease and medical
treatments caused a great deal o f pain, nausea, and fatigue. Her doctor
prescribed pain medications, but they did little to help her pain and nothing
fo r her other symptoms. Fearful o f being accused o f over prescribing
narcotics, he refused to provide more medications. Finding her situation
unbearable, Ms. Howard began to beg her daughter fo r help in taking her
own life. (Merritt et al., 1998, p. 9)

In remission from Ewings Sarcoma cancer, Solom on’s 6-year-old son Nathan
startedfeeling pain in his legs and tailbone in the spring o f 2001. Doctors
took an X-ray o f N athan’s lower body and pronounced him fine. The pain
worsened.
In April, mother and son, who live in the Southern California city o f
Fontana, returned to the doctor, who had ju st received the results o f
N athan’s yearly blood tests. They boy had been throwing up all night. The
doctor walked into the sterile office where Solomon and Nathan were waiting.
“He said, ‘Well, the cancer is back, and it doesn't look good, ’ then he
walked out, ”M artha Solomon recalled. “It was ju st like, ‘B oom. ’”
The cancer had spread all over N athan’s body. He died three weeks
later.
“We were robbed o f precious time because (the doctors) didn 7 take
(Nathan’s pain) seriously, ” Solomon said, believing her son might have lived
a few months longer i f the doctors had caught the cancer recurrence earlier.
But it gets worse. The night o f N athan’s death. . . Nathan was in extreme
pain.
“M y son, he was just—his teeth were ju st clenched together and there
was nothing I could do, ” his mother said crying softly at the memory. “I had
no more medicine to give him. And he was like, M ore pain medicine,
please.' He was ju st so dang polite. ”
The nurse would not administer more pain medicine because doctors
said it would slow N athan’s breathing.
“The look on his face when he died, he looked like he was in agony—
absolute, complete agony—and that is something I can never forget, ’’
Solomon said. “I could live with m yself so much easier i f he had died
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(without pain). It is gut-wrenching to have to im agine. . . I t ’s been ayearand-a-half, and i t ’s like it ju st happened. ” (Harlick, 2002, p. 2)
* * * * * *

In a steel-mill suburb northwest o f Pittsburgh, the leader o f the second wave
o f OxyContin apostles was Curt, a young man, who in 1998 a t the age o f 23,
fou nd him self kicked out o f the A ir Force and living back in his hometown.
He worked the midnight shift running cranes at the mill, and he dealt a little
marijuana during the day. He was p art o f a “drug community ” as he calls it,
20 or so people who worked together, hung out together, went to parties and
concerts and smoked a lot o f pot. Every couple o f months someone would
land a prescription fo r Percocet or Vicodin, and they’d sell the p ills to
friends fo r $5 apiece, a cheap and m ild high.
In April 1999, someone in his circle was prescribed OxyContin. Curt
assumed that it was ju st like any other pain pill. “Everyone thought a t first
that they were like a Percocet, ” Curt says. “Nobody understood how many
milligrams were really in these things. People were selling them like an
expensive Percocet”—fo r $10, in other words, instead o f $5—and swallowing
them whole. A t a party, Curtfigured out the trick o f crushing the p ill and
snorting the powder, and he quickly spread the word. “I showed a lot o f
people, ” Curt says. “A tfirst they were like, ‘You ’re crazy. ’B ut then they ’d
do it, and that would be it. People tell me now, ‘Yeah you ’re the one who
showed me how to snort this thing. ’”
. . . Oxys quickly became very popular in Curt's circle o f friends, and
Curtfound a comfortable niche fo r him self between supply and demand
. .. Before long he had 10 people giving him their p ills to sell, mostly
women in their 3 0 ’s and 40 ’s on welfare or disability. (Patients on M edicaid
pay ju st a dollar fo r a $250 OxyContin prescription.)
. . . One o f the most valuable—and closely guarded—resources in the
local OxyContin economy was a doctor who was willing to write an
OxyContin prescription without asking too many questions. “I t ’s a slow
process, breaking a doctor in, ” Curt explains. “You’ve got to know how to
work him. I ’d say, ‘I ca n ’t take the Vicodins and the Percocets because
they ’re hurting my stomach. Do you have anything that’s, like, time
released? ’ The doctor goes, ‘Oh, you know what, they've got this new stu ff
called OxyContin. ’A nd I ’d say, ‘Oh, yeah? Wow, how’s that work? ’” Some
local doctors, Curt says, knew exactly what was going on, but they needed the
business. One started handing out month-long OxyContin prescriptions every
two weeks. (Tough, 2001, pp. 33-37, 52, 62-63)
These are three o f many such stories which help to illustrate how the public is
significantly affected by policy and law enforcement decisions that aim to strike a
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balance between pain management and the control of legal drugs diverted for illegal
use. Drugs that are appropriate and most effective for the treatment of severe pain are
also addictive for some. Furthermore, they are sometimes used for recreational drug
purposes, an activity which has a significant effect on individual lives and
communities. In a comprehensive study on state pain policies, Jorenson and
colleagues o f the University of Wisconsin Pain and Policy Studies Group found that
identifying the right balance between diversion control and the ability of medical
professionals to treat severe pain conditions remains a dilemma throughout the
country (Jorenson, Gilson, Ryan, et al., 2003).
Statement of the Problem
The management of pain, and indeed the under-treatment of pain, is a major
public health problem in the United States, as is drug diversion. Researchers at the
Center for Work and Health at AdvancePCS in Hunt Valley, Maryland concluded that
pain is the most widespread health condition affecting the U.S workforce, and most
costly in terms of productive work time. (Stewart, Ricci, Chee, Morganstein, &
Lipton, 2003.) Dr. Kathleen Foley (Eisner, 2000, p. 1), a nationally recognized
neurologist at the Memorial Sloan-Kettering Cancer Center in New York, stated,
“Every bit of data we have says that pain is under-assessed and undertreated [sic].”
Others, like Foley, who advocate for better pain control, universally agree that pain
management in this country is in need of a fix. At the same time there is agreement
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that sufficient medical knowledge exists to relieve pain in the vast majority o f patients,
through drug therapies and other treatments.
As the movement to improve pain management continues its journey, an
equally strong movement exists to address the dangers of abuse o f drugs, both
prescription drugs and illegal drugs, and the cost that brings to society. Drugs such as
oxycodone and other controlled substances produce a powerful high, a euphoric
effect that can and does lead to abuse and addiction when used inappropriately.
Regulators such as the DEA and state drug enforcement officials recognize the
potential for diversion of drugs for recreational purposes, and in fact have watched
the use of such drugs for non-pain purposes grow at what some refer to as an
alarming rate in this country. Such abuse causes immense suffering—loss of
productive lives, broken families, poverty, and criminal behavior. This occurs when
drugs are diverted from their intended use, or when prescriptions are illegally
obtained, forged, or written for non-medical purposes by those with prescribing
authority—generally physicians. The age group most affected is young people—from
preteen to age 30. A highly visible example occurred in 2002, when Noell Bush,
daughter of Florida’s Governor Jeb Bush, was arrested and convicted of forging a
prescription for Xanax, an anti-anxiety drug from Controlled Substance Schedule IV.
In addition, radio personality Rush Limbaugh has made national news for his
addiction to controlled substances, including oxycodone—an opioid in Schedule II.
The existence and easy availability of strong pain-relieving medicines has thus
become a blessing and a curse, with several states responding with the enactment of
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laws that closely monitor certain prescription drugs, beyond the monitoring required
by the federal government. These programs, often referred to as PMPs (Prescription
Monitoring Programs) are touted by their supporters as an effective means of
addressing diversion of controlled substances, and as a useful tool for prosecuting
criminals who engage in such illegal activities. Pain management advocates, on the
other hand, claim that such programs are costly, do not result in a significant
reduction of diversion activity, and harm the public by exerting a negative or
“chilling” influence on the proper prescribing of effective pain medications. This
creates physician fears of overly aggressive oversight and investigation, which can
lead them to under-prescribe pain medicines or substitute a less potent drug. Such
activity, they claim, perpetuates the mismanagement of pain and makes it difficult for
citizens in those states to receive proper treatment.
Significance of the Problem

Prescription monitoring programs are a response to the public pressure on
government to address the problem of drug abuse in this country. Within the law
enforcement community, many feel that such programs are extremely effective in
deterring diversion activity as well as illegal drug trafficking, and that they provide a
valuable tool for the investigation of such activity when it is suspected. Advocates of
pain management claim that such programs are not significantly effective in
addressing diversion, that diversion is not the primary cause of drug abuse, and that
such laws produce the mentioned chilling effect on the proper prescribing of pain
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medications which leads to significant under-treatment of pain. Since pain is the
primary reason that most people seek medical help, any activity that is suspected of
generating barriers to pain relief is a major concern to the medical community. People
in severe pain are incapable o f leading normal lives, with the pain taking over every
activity and the search for relief becoming the primary focus. The negative effects on
quality of life and productivity as a member o f one’s community are readily apparent.
Both drug diversion and inadequate pain management reputedly cost billions
of dollars annually. The costs of drug diversion include not only the regulatory and
investigative activities which address diversion, but also the funds which are spent to
purchase legal drugs for illegal use. There is also a tremendous cost to society of the
dysfunctional and often dangerous activity that occurs with the illegal use of drugs.
Similarly, inadequate pain management causes approximately $85-$90 billion in lost
productivity in the U.S. Billions of dollars are used to purchase medications and
therapies to address the pain, and about 50 million people are partially to totally
disabled due to chronic pain—another great cost to society (EPIC MRA, 1997). Pain
is the single most common reason for seeking treatment in hospital emergency
departments, and patients whose pain is not resolved are frequent utilizers of
emergency department services. (Todd, 2006) The problems are significant in terms
of dollars and the people affected, and they are far-reaching, touching lives
everywhere.
Thus, when studying policies such as PMPs, it is important to determine the
effect on diversion and on access to medical help for pain relief. For public health
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reasons, it is necessary to work towards finding the right solution to both problems. If
public policy is created without some certainty that the policy will be successful in
addressing the problem, there are two tremendous risks. One is that the policy will
require administrative resources and tax dollars that will be wasted. The other, more
significant risk is that ineffective policy will likely convince citizens that a problem has
been solved, and government will thus cease to work on the real causes of drug
abuse.
Research and commentary has been conducted by groups on both sides o f the
drug diversion/pain management debate. As a general statement, those in favor of a
strong state regulatory approach to reducing drug diversion concentrate their studies
and reports on how laws and regulations lead to identification, arrests, and successful
prosecution of those who divert drugs to illegal use. Those in favor of allowing the
system to be freer of regulatory restrictions on prescribing generally study and present
results that showcase the extent of under-treated or untreated pain, and how these
undesirable results may be caused by prescribing laws. This group often contends that
PMPs are not satisfying their diversion control intent and instead may create a
significant barrier to good pain management.
Current research does not take a look at the state of drug diversion activity in
a group o f states operating with and without PMPs, so this study will take a more
comprehensive and comparison approach to the diversion issue. As Fishman,
Papazian, et al. (2004) stated, “Very few PMPs have been adequately evaluated to
determine their impact on the availability of controlled substances for legitimate
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medical purposes or the subsequent incidence of drug abuse and diversion” (p. 316.)
Recommendations as a result of this research may help to guide the development and
refinement of future related public policy.
Background
The federal law at the foundation of drug oversight is the Controlled
Substances Act of 1970 (CSA), which established schedules of drugs ranked from
Schedule I (illegal drugs) to Schedule V, classified based on the drugs’ addictive,
abusive, and dependence properties. The CSA gives the DEA Office of Drug Control
the authority to regulate the sale and distribution o f these controlled substances at the
manufacture and wholesale levels. The Government Accountability Office (GAO)
summarizes the controlled substances as follows.
Schedule I drugs—including heroin, marijuana, and hallucinogens such as
LSD and PCP—have a high potential for abuse and no currently accepted
medical use. Schedule II drugs—including methylphenidate (Ritalin) and
opiates such as hydrocodone, morphine, and oxycodone—have a high
potential for abuse and may lead to severe physical dependence, but have a
currently accepted medical use. Drugs on Schedules III through V have
medical uses and successively lower potentials for abuse and dependence.
Schedule III drugs include anabolic steroids, codeine hydrocodone in
combination with aspirin or acetaminophen, and some barbiturates. Schedule
IV contains such drugs as the anti-anxiety medications diazepam (Valium) and
alprazolam (Xanax). Schedule V includes preparations such as cough syrups
with codeine. All drugs but those in Schedule I are legally available to the
public with a prescription. (U.S. General Accounting Office [USGAO], 2002,
p. 5.) [Editor’s note: OxyContin is a sustained-release, manufactured form of
oxycodone.]
The CSA also regulates the distribution of controlled substances. All
physicians who prescribe controlled substances are required to register with the DEA
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and have a registration number assigned. All pharmacies are also required to register
and maintain accurate records of controlled substances that are handled by them, and
to secure the storage of controlled substances.
In addition to the federal legal controls on the manufacture and wholesaling of
controlled substances and as already noted, 16 states had enacted prescription drug
monitoring programs during the time period of this study, with the objective of
addressing the issue of diversion through regulation of the practice of medicine and
pharmacy. The various state PMPs differ in scope, design, and objectives, and are
generally put in place to help state officials (and the DEA) identify diversion activities.
During the time period of the study, there were 34 states that operated without drug
monitoring programs. No study has been done to compare the diversion activity
between states with PMPs to states without PMPs with the specific objective of
determining if PMPs are effective in decreasing diversion. Conclusions such as those
reported in a May 2002 GAO study indicate that states with PMPs experience a
reduction in time in investigating possible drug diversion cases, but do not boldly
state that such programs are the reason for any decreases in drug diversion (USGAO,
2002, p. 15.) In fact, the study suggests that PMPs may just drive drug diversion
across state borders. Or, such laws may move the diversion activity to another
classification of drugs, such as from Schedule II drugs like OxyContin, to Schedule
III drugs like Vicodin and Lortab, which are not monitored in many states.
Drug abuse statistics are gathered by several sources, one of which is the
Drug Abuse Warning Network (DAWN) which monitors the incidence of drug abuse
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through reports of such abuse in emergency department visits. DAWN is operated
under the Office of Applied Studies, Substance Abuse and Mental Health Services
Administration (SAMHSA). The October 2002 issue of the DAWN Report (last year
of this research) stated that the most frequently reported drug of abuse was cocaine,
followed by marijuana and heroin (Ball & Kissin, 2002, p. 3). Methamphetamine, a
Schedule II stimulant, was a very distant fourth. Prescription opioids such as
OxyContin did not make the list of the top four. The 2003 DAWN Report produced
similar results. According to the statistics gathered by DAWN, the critical drug abuse
problem is one of use of illegal drugs, not of diversion of legally available and legally
prescribed drugs.
The seven states in this study that have operating PMPs had additional
information on the results of their monitoring programs, with the depth of such
resources varying from state to state. Most of the seven selected states have had
PMPs in place for several years, California as early as 1940. However, all states in the
study have made changes in the 1990s in their prescription monitoring programs,
generally towards creating electronic tracking systems.
Ultimately, any PMP should also be considered in the context o f its
effectiveness against drug abuse in a comprehensive sense, not as patchwork for a
piece of the problem. This argument is often raised by pain management advocates
who claim that PMPs can cloud the real issue of drug abuse while creating barriers to
pain management.
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Since this research also includes a qualitative research section comparing drug
diversion and pain management in two states, one without a PMP (Florida) and the
other with a PMP (Michigan), background on these two states is provided here.
Michigan, pressured by its citizens when the war on drugs was at its peak in
the 1980s, enacted its Official Prescription Program (OPP) in 1989, with strong
leadership and sponsorship in both the Michigan House and Senate. The original OPP
tracked Schedule II drugs, requiring all physicians who prescribed such drugs to
obtain a special prescription pad, and to write all such prescriptions in triplicate. It
thus created an extra administrative burden for both physicians and pharmacists. The
OPP changed to a single prescription form in 1993 due to a wave of complaints from
physicians, and eliminated methylphenidate (Ritalin) from the reporting requirements.
Many physicians were not receptive to the extra reporting and expressed their
concerns by refusing to register for and obtain the special pads, thus eliminating their
ability to prescribe opioids for pain. This raised concerns and created problems for
those in need of strong pain medication to such an extent that the Governor appointed
two groups to study the issues. It is important to note that Michigan’s PMP cost the
state approximately $750,000 annually to maintain, and was never a primary factor in
any convictions for diversion.
As a result of the recommendations of one of the groups, the Michigan
Commission on End o f Life Care (Thomason, 2001), the OPP was eliminated and
replaced with an electronic monitoring system or PMP in 2003. The new program
was welcomed by the medical community. At the same time it was recognized that
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much physician education would be necessary to equip the many physicians who
originally elected out of the OPP with the expertise to once again use Schedule II
drugs and become effective in developing good pain management care plans for their
patients.
Florida does not currently have a PMP, but has been reviewing the need for
such a program for at least the past two years. In 2002, Senator Burt Locke, then a
candidate for Florida’s Attorney General, introduced a bill designed to reduce the
diversion of legal drugs, but that bill failed to pass during the 2002 session. Early
promotion of a pending bill for 2003 occurred at a Statewide Summit on Prescription
Drug Abuse in Tallahassee, Florida, January 22, 2003. The Summit was hosted by
Governor Jeb Bush and his wife Columba, and included Senate sponsor Mike Fasano,
House sponsor Gayle Harrell, Attorney General Charlie Crist, Office of Drug Control
Director Jim McDonough, Commissioner Moore of the Florida Department of Law
Enforcement and Secretary o f Health John Agwunobi, among others. A bill was
subsequently introduced, but died on the calendar. In 2004, House and Senate bills
nearly identical to the 2003 bill were introduced, but again the proposed law did not
pass. Senator Burt Saunders has introduced a similar bill to be considered by the 2006
legislature.
The Research Questions
The goal of this research was to determine, through comparison of the
presence or absence of prescription monitoring policies in 15 states, whether PMPs
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are likely to reduce diversion o f Scheduled drugs. If drug diversion is lower in states
with PMPs, is the reduction a result of the regulatory climate, specifically laws such
as PMPs, or might other factors influence the level of diversion? If PMPs are effective
in reducing diversion, does the amount of reduction justify the cost of the programs in
dollars? In addition, this research attempted to determine if there is a difference in the
effective treatment o f pain between Michigan, with its PMP, and Florida, which
currently does not have a PMP. This part o f the research is important because it
addresses one perceived “human” cost of PMPs—the tendency of such laws to raise
concerns within the medical community about potential DEA investigations and thus
serve to discourage the prescribing of strong pain medications. This hesitancy to
prescribe those drugs classified as controlled substances has been called the “chilling
effect” of PMPs in many studies and commentaries about such laws. Is it an
acceptable compromise to have less effective pain management, if such a result
produces a reduction in illegal use of legal drugs? The study of the effect that PMPs
have on addressing drug diversion in the 15 states and of the responses from medical
professionals in the two states in the qualitative portion of the research produced
recommendations that will assist other states in determining whether to adopt a PMP,
or to modify or eliminate an existing PMP and seek other means of addressing the
drug abuse and diversion problem in their states.
This research thus addresses the following questions:
1.

Do state controlled substance laws (PMPs) help to contain drug diversion

activities of Scheduled drugs, particularly Schedule II drugs? In particular, did the

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

18
existence o f such laws in seven states significantly reduce such diversion as compared
to eight other states, which do not have such laws in place?
2.

Do PMPs and the regulatory climate limit access to good pain

management? Is access to pain management greater in Florida than Michigan? Did
Michigan’s PMP pose a significant barrier to adequate pain management?
In the report that follows, Chapter II contains the literature review that was
conducted for the study. Seminal studies on drug abuse, drug diversion, prescription
monitoring programs and related pain management issues are presented in that
section. Chapter III describes the methodology used to conduct the research. A
description of the quantitative study and the search for variables is included in this
chapter. A description of the qualitative methodology is also included. Chapter IV
contains details on the development of the multiple regression used to determine if
there is a statistically significant difference in drug diversion between states with and
without PMPs. The results of the multiple regression are presented in Chapter IV.
Chapter V reports the results of the case study between Michigan and Florida.
The concluding pages of that chapter contain two summary tables of key findings.
Chapter VI contains the conclusions and recommendations of the research. There are
seven conclusions, four recommendations, and three suggestions for further research.
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CHAPTER II
LITERATURE REVIEW
This chapter discusses a number of studies, reports, and other documents
related to the three primary subject areas of this dissertation. Analysis and
commentary are grouped into the categories of pain management, Prescription
Monitoring Programs, and drug diversion. The background provided by the literature
review helps to identify the primary issues under consideration in this study, along
with problems and concerns with the current state of analysis of the effectiveness of
PMPs in the control and prevention of drug diversion.
The literature on all three of the subject areas is extensive, which supports the
statement that pain management, drug diversion, and the larger arena of drug abuse
are important topics to the medical and policy-making communities, as well as of high
interest to the general public. In the review of studies and commentaries in the areas
that follow, it is noteworthy that individual stories of problems and concerns were far
more prevalent than actual, statistically significant studies of the referenced issues. It
is not uncommon to find articles that reach conclusions, even in highly respected
journals, that use a few isolated incidences in the analysis, without alluding to the
need for further study. One of the difficulties is the inability to quantify drug diversion
as an activity separate from drug abuse.

19
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Pain Management
The National Institutes of Health report that pain is the most common reason
for medical appointments in the United States. Visits to medical professionals for the
treatment of pain exceed 40 million annually (Partners Against Pain, 2003, p. 3).
Other sources state that pain is the second most common issue brought to the
physician’s office (Dean, 2004, p. 1). Regardless of pain’s number one or number two
position, the treatment of pain and the provision of quality pain management clearly
deserve serious attention. Pain is well studied and researched, with one report
indicating that over 105,000 articles had been categorized with the keyword “pain” in
the years 1990-1999, an increase of 175% over the previous decade, and 350% more
than the decade before that (Fishman, Gallagher, et al., 2004, p. 282).
Pain and its intensity is very individual, with subjective differences in the
severity of pain generally related to each person’s tolerance plus other physical and
psychosocial issues affecting their well being. According to the Oxford Dictionary,
pain is “an unpleasant feeling caused by injury or disease of the body.” Webster’s adds
that pain is caused by the stimulation of nerves. McCaffrey, in his pain manual stated
that pain is subjective; it is “whatever the experiencing person says it is, existing
whenever he/she says it does” (McCaffrey & Pasero, 1999, p. 4; Maroney, Litke,
Fischberg, Moore, & Morrison, 2004, p. 448). Pain is generally described as either
“acute,” lasting for a relatively short period of time, and relieved when the underlying
pathology is resolved or chronic, extending for a longer period, generally worsening
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with time, more difficult to diagnose and treat, and having a more lasting effect on a
patient’s life.
Regardless, for those people who live with a pain condition on a daily basis,
especially one that is severe, it is more than an unpleasant feeling. Instead it is
something urgently in need of hopefully permanent relief, and of quick and accessible
relief. For the millions o f people who suffer from a severe or persistent pain problem,
good pain management is essential for well being and a decent quality o f life. Because
this issue has been with us since life began and is likely the oldest medical problem,
the treatment and management of pain has a lengthy history.
Early physicians did their best to relieve pain, making use of opium and opium
mixtures such as laudanum, which combined opium with sherry. But pain was not
viewed as “bad” for everyone, and for a time was viewed as a sign o f life force. At
one time there was debate over whether pain relief might slow the healing process
(Meldrum, 2003, p. 2470). Medical discussions and approaches to pain evolved in
three general areas: relief of acute pain; palliation of severe pain for those patients in a
terminal condition; and treatment of chronic, intractable pain, all of which
incorporated the use of strong medicines in the plan of treatment. In the United
States, the ability to deliver morphine to soldiers who were injured or suffering was
considered a very desirable option, and dates back at least to the Civil War. Opiates
became the standard of treatment for pain, with production of morphine beginning in
Europe and spreading to the U.S. in the 19th and 20th centuries. In 1898, The Bayer
Company of Germany began to market a derivative of morphine under the trade name
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o f Heroin as a cough medicine (Meldrum, 2003, p. 2471). At one time, morphine,
heroin, and other such pain medicines could be obtained over the counter and even
ordered from the Sears, Roebuck Catalog (Henningfield, 2004, p. 4). However, by
the early 1900s, the potential for addiction to such medications began to frighten the
public as well as concern the medical community, and physicians often withheld
treatment because o f fears o f addiction. The U.S. Government started to pass laws to
control the availability of such medicines in the early 1900s, culminating nationally
with the passage of the Controlled Substances Act in 1970. This Act placed strong
drugs in one of five categories or schedules, depending on their potency and risk of
producing psychological or physical dependence.
Medical schools originally taught the “specificity theory,” that true pain was a
result of a direct response to a specific stimulant. It took a while for psychological
factors to be considered as part of the pain condition. Patients suffering with
unexplained pain, or pain that could not be resolved were often considered as
“malingerers” or drug abusers. It was not until the mid to late 20th century that pain
began to be considered the result of sensory, affective, and cognitive components
(Dean, 2004, pp. 2-3). However, to this day many physicians have continued to be
conflicted between the need for relief of pain and the concern over abuse of and
addiction to pain medicines, especially with the treatment of chronic pain, and with
the possible exception of acceptable use when patients were close to death.
Pain management gradually has come to be understood, but not necessarily
handled, as a multi-disciplinary system of treatment, through the persistent and often
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ignored work o f several noted physicians in the 20th century. The difficulty in
relieving pain conditions, especially chronic pain, continues to plague the medical
profession. Concerns over addiction, the public outcry over drug abuse, and the sheer
complexity of treating someone with a persistent and severe pain condition have often
resulted in poof pain management, with significant personal and public consequences.
Current State o f Pain Management
In reviewing the literature on the state of pain management, it is common to
see statements such as, “Inadequate pain relief continues to be a serious public health
problem in the U.S.” (Pain & Policy Studies Group [PPSG], 2003a, p. 1). In an FAQ
document jointly supported by the Pain and Policy Studies Group, University of
Wisconsin, the Drug Enforcement Administration (DEA) and Last Acts Partnership
(Good et al., 2004), the organizations together agreed that “Uncontrolled pain is an
enormous public health problem in the United States.” The DEA support of this
document was subsequently withdrawn.
David Jorenson, Director of the Pain and Policy Studies Group and
internationally-recognized expert on policy issues related to pain testifies and writes
frequently about the seriousness of under-treated pain and its effect on the public
good (Jorenson & Dahl, 1989; Joranson & Gilson, 1994, 1998; Joranson, Carrow,
et al., 2002; Joranson, Gilson, Dahl, & Haddox, 2002; Joranson, Gilson, et al., 2003).
Joan Teno, M.D., practitioner, professor, and health care researcher states that pain
under-treatment is “a strikingly large problem,” and upon learning that a large number
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of cancer patients receive inadequate treatment stated, “A person with cancer pain
should receive treatment. I find this outrageous, shocking, and scandalous” (Matesa,
1999, p. 2). Karen OrlofF Kaplan, former President and CEO of Last Acts
Partnership, stated, “Under treatment of pain is a major public health issue in the
United States” (Kaplan, 2004, p. 1).
The problem has been acknowledged by several other groups, including the
Joint Commission on Accreditation o f Healthcare Organizations (JCAHO) which
evaluates hospitals and other provider groups. JCAHO added an evaluation module
on pain management to its accreditation process in 2000. Dennis O’Leary, M.D.,
President of JCAHO, stated, “Research clearly shows that unrelieved pain can slow
recovery, create burdens for patients and their families, and increase costs to the
health care system” (JCAHO, 1999, p. 1). The Veterans Administration initiated a
Joint Collaborative with the Institute for Healthcare Improvement in 2000 to improve
the delivery of pain management for veterans (Cleeland et al., 2003, p. 298). The
hospice movement has continually campaigned for and adopted a strong approach to
pain management for the terminally ill. Even the U.S. General Accounting Office
(GAO) recognized reports that “inadequate treatment of cancer and non-cancer pain
is a serious public health concern” (Kaplan, 2004, p. 3) However, in spite of all of the
attention to the need for better pain management, pain remains under treated and
often not treated at all, for significant numbers of patients.
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Extent o f the Problem
A number of studies have been conducted in an attempt to quantify the
seriousness of the issues. In survey results released in 1993, 86% o f 897 physician
respondents reported that patients are under-medicated when experiencing cancer
pain (VonRoenn, Cleeland, Gonin, Hatfield, & Randya, 1993, p. 121). A seminal
study (Bemabei et al., 1998) of 13,625 cancer patients in nursing homes by the SAGE
Study Group (a database established and maintained by Brown University) concluded
that “Daily pain is prevalent among nursing home residents with cancer and is often
untreated, particularly among older and minority patients” (p. 1877). In that study,
more than a quarter (26%) of patients in daily pain received no analgesic agent at all.
The study also found “a strong inverse correlation between the presence of pain and
increasing age and an equally strong relationship between pain and belonging to
minority groups” (Bemabei et al., 1998, p. 1880). Some of the members of the SAGE
group are faculty at Brown University, which has conducted other extensive research
related to the under- and non-treatment of pain among the elderly in nursing homes in
the U.S. and rated excmciating pain among persons in U.S. nursing homes, in two
separate analyses. The investigators determined that over 41% of nursing home
residents who had reported moderate or excmciating daily pain at their first
assessment, reported it as still present 60-180 days later. Other researchers,
providers, and interested organizations have identified many “pockets o f under
treatment” of pain, which may include age barriers related to the inability of the
elderly to communicate due to dementia and confusion issues, as well as language
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barriers in treating patients in different ethnic groups (Freeman, 2000, p. 1045;
Morrison, Wallenstein, Natale, Senzel, & Huang, 2000, p. 1023). Limitations o f this
frequently cited study include the use of the Minimum Data Set (MDS), a federally
required case management database, as the primary measure of pain. The reports on
pain in nursing home patients as recorded on the MDS are often observations of
nurses, and not direct reporting of the patients themselves. In addition, this study
limits its analysis to the first 7-15 days of a nursing home stay, and does not reflect on
any improvement in pain conditions beyond that time frame. The study also only
includes nursing home patients, so the projection of its results beyond that population
is not supported.
A statewide survey of a random stratified sample of 1,500 Michigan adults
conducted in 1997 determined that 20% of Michigan adults (approximately 1.2
million people) were experiencing some form of chronic pain, and 77% of those
individuals stated they had been suffering for over a year, with 40% of those
individuals stating that pain was constant and had a major impact on their lives (EPIC
MRA, 1997, p. 1). Responses to a 2003 Florida survey projected that up to 75% of
Floridians suffer pain on at least a monthly basis and importantly, more than a third of
them described their pain as moderate or severe (MacManus & Schuler, 2003, p. 50).
A 2004 survey o f 800 chronic pain sufferers revealed that nearly 50% do not have
their pain under control—it is “ever present” (American Pain Foundation, 2005,
p. 11). The 2003 Pain in America Survey found that 57% of adults in this country
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have experienced chronic or recurrent pain in the last year (American Pain
Foundation, 2005, p. 8).
Barriers to Quality Pain Management

Many of the noted studies cite other research, which all verify that the
treatment of pain has been an issue for a long time and affects significant numbers of
people. Furthermore, the alleviation of pain is often elusive as well as frustrating to
patients and medical professionals alike. The World Health Organization (WHO)
developed a treatment “ladder” in 1982 for drug administration to cancer patients to
respond to this dilemma, and although the method has wide acceptance, the presence
of a good method o f drug treatment has not resulted in a meaningful reduction of the
numbers who suffer in pain. There are several barriers to good pain management that
have been identified, beginning with the minimal training medical professionals receive
about pain management.
Medical schools do not routinely include pain management courses in the
required curriculum, and most medical schools do not even offer a pain management
elective (IOM 2001 study as cited in Kaplan, 2004, p. 3). Instead, the student is
expected to “pick up” the skills to manage pain from information presented within
required courses, and from practicing physicians as he or she completes rotations and
internship. The 2001 Institute of Medicine study showed that medical schools in the
U.S. provide little or no required, formal education in pain treatment and palliative
care. There is no recognized discipline of pain management, so it cannot be classified
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as a specialty (Fishman, Gallagher, et al., 2004, p. 281). The same lack o f education
on pain management is present in nursing schools and schools of pharmacy. Medical
professionals are not generally required to obtain continuing education in pain
management to maintain their licensure; thus, there is no incentive to pick up the
knowledge after graduation. This means that the practice of pain management is
hampered by a fundamental lack o f knowledge for the vast majority of medical
professionals. In practice, it also means that a chronic pain patient is often referred to
a series of physicians as an attempt is made to obtain relief (Fishman, Gallagher, et al.,
2004, p. 282).
Nearly all pain management care plans contain at minimum a drug regimen
which often includes the use of opioids. Opioids are considered a basic treatment for a
number of severe pain conditions and are accepted as a standard of practice
throughout the world. They are strong medicines and because some patients may
become addicted to the drugs, there is a concern among many medical professionals
regarding potential addiction issues for their patients. These concerns are fueled by
drug abuse issues and fears of sanction if a patient becomes dependent, addicted, or
abuses his or her drugs.
The difference in the concepts of physical dependence, addiction, and
tolerance are not well understood (Savage et al., 2003, p. 655). Physicians without a
level o f comfort in prescribing for pain conditions, especially persistent pain, are often
fearful of regulatory action that has, for some, resulted in prosecution for over
prescribing or prescribing for non-medical purposes (recreational use or resale of the
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drugs). A study of 2,000 physicians revealed that 5% would not prescribe opioids at
all for cancer pain, and nearly 80% would avoid the use of opioids for severe back
pain (Zickler, 2001, p. 3). In addition, regulatory action taken against physicians over
opioid prescribing has created a “chilling effect” on the use of strong medicines in the
treatment of severe, persistent pain, with many physicians restricting the use of
opioids or not using them at all, to avoid any adverse interaction with law
enforcement. Although the number o f physicians actually prosecuted for drug
diversion is very small, the few public prosecutions of physicians have resulted in
widespread concerns over investigation, trial, loss of license and even criminal
penalties (Merritt et al., 1998, pp. 11-12). Congressman Ron Paul of Texas even
posted “The War on Drugs is a War on Doctors” on his website and indicated that
law enforcement was applying laws intended for drug dealers on doctors
(Brushwood, 2004, pp. 1-2). Attempts to counter this “chilling effect” have included
the development of state standards and guidelines, acknowledgment of the need for
balance in regulatory oversight, and assurances by the DEA that physicians would not
be prosecuted for proper prescribing. Those activities have not removed the “chilling
effect” on opioid prescribing, and there have been numerous articles and testimonials
about the fear of regulatory scrutiny and how it contributes to inadequate pain
management (Brushwood, 2003; Joranson & Gilson, 1998; Joranson, Carrow, et al.,
2002; Ziegler & Lovrich, 2003).
Inconsistent access to opioids and other strong drugs also limits the delivery
of good pain management in some areas. It is not uncommon to find that some
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pharmacies stock only certain strengths of opioids, for example, limiting oxycodone
dosages to 40 mg, and refusing to stock higher doses, or too frequently, not stocking
opioids and other Schedule II drugs at all. One study reported that 51% of New York
City pharmacies did not stock sufficient opioids to treat patients with severe pain
(Morrison et al., 2000, p. 1023). That study, along with others, also establishes a
racial injustice in pain treatment for black and Hispanic patients (Freeman, 2000,
p. 1045). This inequity in treatment has been studied extensively with results reported
in several articles (Cleeland, Gonin, Hatfield, et al., 1994; Cleeland, Gonin, Baez,
Loehrer, & Pandya, 1997).
Another barrier that needs to be recognized is the patient’s refusal or
perceived lack of need to obtain treatment. People often do not seek medical help for
pain conditions that they consider minor (MacManus & Schuler, 2003, p. 5; Maroney
et al., 2004, p. 446). This issue needs to be addressed in considering the extent of the
pain problem, since it is likely, and evidence exists to indicate, that people who self
select non-treatment are still included in statistics that define under-treated pain.
Because people who choose to forego treatment are often included in pain studies,
the credibility o f the extent of unmanaged pain is sometimes questioned.
Consequences

The research verifies that nationally, the treatment of pain is inconsistent,
fragmented, and in some cases, non-existent. The failure to manage pain effectively
results in unnecessary suffering, higher health care costs in both the long and short
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term, and has a tremendous impact on a pain patient’s life. Untreated or under
treated, the patient becomes less productive at work if he or she is able to work at all.
Chronic pain is estimated to cost anywhere from $16 billion to over $70 billion per
year in lost workdays, diminished productivity, compensation, and health care costs
(Dean, 2004, pp. 1-2; Stewart et al., 2003, p. 2443). Patients face financial hardships
if unable to remain fully employed while seeking relief, thus adding the loss of income
to the cost of care. For those who cannot get relief from persistent pain conditions,
the road often leads to unemployment, financial devastation, no health care coverage,
compromised or destroyed relationships, drug-seeking behavior, and for some, suicide
(American Pain Foundation, 2005; Dean, 2004; EPIC MRA, 1997; Fishman,
Gallagher, et al., 2004; MacManus & Schuler, 2003). Research America reports that
nearly 40% of chronic pain sufferers have had to make major adjustments in their
lives, including disability leave, job changes, help with activities of daily living, or
moving to different housing (Research America, 2003, p. 1). The impact on family
members is significant. One study showed that 78% of family or household members
indicated that relationships with family members were hurt due to a family member’s
pain (MacManus & Schuler, 2003, p. 50).
In the analysis of the extent of the pain problem, the fact that most pain is
treatable and preventable is often diminished or not mentioned at all. There are
pockets of excellence, perhaps most notably the hospice movement, with the
comment often heard that pain is manageable, but the patient has to be dying to get
relief (Miller, Mor, Wu, Gozalo, & Lapane, 2002, p. 507).
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In addition to the costs to the patient, business pays a cost in lost productivity
and the rising costs of health care coverage, as employees with severe pain conditions
make extensive use of their health care plan. The 1996 study of Pain and Absenteeism
in the Workplace found that 14% of all full-time employees took sick days in 1995
due to pain conditions, resulting in more than 50 million work days. This translated
into more than $3 billion in lost wages due to pain conditions (American Pain
Foundation, 2005, p. 1). Another study reported that 36% of pain sufferers that were
employed missed work due to that pain (EPIC MRA, 1997, p. 1). Significant
diminished productivity issues were highlighted in the report from the Stewart study
on lost productive time and costs (Stewart et al., 2003, p. 2446). The National
Institutes of Health estimates the financial burden of untreated or under-treated pain is
in excess of $100 billion annually, in medical costs, lost wages, and business
productivity (National Institutes of Health, as cited in Partners Against Pain, 2003).
Poor pain management has a public cost as it affects the budget for the
Medicare and Medicaid systems, as well as managed care organizations and private
health insurance (O’Leary, as cited in JCAHO, 1999, p. 1). As these costs continue
and even rise with the aging of America, they drive up the costs of health care for
everyone, as health coverage premiums continue to increase. Thus, the cost burden of
unresolved or poorly resolved pain is everyone’s cost problem. The consequences of
poor pain management reach every comer of the nation, and any barriers—real or
perceived— should be addressed and resolved.
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Prescription Monitoring Programs

In order to address the associated issues of the diversion of legal drugs and
related substance abuse, several states have implemented a variety of laws and
policies that supplement federal controlled substance laws. One type o f such policies
is a Prescription Monitoring Program or PMP. In general, PMPs are state laws which
are designed to fight drug diversion at the state level. By the end of 2001, there were
16 states with PMPs, leaving 34 states operating without PMPs. The PMPs vary in
their content and regulatory authority by state; however, all contain more restrictions
on the prescribing of controlled substances than are present in federal law. Although
the federal government through the FDA and the authority of the Uniform Controlled
Substances Act has placed all legal prescription drugs in either Controlled Substance
Schedules II-V or deemed them to be non-scheduled drugs, various states have re
classified some of the controlled substances because the states feel some drugs have a
potentially more dangerous effect than that determined by the federal government.
Some o f the history, background, and basic information regarding the selection and
regulation of controlled substances was presented in the first chapters. This section
presents additional background and studies related to the benefits, limitations, and
other commentary on the effectiveness of PMPs.

History and Definition o f PMPs
The sole purpose of prescription monitoring programs is to reduce diversion
of prescription drugs in one or more controlled substance categories. Additionally,
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PMPs are only designed to detect and address diversion from one source, health
professionals’ prescribing of medications to patients. A division of the U.S.
Department o f Justice (USDOJ) stated on its website, “Prescription monitoring
programs help prevent and detect the diversion and abuse of pharmaceutical
controlled substances, particularly at the retail level. . .” (USDOJ, 2003, p. 1). The
Pain and Policy Studies Group (PPSG, 2003b) of the University of Wisconsin offers
the following definition: “PMPs collect prescribing and dispensing data from
pharmacies, conduct review and analysis of the data, and make it available under
certain circumstances to regulatory and law enforcement agencies . . .” flfl)
The first continuously operating prescription monitoring program was
implemented in California in 1939 and applied to limited drugs such as opium,
cocaine, and marijuana—all drugs that subsequently became illegal to prescribe. In
1914 the state of New York became the first state to place controls on prescribing
through special prescription pads for certain potent drugs, but that was not a
continuous effort. New York did not adopt continuous controlled substance
prescribing controls until 1972 (Fishman, Papzian, et al., 2004, pp. 312-314). All
seven states included in this study that have experience with a PMP began their efforts
with some sort of special prescription pad, all with triplicate copies, except
Massachusetts. That state met with heavy resistance to a required special prescription
pad from the medical community, and opted to begin its PMP as an electronic data
monitoring system (EDT). Of the nine states that started their PMP with special
prescription pads, only New York and Texas currently (as o f2004) require a special
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form for full monitoring, and it is a single copy form. All other states have now
converted to an EDT program. The State of Washington has maintained a special
triplicate form for disciplinary purposes only, and not for prescription monitoring. The
drug schedules monitored by the programs differ from state to state, with every state
monitoring at least Schedule II substances (Alliance of States with Prescription
Monitoring Programs, 2005), the category of drugs deemed by the DEA to have the
most potential for dangerous side effects, abuse and addiction. As of 2001, nine states
included the monitoring of other Scheduled drugs in their PMP. See Table 1 on the
next page for a summary o f each state’s program, as of 2001.
As national concerns increased over the diversion of legally available drugs,
more states considered and several have adopted PMPs; all now are EDTs except the
noted states. By the end of 2001, the last year of this study, there were 16 states with
some type o f monitoring program for prescribed drugs in various combinations of the
five controlled substance schedules, with the state of Washington included as a 17th
state although its monitoring was limited. In general, the primary reason most of the
states have converted to an EDT system from a special prescription pad program is
the cost of a paper system, although resistance by the medical community to the
requirement of a special prescription pad continues to be a strong force. The federal
government is supporting the development of PMPs as evidenced by its 2003 grant
funding to assist states in the development of PMPs. (USDOJ, 2003, p. 1.)
Throughout the history of the development of PMPs in the various states, the
proponents—generally state agencies and law enforcement personnel—have argued
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Table 1
States With Prescription Monitoring Programs
State
California

Year
Enacted
1939

Monitoring System
Triplicate + electronic (1996)

Drug Schedules and
Groups Monitored
C-II

Managing Agency Type
Justice Department

Hawaii

1943

Duplicate and Electronic

C-II (Dup.) and C-II, III, IV (elect.)

Public Safety Department

Idaho23

1967

Duplicate and Electronic

C-II p u p .) and C-II, III, IV (elect.)

Pharmacy Board

Illinois

1961

Electronic (1999)

C-II

Human Services Department

Indiana

1987

Single copy + Electronic

C-II, III, IV, V

Public Safety Department

Kentucky

1998

Electronic (1999)

C-II, III, IV, V

Health Department

Massachusetts

1992

Electronic

C-II

Health Department

Michigan

1988

Single copy serialized + Elect.

C-II

Consumer & Industry Srvcs Dept.

Nevada

1995

Electronic

c-ii, in, iv

Pharmacy Board

New Mexico

1994

Electronic

C-II

Pharmacy Board

New York

1972

Single copy serialized +
Electronic (1998)

C-n and Benzodiazephines

Health Department

Oklahoma

1990

Electronic

C-II

Rhode Island

1978

Electronic

C-II, III

Narcotics & Dangerous Drugs
Control Bureau
Pharmacy Board

Texas

1981

Single copy + electronic (1998)

C-II

Public Safety Department

Utah

1995

Electronic

C-II, III, IV

Professional Licensure Division

Washington

1984

Triplicate for discipline only
(not a true PMP)

C-II, III, IV, V

Pharmacy Board

West Virginia

1995

Electronic

C-II

Pharmacy Board

Note. Information as of March 2001 per NASCSA website.
U)

as
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that such programs decrease drug diversion while still allowing legitimate medical
use, which is very important to proponents of accessible, high quality pain
management. One o f the arguments used to support the absence of prescribing
barriers in policies such as PMPs is that the prescribing of scheduled drugs, with an
emphasis on Schedule II drugs, has continued to increase overall. It is thus concluded
that the presence of a PMP is not affecting prescribing patterns for pain management.
While using statistics such as increased consumption, some regulators cite the data
compiled by the DEA to indicate the growing problem o f drug abuse in the U.S. The
Drug Enforcement Agency has a variety of statistics and information on its website,
www.dea.gov. Opponents o f PMPs—generally medical groups and pain management
advocates—acknowledge the drug abuse problem, but argue that the mere increase in
use of a class of drugs does not indicate that optimum pain management is occurring,
unfettered by policies such as PMPs. These opponents cite other factors that could
lead to increased consumption with or without a PMP, such as increases in
population, technology changes, and the discovery of better drugs, to name a few.
Opponents also caution that laws such as PMPs may encourage physicians to
prescribe drugs from a lower schedule of drugs that is less potent, thereby not
adequately addressing pain problems and setting the stage for undesirable side effects
of such less effective drugs (Joranson & Gilson, 1998, p. 160; Wastila & Bishop,
1996, p. 4).
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Benefits and Limitations o f PMPs
One of the seminal studies on the use of state prescription monitoring
programs was conducted by Susan Peine of the Office of Diversion Control of the
DEA, USDOJ in 1998-1999. Entitled “A Closer Look at State Prescription
Monitoring Programs” (USDOJ DEA, 2000), one of the four goals of the study was
to determine the effectiveness of PMPs. In the introductory comments to this study,
the authors stated:
For many years states have struggled with the knowledge that the diversion
and abuse o f pharmaceutical controlled substances exists and the extent of the
problems is much worse than known by the public (p. 3). They added, Major
benefits of prescription monitoring programs whether they are multiple copy,
electronic data transmission (EDT) or EDT with a single-serialized form,
include diversion prevention and deterrence, increasing the probability of
catching culpable practitioners when diversion does occur, reducing the
consequences o f abuse (accidents, injuries, lost productivity), and reducing
unnecessary expenditures for heath care services, (p. 7)
The study reports the increasing number of states that have implemented
PMPs of some type, beginning with California in 1939 and including 16 states at the
time of the research (USDOJ DEA, 2000, p. 11). The study acknowledges the
controls imposed on all states by the Controlled Substances Act of 1970, and
supports the additional controls imposed by states through PMPs. Diversion activity
in each PMP state was reviewed using both statistics and anecdotal commentary, with
the caveat that the full extent of the problem cannot be quantified because so much of
the diversion problem goes unreported. This point is a limitation of the study, as it
leaves no measurable means of determining if PMPs actually played a role in
decreasing drug diversion. However, a few states were able to provide some data to
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support PMPs. For example, after Indiana discontinued its PMP in the mid 1990s, the
Indiana State Police reported an increase in the number of patients from Michigan
(which had a PMP) who traveled to Indiana to obtain Schedule II drugs (p. 19). No
evidence was provided to indicate that such drugs were then diverted to illegal use,
which is another problem with the study. In Oklahoma, the number of undercover
purchases o f controlled substances went from 715,000 over a 5-year period before the
implementation of Oklahoma’s PMP, to 281,383 purchases during the 5 years after
the PMP went into effect (p. 22). However, no information was provided to indicate
whether this was caused by a change in law enforcement resources or priorities during
that same period. In Michigan, reduced prescribing of Schedule II drugs occurred
after the implementation of its PMP, and was cited as evidence that diversion of such
drugs was thus addressed (p. 32). Opponents of PMPs would use the same statistics
to indicate that the reduced prescribing indicated that pain patients were not being
properly treated.
Throughout this often-cited study which remains on the DEA website as
evidence o f the effectiveness o f PMPs, there are many examples of drug diversion and
the extent o f the problem. The study does a very good job of providing evidence that
the diversion o f legal drugs to illegal use is a problem in the U.S. It also provides
some evidence that the information collected using PMPs is a valuable tool in the
investigation and arrest of those suspected of diverting drugs. In Indiana, the PMP
was credited for more than 41 arrests during an unspecified period (USDOJ D EA
2000, p. 30). In Illinois, a few examples were provided that connected fraudulent
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prescribing practice discoveries to its PMP. However, in the 15-year period of
Illinois’ PMP, referrals from its PMP only contributed to disciplinary actions against
25 medical providers, less than two per year (p. 29). In Michigan, the study estimated
that the absence o f its PMP would have put over 2 million dosage units of Schedule II
drugs on the streets each year—with a street value of up to $50 million (p. 32). The
study claims the PMP has “virtually eliminated” this problem, in spite of the fact that
in 10 years, no legal action against any physician was initiated due to the existence of
Michigan’s PMP. The section on New York states that the forgery and counterfeiting
of Schedule II prescriptions was virtually eliminated due to its PMP. Again, no data
were provided to substantiate those statements. In Texas there was only one
conviction by the Texas Department of Public Safety (DPS) of an individual for drug
diversion prior to the implementation of its PMP. After implementation, the DPS
indicted 18 medical practitioners over an 18-month period, with another 17
practitioners surrendering their rights to prescribe Schedule II drugs. This was a
supported statistic; however, it is not known what other factors might have
contributed to the increase in legal actions in Texas. For example, the DPS might
have increased or reassigned its law enforcement officers during the same period. And
o f course, an indictment is not a conviction, so the example is not as meaningful when
making a case for the benefits of a PMP in the prevention of drug diversion in Texas.
However, this report does provide some excellent examples of the extent of
drug diversion, the advantages of the availability of PMP data in specific cases, and
the desirability of such programs on the part of law enforcement officials. It fails to
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draw a credible correlation between PMPs and a significant reduction in drug
diversion, and it does not control for other confounding factors such as population
changes, increases or decreases in law enforcement resources, changes in disease
prevalence, and the availability of new medications for the treatment of chronic pain
conditions. The study also uses some examples to justify activities that are then
contradicted in other areas of the study. For example, in Illinois the prescribing of
Schedule II drugs increased after the state PMP was implemented, a fact that was
used to indicate there was no “chilling effect” on proper prescribing. In other areas of
the report, similar increases in prescribing were used to support the extent of the drug
diversion problem. Opponents of PMPs might argue that this was evidence that the
PMPs might not be working. And the statistics presented for some states such as
Michigan which showed reduced prescribing of Schedule II drugs could be
interpreted to mean that the PMP was working, or that prescribers were more
cautious in their prescribing and thus pain patients were not receiving the drug
therapies needed. There were several examples of using the same information to
support opposing arguments throughout the study. There was no conclusive evidence
presented to indicate that PMPs significantly reduced drug diversion after
implementation. In fact, in the opening comments, the authors stated, “It was
determined that due to the many factors that affect the collection of the data by each
state, a purely scientific statistical analysis would be an impossible task” (USDOJ
DEA, 2000, p. 4). This issue and the lack of adequate studies were included in the
American Alliance of Cancer Pain Initiatives (AACPI) Statement on Prescription
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Monitoring Programs that was released in June, 2002 (AACPI, 2002, ^fl). In general
the methodology used to support the existence and growth of state PMPs was limited
to reporting individual state incidences and general statistics, without any scientific
data that was consistently measured from state to state.
One o f the study’s conclusions was a commentary on the difference from state
to state in the structure of PMPs. Stating that “no two programs are alike,” the
variables differentiating between state PMPs were reported as significant and make
outcome and program evaluation very difficult. This supports the report’s initial
comments on the difficulty in determining how effective PMPs are in controlling drug
diversion.
Brushwood (2003, p. 42) agreed with that conclusion, stating that there are
no national standards for PMPs; there is a lack of accuracy, a lack o f national
integration (abusers can cross state lines to obtain their drugs); and the issue of
confidentiality is problematic. He states:
It may be difficult for researchers to find a direct correlation between the
ultimate outcome of reduced substance abuse and the implementation o f
electronic prescription monitoring programs, even if such a correlation exists.
Yet, despite the difficulty of outcomes research, it is outcomes to which the
health care community has turned for meaningful program evaluation, (p. 45)
He further states, “it is not unreasonable to provide clear evidence of positive
outcomes from their programs.”
In another study, Wastila and Bishop (1996) determined that the presence of a
PMP in the form o f a multiple copy prescription program (MCPP) did reduce
prescribing of Schedule II drugs, but that was done by merely changing prescribing
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patterns to a less potent drug from within the Schedule III classification. They stated,
“These patterns suggest that less potent drugs are substituted for Schedule II
analgesics in MCPP states. This study finds that MCPPs alter analgesic utilization
patterns, which has implications for physician practice patterns and patient access to
analgesic therapy” (p. 4). They also point out the difficulties in studying the issue
from a statistically significant viewpoint, indicating that “all studies to date fail to
incorporate in a multivariate model other potential confounding and explanatory
variables, including patient diagnostic information, physician specialty, and other
related prescribing and reimbursement factors” (p. 6).
This reinforces the comments made in the DEA study and the Brushwood
article. There is a presumption that there could be (or could not be) a correlation
between PMPs and a reduction in drug diversion; however, no study has been done to
verify that presumption. In fact, the Wastila and Bishop study provides some evidence
that the presence of a PMP for the period of their study actually did reduce the
prescribing of Schedule II drugs, which some would argue means a reduction in drug
diversion—a conclusion that cannot be drawn from the research. The study also
reports an increase in the prescribing of Schedule III drugs, perhaps indicating that
patients may be receiving a less potent drug than desirable, reducing the quality of
their pain treatment. Others would argue this is evidence of a decrease in drug
diversion. Thus, the conclusions can be misinterpreted and misapplied. Limitations of
the study include the inability to account for variations in PMP programs and length
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since implementation across states. In addition, the medical environment of the states
in the study vary.
The fact that laws and policies such as PMPs might have the potential to cause
some physicians to under-prescribe for pain conditions was a caution issued early by
several pain treatment proponents, most notably Joranson and Dahl of the University
o f Wisconsin Pain and Policy Studies Group (Joranson & Dahl, 1989, p. 202).
Cautions without significant supporting studies, however, did not prevent the
continuing growth of PMPs, although the structure and design has changed over time.
It is interesting to note that studies which imply that PMPs decrease drug
diversion do not address the confounding factors of activities other than prescription
fraud by which drugs are diverted, such as pharmacy theft, nursing home, hospital and
clinic theft, and the movement of diversion activity across state and national borders.
PMP studies place an emphasis on controlling prescribing activity that results in drug
diversion. This fails to address the global problem and for critics is viewed as a “bandaid” approach to a significant issue.
PMPs, as indicated, take many forms in the states under study as well as the
other states not a part of this study. Since they seek to identify prescribing that is
illegal, fraudulent, or in a pattern that is outside the norms for the area of enforcement
or physician specialty, they are subject to errors in determining “normal prescribing.”
Thus, if area physicians in a particular specialty are under-prescribing for pain
conditions, then a physician who is providing optimal pharmaceutical care for pain
patients would be suspect, if the area averages were used as the norm. Several articles
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address this concern (Brushwood, 2003, pp. 45-47; Hill, 1996, pp. 289-290;
Jorenson, Carrow, et al., 2002, pp. 232-234). Hill states:
The methods used by boards/agencies to determine standards of practice for
opioid use result in interpreting the language in these regulations based on
myths, prejudices, and misinformation about opioids, and the unexamined
belief that mere exposure of patients to these drugs causes psychological
dependence (addiction) on them to all patients in all instances, (p. 288)
He further states, “Therefore, practitioners who prescribe adequate doses for proper
time intervals and who provide adequate quantities of opioids to the patient for a
reasonable number of days are often considered, prim a facie, outside the standard of
practice” (p. 291).
Another limitation of PMPs is the delay in data collection and disbursement.
Although most states with PMPs are now collecting data electronically and have
discontinued the use of special pads, using PMP data to control drug diversion is
addressing the issue after the fact. In a typical electronic PMP process, a prescription
is electronically sent to the data collection agent (often a state department) and is
maintained there until data are requested. Thus, a series of illegal prescriptions could
be recorded, but until someone retrieves and reviews the data, there would be no
knowledge o f the activity. States with electronic PMPs do not (and will not, given
current HEPAA laws) allow carte blanche access to the prescription database; thus,
the ability to use the information is limited in its usefulness. One could argue that such
regulatory policies are thus not truly preventive in nature. This limitation was
mentioned in the interviews which are a part of the qualitative research conducted for
this study.
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Prescribing Patterns and Control o f D rug Diversion

The “chilling effect” mentioned earlier has been reported by nearly all those
who study and report on the negative effects of PMPs as an undesirable consequence
of such laws. On the other side are law enforcement officials who generally claim that
no chilling effect occurs, and that the changes in prescribing are evidence that the
PMPs are working. A 1997 Michigan report by the Michigan Board o f Pharmacy
presented statistics indicating that although the use of oxycodone, hydromorphone,
and meperidine prescriptions (all Schedule II drugs) declined from 1990-1995,
prescriptions for Fentanyl and morphine (also Schedule II drugs) increased. They
claimed that those statistics indicated no chilling effect (Baran, 1997). The same
report included numbers that showed the disciplinary actions of medical doctors and
doctors of osteopathy to be exactly the same (76) in 1994 and 1995, which is less
than one quarter of 1% of all licensed physicians (over 35,000 each year) in the state.
Opponents of PMPs state the low number of enforcement actions indicates the PMPs
are thus not necessary. (Brushwood, 2003, p. 46; Johnson, 1996, p. 320; Skelly,
1994, p. 19; Szalavitz, 2004, p. 7). Johnson also refers to the chilling effect of such
laws:
Doctors’ fears of disciplinary action and criminal prosecution are justified.
There is no evidence that large numbers of physicians are sanctioned for their
treatment o f patients in pain, but the impact of the process on those physicians
who are only investigated, or only charged but not disciplined, or only warned
or cautioned but not penalized is severe, (p. 320)
The Reasononline website (2004) provides details on physicians whose
practice and indeed personal and economic life were devastated by regulatory activity
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directed at decreasing drug diversion, and how such public exposure can cause other
physicians to change their prescribing decisions. The October 2004 web article states,
“While the OxyContin panic does not seem to have deterred addicts, it has scared
doctors. Every time there is one of these trials . . . another 50 to 60 doctors drop off
from prescribing” (p. 5). Statements like this are not uncommon in anti-PMP articles;
however, no substantive study has occurred to indicate that physicians are actually
changing prescribing patterns because of PMPs.
Some studies and data are available to indicate that fewer physicians prescribe
Schedule II drugs when a PMP is implemented. For example, in California, 69% of
physicians responding to a survey indicated that the potential for disciplinary action
made them more conservative in prescribing opioids (Skelly, 1994, p. 15). A review
of Michigan records on special prescription pad licenses for Schedule II drugs
indicated a significant decrease in the number o f physicians applying for such
privileges after a PMP was implemented in Michigan, resulting in significantly fewer
physicians able to prescribe the most effective pain medications. Proponents of PMPs
say this means that unethical physicians have ceased to prescribe—that the “bad”
doctors voluntarily elected non-renewal of their prescribing rights for Schedule II
narcotics. Opponents of PMPs state this means that physicians feel the extra work
required to prescribe and the threat of extra oversight are too much hassle, so they
elect non-renewal. This is another example of the use of the same statistic to support
opposing assumptions.
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In his continuing analysis of regulatory effects on prescribing controls on
physicians, David Brushwood of the University of Florida collected data from several
states to determine the number of criminal prosecutions of physicians for offenses
related to prescribing opioid analgesics from 1998 through 2003. O f the 27 states in
his report, 124 physician prosecutions were reported, with 64 of those either pleading
guilty or being convicted. Of the more than half million physicians licensed in those
states, the prosecutions represent a miniscule portion, less than 1% of all physicians.
O f the states in the Brushwood report, 12 had PMPs of some sort in force during at
least a part of the 6-year summary, and included 39 of the prosecutions. Thus, 44% of
the states in the report had 31% of the prosecutions. Proponents of PMPs would infer
that meant the PMPs were working—that the number of prescription diversion crimes
was less in the PMP states. Opponents of PMPs might infer otherwise, namely that
the statistics showed the ineffectiveness of PMPs. It could be argued that there should
actually be more prosecutions with the extra law enforcement data tool of the PMPs,
and that the numbers were too small to draw any conclusion.
A study of four states by the USDOJ showed a 50% or greater reduction in
the prescribing o f Schedule II substances after the implementation of a multiple copy
PMP (Angarola & Joranson, 1992, p. 10). Statistics compiled by the USDOJ indicate
that the five states with the lowest number of OxyContin prescriptions per capita have
PMPs and have reported few diversion problems with the drug. Conversely, the five
states with the highest OxyContin prescriptions per capita do not have PMPs and
have reported diversion and abuse. Although one study can infer that PMPs are
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effective, very often the same study infers that PMPs may have little to do with
diversion of controlled substances. As mentioned, most of the studies to date have
failed to control for other factors; thus, a clear conclusion has not been possible.
An additional concern expressed about the effect of PMPs is the potential
decrease in access to strong pain medications because of a reduction in pharmacy
inventory. Owners of pharmacies are likely to limit their inventory o f drugs that have
little demand due to physician reluctance to prescribe or due to fear of investigation.
Angarola (1994) states, “Some pharmacies are so concerned about drug diversion and
the possibility of DEA investigation that they do not stock Schedule II and other
controlled substances” (p. 32). A subsequent study by Cleeland as noted earlier,
indicates that access related to low pharmacy inventory in ethnic neighborhoods also
continues to be an issue. This limited access in some areas enhances the “substitution
effect” or the prescribing of weaker drugs in PMP states to avoid scrutiny—drugs
that are less efficacious, with more side effects when heavier doses are needed.
(Angarola & Bormel, 1996, p. 53). Although this study established the existence of
the substitution effect, there was no evidence that such change in prescribing patterns
actually lowered the quality of pain management.
A more recent, although selective, study o f analgesic prescriptions for
muscoskeletal pain does provide some statistical evidence that the prescribing of
opioids and NSAIDS for this type of chronic pain has increased, in spite of additional
regulatory activity. This study might support the argument that PMPs produce no
chilling effect. The study was substantial and included a comparison of prescribing as
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a result of office visits in various areas of the country in 1980 and 1999 to determine
changes in prescribing preferences. The researchers found that prescribing for both
NSAIDS and opioids as a percent of office visits increased significantly over the study
period. The data were collected by examining the results of the National Ambulatory
Medical Survey, which compared 89,000 visits in 1980-1981 to 45,000 visits in 19992000. Physician participants were randomly selected. The study was done to look at
prescribing pattern changes for acute and chronic pain conditions, but it also makes a
statistical case against the chilling effect. Limitations of the study include not
controlling for increased public awareness o f the pain treatments available, the fact
that NSAIDS were only available by prescription in 1980 and many were available
over the counter by 1999, and the introduction of new and better pain medications.
The numbers do, however, indicate that physician reluctance to prescribe for
musculoskeletal pain conditions has not increased during the period of growth of
PMPs (Caudill-Slosberg, Schwartz, & Woloshin, 2004, p. 514).
Effect on Drug Diversion
Since the primary purpose of PMPs is to reduce drug diversion, it would seem
logical that evaluations at the various state levels would have been completed, to
determine the impact on drug diversion and to ascertain the cost-effectiveness of such
policies. If one removes the quality of pain management from the argument for or
against PMPs and concentrates on subsequent reduction in drug diversion after a
PMP is implemented, at least that objective could be tested. In fact, drug diversion
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continues to increase in the United States, according to the DEA website and other
sources: A wealth of information is found on these websites: www.DEA.gov,
continuous reports; www.drugabusestatistics.samhsa.gov, continuous reports; and
www.NASCSA.org. The Florida Office of Drug Control also published an extensive
report on the increase in drug diversion in Florida in its document, Florida Drug
Control Strategy, 1999-2005 (Florida Office of Drug Control, 1999).
As previously mentioned, one of the challenges in establishing a correlation
between reducing drug diversion and PMPs is the fact that PMPs are only designed to
address diversion by prescribers, and such diversion is difficult or impossible to
separate from other sources of diversion which notably include theft and loss from
pharmacies and facilities that store an inventory of drugs such as hospitals and nursing
homes, not to mention the growing concern with diversion through purchases from
internet pharmacies. The pain community continues to acknowledge that drug
diversion and drug abuse is a growing concern as publicized in a statement released
October, 2001 by 21 health care organizations (American Alliance of Pain Initiatives,
2001, p. 1). The DEA and various law enforcement organizations believe they have
statistics to verify that drug diversion is less in states with PMPs. The pain community
does not necessarily dispute that such laws have an effect on drug diversion; the
concern is that the effect may be so small on diversion using prescribed drugs, as not
to be worth the resources expended. There is also a fear that pain management is not
as good in those states with PMPs.
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One of the indicators used by regulators and others to determine the extent of
drug abuse is the DAWN data, which is used in the quantitative portion o f this
research. These statistics are obtained from the records of selected, large metropolitan
hospital emergency department medical records to monitor national drug abuse trends
(Avww.dawninfo.samhsa.gov, ongoing.) These statistics indicate increasing drug
abuse; however, the majority of abuse problems are associated with illegal (non
prescription) drugs and alcohol in combination with drugs, so the projections are not
conclusive for the diversion of legal drugs. In its 1994-2002 report, DAWN statistics
showed a 120% increase in mentions of narcotic/analgesic combinations at DAWN
sites nationally, an increase greater than the 11% population groAvth for that same
period (U.S. Department o f Health and Human Services, 2003, pp. 62-63). DAWN
statistics from PMP states will be used as the dependent variable in the quantitative
analysis section o f this research to determine if such increase is greater or less in PMP
states. Limitations of the DAWN statistics will be discussed in that analysis.
The existence of PMPs has not had a significant effect on addressing drug
diversion through legal actions. The Reasononline website reports the following
national arrest numbers o f physicians for drug diversion for 3 years of this study:
1999, 81 arrests; 2000, 83 arrests; and 2001, 78 arrests (Szalavitz, 2004, p. 7). The
number of arrests has remained relatively stable over the 3-year period and does not
appear excessive, given the number of licensed physicians, and given that the number
of PMPs has steadily increased. It should also be noted that the number of arrests is
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hardly the same as the number of actual convictions. This might suggest that PMPs on
a national basis are having little effect on successful prosecutions of drug diverters.
The literature as a whole thus remains inconclusive regarding the effects of
PMPs on drug diversion. Although the pain community concedes the growing
problem of drug diversion and the related drug abuse, it does not feel that PMPs
should be implemented if that is done at the expense of good pain management. The
law enforcement community concedes that untreated pain is a social and public health
problem, but contends that PMPs and other regulatory means Of addressing drug
diversion do not interfere with access to quality pain management and are necessary
for public safety. They stress the use of PMPs as a tool for physicians to use in
assessing the credibility of their patients.
Pharmaceutical companies, which have a stake in the issue, tend to take the
best political path in each state. For example, in Michigan several pharmaceutical
companies worked with health care organizations to eliminate Michigan’s PMP laws,
citing the “chilling effect” on prescribing. In contrast, in Florida, one pharmaceutical
company offered the state $2 million to start a PMP, to assist the Office of Drug
Control and provide a tool for physicians.
In conclusion, there is no clear evidence from current studies that PMPs are
effective policies in the war on drug diversion, nor is there clear evidence that PMPs
serve as a barrier to good pain management. In light of this, the AACPI issued the
following statement: “However it (AACPI) believes that no new PMPs should be
established until and unless existing information sources have been fully utilized”
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(American Alliance of Cancer Pain Initiatives, 2002, p. 1.) The AACPI goes on to
define an ideal PMP, when and if such a policy were deemed effective .Varied
opinions and measurements of effectiveness and a lack of conclusive studies indicate
that we do not know if PMPs achieve their stated goals—and may never know. This
fosters concerns over the cost of such programs (Michigan reported costs in the range
o f $750,000 per year just to collect the data) and provides the incentive for further
study before additional PMPs or a national PMP are put in place.
Drug Diversion
The literature specific to drug diversion, as distinguished from the larger topic
of drug abuse, is very limited and there were no studies of a strictly academic nature
that were identified for review. There were, however, a number of reports and
analyses which relied on anecdotal evidence combined with some statistics, which
were used to formulate conclusions regarding drug diversion in a number of reports.
The public is naturally opposed to drug diversion and drug abuse as such
activity creates situations that are dangerous and even fatal to individuals and society
as a whole. The reports and articles that support public opposition to illegal drug use
are numerous and contemporary. The prevention of drug abuse and drug diversion
has strong public appeal, especially since such actions address activities that are
known to be harmful to children and young adults. Additionally, crimes by drug
cartels and gangs are often horrific and well publicized. The war against drug
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diversion and abuse is a popular political platform, embraced by public officials and
those who wish to be or remain public officials.
In the studies noted in this section, there is an inherent assumption that drug
abuse and drug diversion can indeed be prevented. There is also an orientation in
most of the studies to use the terms drug abuse and drug diversion interchangeably.
That is incorrect, as drug abuse can be facilitated by the diversion of drugs, but it is
not the same thing. As stated earlier in this study, drug diversion is defined to mean
the illegal use of legal drugs. Drug abuse occurs when both legal and illegal drugs are
used for non-medical purposes. Drug diversion is thus a part of the drug abuse
picture, but should be viewed as one of many avenues to drug abuse. To illustrate,
drug abuse occurs when illegal drugs such as heroine or marijuana are used; it also
occurs when alcohol (an “over the counter” drug) is misused; and it occurs when
legally prescribed drugs like Xanax or OxyContin are used for non-medical reasons.
Only this last case is considered an example of drug diversion, because the drugs were
diverted from their intended and FDA-approved use for another purpose (to get
“high” or self-medicate in dealing with some other problem).
Seminal Studies

An annual and oft-quoted study o f drug abuse and diversion is the annual
National Survey on Drug Abuse (NSDA), which was entitled the National Household
Survey on Drug Abuse prior to 1999. This study has been called “The primary source
on the use of illicit drugs, alcohol, and tobacco by the non-institutional population”
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(Office of Applied Studies, 2005b, If 6). This study provides annual estimates of such
illicit use, the results o f an extensive and representative study of U.S. households. In
general, over 70,000 individuals are interviewed for the survey each year. The study
has been conducted since 1971 although it was re-designed for the 2002 survey,
which makes following current trends difficult except for a limited number of
variables. Study results are posted on the SAMHS A website and extensively reported
and quoted elsewhere. The statistical significance of the results is well documented.
However, in the reporting, statistics are often selectively quoted, which can give a
more extensive meaning to the results than the survey data can actually support. For
example, the National Institute on Drug Abuse in its July 2001 Research Report,
quoting the NSDA, states that “An estimated nine million people aged 12 and older
used prescription drugs for non medical reasons in 1999” (Leshner, 2001, p. 1). Later
in the same report, the author states that in 1999 “an estimated four million people
were currently (use in the past month) using certain prescription drugs non-medically”
(p. 4). The study does not appear to distinguish regular use from occasional use in the
reporting of survey results, and the 9 million study result is the statistic of choice for
many articles and other commentaries. In this referenced comment, reported survey
results first cited the larger number of users, even though there is a distinct difference
between current users and non medical use in the past year. The reported results also
do not distinguish between regular use and a one-time occurrence. Thus it is very
likely that a number of one-time, fairly harmless and innocent uses of a prescription
drug are included in the 9 million and 4 million figures above. Examples of such
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innocent use are easily conjectured: taking a friend’s pain medicine for a headache,
older couples sharing a blood pressure medicine, and so on. These activities are, by
the letter of the law, drug diversion, but certainly not the diversion that concerns law
enforcement and the public. However, such ambiguity can disguise the actual
incidence of drug diversion implied by the NSDA. Thus, the survey results should not
be considered a reliable, quantifiable measure of the growth in illegal and harmful
diversion of prescription drugs, and indeed does not make such claims, although the
results are often used to that purpose.
With the above limitations noted, the existence of an increase in the diversion
of legal prescription drugs was supported by NSDA study results. A review of the
press releases for the study years 1998-2001 shows no mention of diversion of legal
drugs in 1998—meaning the issue was not deemed significant enough to be reported
to the press. By 2000, the NSDA reported 4 million people used legal drugs for non
prescribed reasons at some time in the past month—a “current” user. In 2001, there
were 6.2 million current users. Clearly the increase in sheer numbers would be enough
to cause public concern and indicate a problem, even though it appears that someone
could be classed as a current user if the person only used another’s medicine once in
the past month. Thus, in spite of some questionable use of the results, the NSDA
study results still support the claim that the diversion of legal drugs to illegal use is
increasing. The study results should, however, be considered in total. Of note is the
fact that the most commonly used illegal drug identified by the NSDA in 2003 is
marijuana (6.2% of the population) and the most commonly abused legal drug is
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alcohol (54% had participated in binge drinking in the past month—23% of the
population). In the same year, 2.7% of the population used prescription medications
non-medically (U.S. Department of Health and Human Services, 2004, pp. 2-3). It is
important to keep this in mind as anti-drug abuse policies and laws are considered,
and attempts are made to quantify the level of diversion o f prescription drugs using
drug abuse statistics as justification.
The U.S. General Accounting Office (GAO) published a federal report in
May, 2002 entitled Prescription Drugs: State M onitoring Programs Provide Useful
Tool to Reduce Diversion. The GAO refers to DEA statistics in its assertion that drug
diversion is a growing problem. The report is intended to review the effectiveness of
PMPs in deterring drug diversion and the positive effects of such policies in the states
with PMPs. The report studies both benefits and challenges of PMPs and concludes
that “States with PDMPs have realized benefits in their efforts to reduce drug
diversion” (p. 3). This study looks at the different anti-diversion objectives of PMPs,
and states that the anti-diversion effectiveness depends on the objectives of such a
program as well as the funding allocated to the program. The researchers for the
study reviewed information from several sources, including the DEA, the DOJ, and
the National Alliance for Model State Drug Laws, as well as the National Association
o f State Controlled Substance Authorities. The researchers also studied PMPs in
three states—Kentucky, Nevada, and Utah. They found that PMPs shortened
investigation time in some diversion cases, and their mere existence had a deterring
effect on potential diverters (p. 3). PMPs were also found to be useful in alerting
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physicians to potential diversion activity in Nevada and Utah. The Nevada program
also encourages referral o f drug diverters to pain clinics and addiction clinics (p. 10).
In the above study, challenges to the implementation of a PMP were centered
on public education and acceptance, especially the confidentiality issue that must be
addressed, and the costs of start-up and operation of such a program. In Kentucky,
the start-up costs and first year operating expenses approached $1 million (U.S.
General Accounting Office, 2002, p. 3). In addition, most programs were reported to
operate reactively, meaning they were not structured to prevent drug diversion, but to
identify such activities after they occurred, in the form of prosecution or other actions
(p. 10). To make PMPs truly effective in quantifying and preventing drug diversion,
they would need to be restructured to provide same day information, which was
viewed as cost prohibitive. The study also indicated that PMPs may not necessarily
prevent drug diversion; they may just move such activity across state borders. “The
presence of a PDMP helps a state reduce its illegal drug diversion, but diversion
activities may increase in contiguous states without PDMPs” (p. 15). Throughout the
GAO study, several comments were made regarding the growing problem of drug
diversion. However, even this government-ordered study was unable to quantify the
level of drug diversion and the actual growth trend. Instead, it simply concluded with
a general belief that PMPs have a role in detecting and deterring drug diversion.
In 2002, the Office of Inspector General was asked to review the DEA’s
efforts to investigate cases of controlled pharmaceutical diversion (Office of Inspector
General, 2002). The report accepts the DEA contention that drug diversion is
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occurring, stating, “although the quantity o f controlled pharmaceuticals diverted is
unknown, controlled pharmaceuticals account for 30 percent of all reported deaths
and injuries associated with drug abuse” (p. i). A footnote to this comment states,
“The data available for our analysis does not specifically identify what percentage of
the problem is attributable to diversion o f controlled pharmaceuticals versus the abuse
o f legally obtained prescriptions” (p. i). This report, while acknowledging the
existence of a drug diversion problem, was also unable to cite sources that could
verify the extent of the problem, and suggested that the DEA should be responsible
for more activity to address this problem. The OIG report concluded with four
recommendations to the DEA to increase its impact on diversion o f prescription
drugs: (a) to increase DEA investigative resources for diversion problems, (b) to
clarify the roles of diversion officers, (c) to ensure adequate training for DEA agents,
and (d) to fully implement a proposed online project (p. iii). The report does not
include any reference to assistance from states in the form of laws and policies to
prevent and control diversion. The report implies that diversion of legal drugs may
not be an important enough issue to the DEA to devote resources and training, which
again suggests that the extent of diversion may be exaggerated. This is another study
without supporting statistics related to diversion.
DA WN Data as a Measure o f Drug Diversion
Much of the current concern over drug diversion was initiated when the abuse
of OxyContin became a national story. OxyContin, manufactured by Purdue Pharma,
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is a controlled release Schedule II medication used primarily for severe pain
conditions. It is a very effective drug when used as recommended for such conditions;
however, abusers have discovered that crushing the tablets and using OxyContin in its
crushed state can provide a heroin-like “high,” thus creating a market for diversion of
the drug. The illegal use of OxyContin became widely reported, as stories emerged in
many economically depressed areas and eventually other areas, and deaths from
overdoses began to be reported in the media (Gallop, 2003; Meier, 2001; Police haul,
2003; Rippel, 1998; Satel, 2003, 2004; Silver, 2001; Smith, 2003; Thomas, 2003,
p. 42; Tough, 2001, p. 33).
The Drug Abuse Early Warning Network (DAWN) statistics, which report on
emergency department visits for drug-related reasons, supported the claimed
increasing presence of oxycodone, though not specifically OxyContin, since brand
names cannot be identified by lab test. DAWN reported that the number of emergency
department “contacts” identifying oxycodone in the blood increased from 1,178 in
1999 to 14,087 by 2002—an increase of over 1000% (Meyer, 2004, p. 4).
Purdue Pharma, the manufacturer of OxyContin, and other researchers studied
the relationship o f OxyContin use in such reported deaths, and published a report with
its findings in March of 2003 (Cone et al., 2003). The report studied 919 drug abuse
cases which resulted in death, according to DAWN statistics. The report concluded
that multiple drug use was found in nearly all (96.7%) of the deaths (p. 56). The most
common combinations included alcohol, cocaine, marijuana, benzodiazepines, other
narcotics, and other depressants. The report makes the case that while oxycodone
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may be present in the body at the time o f death, death can rarely be attributed to
oxycodone alone, and drug combinations may be the culprit, not any particular drug.
Since this study was funded by Purdue Pharma, there may be some concerns with
credibility and conflict of interest issues. Cases used in the study were reported
voluntarily; thus, the credibility provided by randomization was not present.
Furthermore, only deaths with oxycodone present were studied and only from areas
that had media reports of overdose deaths involving OxyContin, which limits the
study conclusions to only some parts of the country. The study also expressed
concern about the use o f DAWN data in studying polydrug deaths, since DAWN
currently only lists up to six of the potentially contributing drugs in mortality cases.
Some abusers exceed this amount of drugs in their abuse patterns (p. 65). The study
does, however, support the use of DAWN data as a means of measuring drug
diversion, in lieu of any better source of quantifiable events currently available. It cites
the DAWN system as the “largest and most standardized system for reporting drug
abuse morality data in the United States” (p. 65). Interestingly, alcohol was present in
over 25% of the cases studied, supporting other statistics related to the role that
alcohol may be playing in polydrug use and deaths (Best et al., 2000, pp. 319-321;
Florida Office of Drug Control, 1999, Chapter 2; Office of Applied Studies, 2005a,
pp. 1-2).
Actual DAWN statistics and the use of the DAWN data will be covered in the
quantitative section o f this study. However, it should be noted here that DAWN
reports do verify an increasing trend in drug-related emergency department visits in
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the metropolitan areas that are part of the DAWN system. Reviewing DAWN reports
online (www.Dawninfo.net), the percentage increase in drug-related emergency
department visits was 77% from 1995-2000, and 153% from 1995-2004. During this
time, the population increase was just under 10%. Although there are limitations to
DAWN data, there appears to be enough evidence from these statistics to support the
conclusion that there is an alarming increase in drug abuse. Since diversion o f legal
drugs is included in the definition of drug abuse, the DAWN statistics provide another
argument for continued attention to programs and policies that address diversion
issues. It should be noted, however, that DAWN statistics do not provide clear
evidence that the diversion of legal drugs increased at the same rate as its entire
category of drug abuse.
The issue of distinguishing between drug abuse and the subset of drug
diversion was and is a focus of the National Association of Attorneys General
(NAAG). A group of 29 Attorneys General sent a letter to DEA Administrator Karen
Tandy in early 2005, asking the DEA to “find ways to prevent abuse and diversion
without infringing on the legitimate practice of medicine.” Supporting another
approach, former NAAG Chair Drew Edmundson further stated, “We should
concentrate on drugs that are illegally on the streets and work backwards to find out
how they got illegally on the streets,” he said. “It should not be the other way around
looking at doctors” (Robeznieks, 2005, pp. 1-2).
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Other Studies and Testimony
In February of 2002, Dr. Donald Meyer o f the FDA expressed the concerns of
the FDA over the diversion of legal drugs (Meyer, 2004, p. 3). Citing DAWN
statistics and the NSDA survey as sources for FDA concerns, Dr. Meyer reported on
the responsibility of the FDA to address diversion potential. This includes a
responsibility in the drug approval process to make sure that any approved drug is
safe and effective for label uses, that any necessary warnings are on the label, and that
the drug is properly placed on a controlled substance schedule if so indicated. Dr.
Meyer stated, “Most approved controlled-release, high strength opiates contain a
‘black box’ warning, indicating that a serious risk has been identified” (p. 8). This
type of warning is thus generally found on all Schedule II drugs, including OxyContin.
The FDA also monitors pharmaceutical company advertising for false and misleading
statements that could lead to abuse. However, the penalty for such violation may be
minimal. In the case of Purdue Pharma’s questionable advertising of OxyContin at
one point in time, the punishment was to correct the advertisements.
In his testimony to the Subcommittee, Dr. Meyer indicated that several
activities were necessary to address the growing problem of drug diversion.
Collaboration with other government agencies was stated as a primary means of
developing successful initiatives. In addition, physician education, PMPs (“strongly
supported” by the FDA), federal-state task forces, new product assessment for abuse
potential, and FDA’s Office of Criminal Investigation are all listed as activities that
help to address the diversion problem (pp. 15-16). Collaboration with the DEA and
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other law enforcement groups has produced legal action against diverters such as four
clinicians in Indiana who dispensed controlled substances outside the scope of
practice, and a physician involved with a web-based pharmacy (p. 17). From 1998
through early 2002, 46 criminal investigations were opened relating to OxyContin,
with 24 of those cases successfully adjudicated (p. 15). There were no examples given
in the testimony of successful actions to reduce drug diversion, other than the law
enforcement collaboration which resulted in the enforcement actions reported above.
And other than law enforcement collaboration, the testimony did not provide any
documented examples of anti-drug diversion activities that were successful in slowing
and preventing the growth of drug diversion.
Another study that looks at drug abuse by prescription drugs is conducted
through the OAS within SAMHSA, a division o f the U.S. Department of Health and
Human Services (HHS). Reports based on information gathered through the Drug
and Alcohol Services Information System (DASIS) in 2002 indicated that treatment
admissions for prescription narcotics grew from approximately 12,500 in 1992 to
42,900 in 2002. Treatment admissions are those reported to SAMHSA’s Treatment
Episode Data Set (TEDS). In 2002 there were 1.9 million treatment admissions
reported to TEDS, 4% of which cited prescription and OTC drugs as the primary
substances of abuse (Office of Applied Studies [DASIS], 2005a). Although the
DASIS reports are helpful in identifying some trends of drug abuse involving
prescription drugs, the studies do not collect data on what portion of the drug abuse
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statistics are directly due to drug diversion. The bulk of the TEDS admissions list the
primary substances o f abuse as illegal drugs and alcohol.
Testimony given by Dr. Ernest Cantley of the Stewart-Marchman Center in
Daytona Beach, Florida, provided admission trends for the Center for Abuse of
prescription drugs (Cantley, 2004). Statistics for the Center were used to substantiate
Cantley’s statement that misuse and abuse of prescription drugs is increasing.
Although his data showed a 260% increase in admissions for abuse of all prescription
drugs between 2001-2003, the numbers are small (from 152 to 402 admissions). And
although Dr. Cantley stated that “Our most significant problem is the abuse of
prescription opiates in general and the drug OxyContin in particular,” the admission
numbers do not support his characterization of a “significant problem.” Admissions to
the Center with OxyContin as the primary problem were zero in 2001, 6 in 2002 and
26 in 2003, not large enough numbers to be significant, although Cantley testified that
this was a “disturbing trend.” As mentioned in other studies in this chapter, the
Center’s admissions do not distinguish between drug abuse and drug diversion. In
addition, the statistics were not controlled for increased marketing of the Center,
cost/reimbursement issue improvement for such admissions, and a decrease in such
admissions in other nearby treatment locations. Once again the data presented have
limitations when used to discuss the extent of the drug diversion problem.
One o f the concerns with the collection and reporting of data related to drug
diversion is the inconsistent collection of such data across the United States. No
national parameters for such collection have been established, and even the DAWN

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

67
data which have been collected for several years point to inconsistency in the
reporting o f cause o f death from drug abuse. The practice standards for attributing
cause o f death to drug abuse can vary from state to state and even county to county,
since cause of death is a decision of the medical examiner or coroner. Narrowing the
cause o f death to distinguish diversion of prescription drugs is not even attempted.
The state o f Florida, which publishes an annual Report on Drugs through the Medical
Examiners Commission and the Florida Department of Law Enforcement, stated in its
2000 Report that “A drug was listed as having "caused” death [italics mine] when the
medical examiner, after considering the circumstances, autopsy findings and
toxicology findings, made the opinion that the drug was intoxicating” (Florida
Department of Law Enforcement, 2003, p. ii). Thus, the cause of death is an educated
opinion, based on some pre-set standards, which may or may not apply to the
individual involved. As a result of these difficulties in identifying accurate drug abuse
statistics, it appears to be much more difficult to identify drug diversion, a subset of
drug abuse, with any accuracy.
However, even in the absence of clear guidelines, there is evidence as
indicated in this section, that drug diversion is occurring, and probably increasing.
Florida, through its Office of Drug Control (FODC) is one of the few states with
extensive studies on drug abuse and selected studies on drug diversion. The program
to determine the extent of abuse and diversion in Florida began in 1999, and the data
collection and analysis has become more refined each year since. Florida now requires
medical examiners to more clearly identify drugs that cause death as differentiated

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

68
from deaths where drugs were present. The NSDA was expanded for Florida at the
state’s request, to gain a better picture of drug abuse for those age 12 and over.
Florida has gathered an extensive set o f statistics on drug abuse and developed a
comprehensive plan to address drug abuse. The diversion of legal drugs is discussed
in the plan, but the plan provides no clear statistics on the extent of drug diversion in
Florida. Furthermore, it cannot specify a trend in diversion other than to state that
“The illegal diversion o f prescription drugs has become a significant problem in
Florida” with no documentation provided (Florida Office of Drug Control, 1999,
pp. U-3 l-U-32). Statistics used by the FODC to suggest an increasing trend in drug
diversion are often related to the use of OxyContin and other Schedule II drugs,
which may not support the claimed increase in diversion. For example, in 2002
Florida reported 589 deaths where oxycodone was in the system. Annualizing the first
6 months’ data for the same statistic in 2003 produces 584 deaths with oxycodone
present, which is actually a slight reduction in oxycodone presence. This, however, is
just a small snapshot of the issue of drug diversion, which has not been reliably
measured by any study.
In testimony to the Subcommittee on Criminal Justice, Drug Policy and
Human Resources, FODC Director McDonough stated that “Florida has a serious
problem with illegal prescription drug diversion and abuse” (McDonough, 2004,
p. 1). As with other reports already analyzed, the statistics used to verify drug
diversion are generally those establishing drug abuse, but not necessarily abuse that is
the result o f drug diversion. Statistics used in McDonough’s testimony were not
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linked to any studies for verification; however, statistics such as 3,324 deaths in
Florida in 2002 were caused by prescription drugs, and 5 Floridians die per day solely
from prescription drug overdoses were provided in the testimony, without any
reference to the analysis generating such statistics. The testimony does concede the
lack of clear data when it reports that the Florida Grand Jury Report on Medicaid
recipient fraud indicated that “it is almost impossible to know the true extent o f the
prescription drug abuse problem because so much o f the problem goes unreported”
(McDonough, 2004, p. 4). The testimony also states that drug diversion activity is
complex; diversion can be a simple resale of a prescription on the street to wholesale
doctor shopping, pharmacy shopping, pharmacy theft, theft from nursing homes and
other institutions, or doctor/pharmacist arrangements, to organized crime
(McDonough, 2004, p. 3).
Director McDonough does cite a few cases of drug diversion that have
resulted in criminal investigations and penalties. One physician case resulted in a
conviction, another in an arrest, another in practice sanctions, and a fourth physician
was charged with manslaughter as of the date of the referenced testimony. The
conviction and arrest were both linked to oxycodone investigations. Also cited in the
testimony was a series of articles by the Orlando Sentinel regarding fraudulent
prescribing of drugs to Medicaid patients (McDonough, 2004, pp. 5-6). This series
was also linked to oxycodone abuse and was often quoted, but the Sentinel was
forced to retract its accusations directed at OxyContin at a later date. An interesting
comment from McDonough’s testimony was related to other causes of drug abuse.
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He stated “that it may not be illegal diversion alone that contributes to the extent of
the problem. It may also be fed by inappropriate degrees of classification and
education” (p. 6). He also stated, “according to the Florida Medical Examiner’s
reports, the majority o f drug-related fatalities occur from a lethal cocktail o f several
drugs” (p. 7). It is noted that not all the drugs in the cocktail are prescription drugs,
with alcohol being the most common drug in the mix across the cases. The testimony
includes a final statement emphasizing that drug abuse has multiple causes, only one
o f which is diversion of drugs (p. 9).
In a study done for Michigan Governor John Engler in 2001, the Michigan
Commission on End of Life Care presented its analysis of possible drug diversion
problems from the perspective of how investigations of such activity might affect pain
management. The Commission concluded that Michigan had policies and programs
that “impaired the delivery of quality pain care for Michigan citizens,” and named the
Official Prescription Program (a PMP) as one of those programs. Further, the
Commission found that this program, directed at reducing diversion of Schedule II
drugs, was ineffective, and that the amount of drug diversion the program had
identified in its 10-year history was minimal. The Report stated that of the 192,000
licensed medical practitioners in Michigan in 2000, only eight cases of drug diversion
had occurred (Thomason, 2001, p. 22). No source was provided for that statistic. The
Report, targeted at improving pain management at the end of life, did not feel the
incidence of drug diversion was significant enough to warrant the continuation of
policies such as Michigan’s OPP.
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The common theme in all o f the literature reviewed on the specific topic of
drug diversion was that it was difficult if not impossible to quantify, and the default
quantifier was drug abuse, which is a much broader problem than drug diversion. Also
and importantly, all studies that looked at both abuse and diversion reported concerns
with polydrug use—the presence of more than one strong drug in the abuse mix. In
spite of the inability to more clearly identify drug diversion, 16 states had
implemented full PMP programs by 2001 to help reduce and even prevent diversion.
In light of the lack of good statistics which identify a significant increase in drug
diversion and studies that support the role of public policies in preventing such
activity, the benefits of more research regarding effectiveness and cost justification of
PMPs seem clear.
Summary
Although the issues of pain management, prescription monitoring programs
and drug diversion are reviewed in separate sections in this chapter, the topics are
clearly connected. Studies of one of the three topics often mention at least one of the
other two areas, and sometimes both. In general, the studies agree that people with
severe chronic and acute pain conditions deserve to receive the best treatment
available. The studies and reports also tend to agree that the diversion of legal drugs
to illegal use is increasing. More credibility is given to the fact that drug abuse is
increasing. The definition of drug abuse includes but is certainly not limited to drug
diversion. Finally, PMPs are believed by many to be effective, but there is little
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evidence in the literature to support such a belief. PMPs are also believed to be a
barrier to good pain management, another assumption without credible evidence.
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CHAPTER III
METHODOLOGY
This research consists of a qualitative case study and a quantitative analysis in
the form of a multiple regression, in the belief that both research methods will allow
for stronger conclusions than either study alone. This chapter will describe the
development of the two study processes and reveal some of the unexpected barriers
to the research that were imposed by actors within the regulatory and health care
system in finalizing the design of the study.
The desirable goals of prevention of drug diversion and abuse even while
continuing to assure the availability of appropriate drug therapies for pain
management appear to be incompatible to many. This inference could be drawn from
much of the literature reviewed for this research. Stated simply, those in law
enforcement who are addressing the prevention of drug diversion and the larger arena
of drug abuse are focused on that issue, and by virtue of their profession, generally
pay less attention to the delivery of good pain management treatment. Those in the
business of treating pain often tend to consider laws and regulations that address drug
diversion to be barriers to good pain management, and correspondingly find
enforcement activities to identify and prosecute suspected diversion to be a problem.
Although leaders on both sides of the argument have publicly indicated a desire to
collaborate (American Alliance of Cancer Pain Initiatives, 2001), in actual practice
73
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collaborative efforts are not widespread and there is no formal national plan for such
collaboration. This research methodology was designed to provide a more in-depth
look at whether prescription monitoring programs to track and prosecute the illegal
diversion o f legal drugs are an effective tool in addressing that goal, or if such policies
are overrated in their effectiveness, and serve to create policy that consumes public
and private resources with little effect on the problem. The research design also
includes a qualitative component in the form of a case study to determine if such laws
encourage the under-treatment of pain.
Quantitative Methodology
The quantitative analysis draws its conclusions from the review of selected
statistics from 15 states, during the 4-year period, 1998-2001. Seven o f these states
operated controlled prescribing programs during the study period, all of which
imposed state regulations on the prescribing and use of Scheduled drugs. The
controlled prescribing programs for these 7 states were adopted and implemented by
1997, with one exception. The states selected for this group are California, Illinois,
Massachusetts, Michigan, New York, Texas, and Washington. The other 8 states had
no controlled prescribing laws operating during the study time period. Those states
are Colorado, Florida, Georgia, Louisiana, Maryland, Minnesota, Missouri, and
Pennsylvania. The population in these 15 states represents approximately 60% of the
U.S. population over the study years; thus, a majority of the nation’s citizens are
included in the states selected for study.
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All 15 o f the states are included in the DAWN network o f data collection and
reporting, a rich source of information on drug-related emergency department visits
for a majority o f the population in each o f the selected states, and the source of data
used as the dependent variable in the multiple regression analysis. DAWN statistics
are used as the dependent variable for the study, and are covered in depth in that
section of this chapter.
Initially, it was the intent to limit the quantitative analysis to the diversion of
legal drugs classified under Schedule II o f the DEA’s drug classification system. This
decision was made for two primary reasons. First, because drugs in this class are the
most addictive, they have the highest potential to be sought for recreational and other
illegal purposes, and are thus the most regulated drugs. Second, this class of drugs
contains opioids, which are the drugs of choice for the treatment of severe, hard-tomanage pain, widely recognized as such by the medical community in the United
States and by the World Health Organization. Therefore, Schedule II drugs have a
role in drug diversion as well as treatment of pain.
As the research progressed, it was determined that the study needed to include
some discussion o f drugs in other Scheduled classes, because the issues with drug
diversion were far more complicated than would be apparent if the study were limited
to an analysis of Schedule II drugs alone. For example, in some states the prescribing
o f Schedule III drugs increased when more regulations were imposed on Schedule II
drugs (Wastila & Bishop, 1996, p. 4). In addition, the proxy selected to measure drug

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

76
diversion in the multiple regression included some Schedule III and IV drugs, and it
would have been impossible to use that proxy without the inclusion of such drugs.
Identification o f Dependent Variable
Several potential variables were reviewed for inclusion in the development of
the multiple regression used in the quantitative part of the analysis. The first challenge
was to identify a variable that would represent the level of drug diversion in the areas
o f study. As was evident in the literature review, there are no data available that
clearly measure drug diversion, specifically on a state-by-state basis. Initially, several
potential sources of data were considered for use in creating a variable that would be
representative of drug diversion. Deaths caused by drug diversion were considered as
one of the data pieces. However, the means of collecting and reporting such deaths
varies from state to state, and even county to county, with no credible consistency
across the geographic areas in the study. One of the difficulties with death statistics
related to drug diversion is the fact that death from illegal use of prescription drugs
seldom occurs in isolation. Most drug-related deaths report the presence of multiple
drugs in the patient’s body, some of which may be illegal drugs (cocaine, marijuana,
and similar substances) and legal drugs such as alcohol as well as prescription drugs.
In fact, it may be the very combination of drugs that caused the death, not any single
drug in isolation. Additionally, it was determined that the reporting of cause of death
can be very inconsistent across counties and the country as a whole. A variable that
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measures deaths caused by the diversion of prescription drugs was thus not available
and received no further consideration.
Another factor considered in building the dependent variable was arrests and
convictions for drug diversion activity. It was felt that an assumption could be made
to connect the increase in such activity to an increase in drug diversion. The effort to
obtain arrest and conviction information included seeking such data from the DEA,
from local law enforcement records, and from state law enforcement files. Research
into this statistic revealed that the attention to drug diversion activity varied
extensively from location to location, and the state and local data were determined to
be without consistent credibility. DEA statistics, however, were more consistently
reported, so extensive efforts were made to obtain DEA statistics on arrests and
convictions for drug diversion. Arrests were considered relevant, even if no
conviction occurred, due to the practice of settling cases out of court. In considering
the inclusion of arrests data, it was assumed that several arrests that did not result in a
conviction were actually legitimate drug diversion cases, but a number of factors
prevented the case from going to the full conviction stage.
The attempt to obtain arrest and conviction data from the DEA involved an
interesting, lengthy process. There are 20 state DEA Field Offices plus a Field Office
in Washington DC. Each Field Office covers several states or a large area. For
example, the Detroit Field Office covers activity in Michigan, Ohio, and Kentucky.
The Miami Field Office covers the Bahamas as well as Florida. In addition to the state
offices, several states such as Florida have District Offices in other selected areas
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throughout the state. Eighteen of the DEA Field Offices are involved in the 15 states
included in this study. A listing of the DEA Field Offices and coverage areas are
included in Appendix D.
In addition to asking for arrest and conviction data for drug diversion from the
DEA, data on pharmacy theft and loss were also requested as a probable indicator of
drug diversion, to be either included as an independent variable or as a control in the
multiple regression equation development. An increase in pharmacy theft and loss
would logically result in an increase in drug diversion, since drugs are stolen for illegal
(that is, diverted) purposes. In seeking this data, an assumption was made that
pharmacy theft and loss resulted in diversion in the same state where the pharmacy
was located. Pharmacy theft and loss data are required to be reported to the DEA, on
DEA form 106, and are authorized by the Controlled Substances Act of 1970.
The process to request the arrests, convictions, and theft and loss data was
made to the DEA on an informal basis in early July 2004, followed by a full Freedom
of Information Act (FOIA) request on July 19, 2004. Through a lengthy process
which included repeated contacts with DEA staff and requests for assistance from
Florida’s Congressman Allen Boyd and Senator Bill Nelson, the DEA repeatedly
refused to provide the requested information. However, one year of theft and loss
data were provided by the DEA, probably accidentally, and will be discussed in the
analysis and results chapters. During the FOIA process, each of the DEA Field offices
was individually contacted by phone, or mail or email if requested, for arrest and
conviction information, and three Diversion Program Managers provided the
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requested data for four states, willingly and with little concern. However, as the
remaining Diversion Control Managers were contacted, the flow of information was
blocked, with one Manager reporting that the “word from DC” was that statistics
could not be released by the Managers, and they were prohibited from releasing any
data directly to the researcher. Subsequent contacts with the DEA confirmed that the
statistics desired for the dependent variable would not be available in a timely manner
for this study. DEA contact information is provided in more detail in Appendix D.
DAWN Data
Although certainly not ideal, it was finally concluded that the most reasonable
data available for measuring drug diversion came from the set of statistics gathered
and analyzed by the Drug Abuse Warning Network, or DAWN. As required under
Section 505 of the Public Health Services Act, the federal Substance Abuse and
Mental Health Services Administration (SAMHSA) is the agency responsible for
DAWN, and collects data on Emergency Department (ED) visits induced by or
related to substance abuse, which includes abuse of both legal and illegal drugs. The
DAWN program relies on a sample of hospitals in 21 major metropolitan areas
(MSA’s or metropolitan statistical areas) to submit such information. DAWN has
been collecting data using this design since 1988, with earlier data collected since
1972. DAWN collects and reports data both by Drug Episode and Drug Mention, as
defined below.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

80
Drug Episode: A drug-related ED episode is an ED visit that was induced by
or related to the use of an illegal drug(s) or the non medical use o f a legal drug
for patients aged 6 to 97 years.
Drug Mention: A drug mention refers to a substance that was recorded
(“mentioned”) during a drug-related ED episode. Because up to four drugs
(and alcohol) can be reported for each drug abuse episode, there are more
mentions than episodes cited in this report. (U.S. Department of Health &
Human Services, 2003, p. 25)
This is an important distinction when using DAWN statistics, since each drug episode
by definition can contain more than one drug mention. One reported visit can thus
include up to four drug mentions plus alcohol. Because this distinction is not always
provided, the reporting of drug abuse can be misinterpreted. For example, one
patient’s visit to the ED could be reported as five mentions if four drugs and alcohol
were present. It should also be noted that some drugs are not reported at all, if more
than four and alcohol are found in the examination, as only the four most dominant
are then reported. In this research, drug episodes are used in the design of the
dependent variable for the study—Drug Diversion (DD).
DAWN data are collected by a DAWN designated “reporter” in each selected
hospital in an MSA. This reporter reviews the medical records for each reportable
episode. The patient is not required to be interviewed for data collection purposes and
in fact may be unconscious or deceased. The patient must meet five criteria to be
included in the DAWN report. The patient must be between 6 and 97 years of age,
receive treatment in the hospital’s ED, and indicate that the visit to the ED was
induced or related to drug use. The episode must also involve the use of an illegal
drug, or a substance used illegally, and the patient’s reason for using the substance(s)
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must have been dependence, suicide attempt or gesture, or psychic effects. The data
are reported by metropolitan area. It uses sampling weights and produces estimates
representing all ED drug episodes and drug mentions in the total coterminous U.S.
Statistics from the DAWN data that were used to create the dependent
variable, Drug Diversion, are the estimates of drug episodes and drug mentions for
psychotherapeutic agents and for narcotic analgesics and narcotic analgesic
combinations. These categories were selected due to the number of Scheduled drugs,
especially Schedule II and III drugs that are included. DAWN does not report state
statistics based on the Controlled Substances Act Schedules, so it was impossible to
limit the quantitative portion of this study to Schedule II drugs. DAWN defines drugs
in each of these categories as follows.
Psychotherapeutic agents are divided into the following categories:
• Antidepressants
- MAO Inhibitors
- SSRI antidepressants
- Tricyclic antidepressants
- Miscellaneous antidepressants
• Antipsychotics
- Phenothiazine anitpsychotics
- Psychotherapeutic combinations
- Thioxanthenes
- Miscellaneous antipsychotic agents
• Anxiolytics, sedatives, and hypnotics
- Barbiturates
- Benzodiazepines - this category excludes the benzodiazepine
flunitrazepam (Rohypnol), which was assigned to major substances
of abuse.
- M iscellan eou s anxiolytics, sedatives, and hypnotics

• CNS stimulants. This category excludes the CNS stimulants that were
assigned to major substances of abuse: amphetamines, methamphetamine,
and MDMA (Ecstasy).
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* Narcotic analgesics and narcotic analgesic combinations—This category
excludes heroin, which is classified as a major substance o f abuse. This
category includes drugs reported to DAWN simply as opiates. (U.S.
Department of Health and Human Services, 2003, pp. 43-44)
Identification o f Independent Variables
As with the design o f the dependent variable, several statistics were
considered as independent variables. The presence or absence of a PMP was included
as an independent variable since it is a primary focus of this research. In addition, the
availability o f statistics reporting deaths from the use of scheduled drugs was sought.
It was determined that such statistics were not maintained consistently across the
states in this study, and they did not clearly identify Schedule II and other scheduled
drugs. Furthermore, death statistics themselves were very limiting and unreliable in
reporting cause of death, as indicated earlier in this chapter. Because identification of
controlled substances in the body can occur only through lab tests, there are certainly
unknown numbers of deaths where drug-related causes go unidentified. For example,
an individual who dies in a car accident without other suspicious evidence is likely to
be reported as death by accident, even if the accident may have been caused by
excessive use o f drugs. In this case, unless an autopsy or other testing occurred, the
presence of drugs may never be revealed.
Another possible statistic was the use or availability of Schedule II drugs, as
measured by the DEA through their quota and distribution monitoring system. This
information was initially considered because review indicated that the more a
controlled substance was used in practice, the more likely it would be abused. As
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Angarola and Joranson (1992) put it, “Experience has shown that the more a
controlled substance is used in medical practice, the more it will appear in monitoring
systems such as the Drug Abuse Warning Network.” Additionally, the statistics are
available on a state-by-state basis. In considering these data, it was assumed that a
statistically significant increase in availability of strong medicines would also produce
an increase in drug diversion. Use data, however, were rejected for the regression,
because of the inability to factor in loss and theft data, and because the data were
reported differently from the data used for the dependent variable. Quotas and
production allowances are maintained by specific drug and chemical names, and not in
the categories used by the DAWN program.
An increase or decrease in disease prevalence was another factor considered
to independently increase or decrease the availability of medications and thus the
opportunity to divert and use such medicines illegally. Initially, an increase in hospice
patients, traditional users of strong drugs in the Schedule II and III categories, was
reviewed for use; however, such numbers were not available in a reliable manner for
all of the sample states during all the years of the study. Changes in the prevalence of
diseases and diagnoses of conditions likely to increase the usage of Scheduled drugs
(pain conditions, severe mental illness, painful cardiovascular and respiratory
conditions) were also considered for use as independent variables, but accurate data
in these categories were either not available at all, or not available in a reasonable,
consistent format and timely manner. It is also difficult and seemingly impossible to
extract such information from medical records, because many people with a chronic
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illness have multiple medical problems and multiple physicians, and the prescribing of
drugs cannot always be assigned to a certain disease with any supportable accuracy.
Cancer statistics, however, were available by state for the study period, and
were selected as an independent variable as representative of disease increase or
decrease. Cancer pain is widespread among cancer patients, and drugs in the
controlled substances categories, especially Schedules II and III, are often used to
control cancer pain along with related symptoms and side effects. The American
Cancer Society maintains statistics by year and by state for a number of cancer-related
categories. For this study, the ACS statistics on new cancer case by state was used as
an independent variable.
Demographic data were considered in various combinations, including age,
income, and education. After review of the characteristics of drug diverters and
abusers, it was determined that such information was not a predictor of drug
diversion, as such activity occurs within a wide range of different population
characteristics. However, population growth or decline as a whole was considered a
reliable and relevant independent variable and is used in the regression equation. The
assumption incorporated into the use of population is that an increase in population
will result in an increase in diversion activity. Population statistics were obtained from
the U.S. government census website.
M odel Specification
The regression equation is >>= a + biXi + e, where
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y = drug diversion.
X \ = POP, population as taken from the U.S. Census figures and interim
estimates.
X i = NEWCAN, new cancer cases per 100,000, as provided by the American
Cancer Society, Cancer Facts and Figures, 1998-2001.
X 3 = Absence or presence of a state PMP. Those states with a PMP are coded
as 1; those states without a PMP are coded as 2.
A ^-intercept is included in the equation, because it is assumed that there would
always be some drug diversion occurring, regardless of any action by government and
other factors. Each of these variables is discussed below, with the limitations and
assumptions presented.
Dependent Variable—Drug Diversion
In order to measure drug diversion in a format that was compatible with
population and new cancer cases, it was necessary to re-configure the DAWN
statistics for each of the 15 states in the study with reference to the number of visits.
Each state’s MSA DAWN reports were analyzed for each of the years of the study, a
total of 60 DAWN reports. It was determined that some assumptions would need to
be made to estimate the number of drug-related ED visits for drugs relevant to this
research, if the DAWN statistics were used. The assumptions are covered later in this
section; however, in the development of DAWN “visit” statistics, it is helpful to know
that it is assumed that only one visit per person occurred during each study year.
DAWN reporters collect data on a number of factors, including the number of
episodes reported each year and the number o f mentions per year. For each episode,
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there could be up to four drugs recorded per patient plus alcohol. Since only the
episodes in the MSA hospitals are included, it was necessary to convert the MSA
episodes to an estimate of the number of visits to the ED projected for the entire
state.
Using SAMHSA statistics for MSA populations and DAWN MSA “mentions”
for the same year, “mentions per 100,000 population” for the MSA area were
calculated. DAWN also reports raw data on “mentions” and “episodes” for all
DAWN drug categories, not just the categories used in this study. The number of
annual “mentions” of the study’s selected drugs for each state was divided by the
number of episodes to obtain the average number of mentions per episode. Stated
another way, these calculations provided the number of drugs present per ED visit.
This statistic was then divided into the DAWN number for “mentions per 100,000
population in the MSA area” to obtain visits per 100,000 MSA population. The
number of visits per 100,000 in the MSA area was then projected over the full state,
using census figures for the years of the study. Tables 2-5 contain the statistics and
calculations used to determine the estimate of ED visits related to psychotherapeutic
agents and narcotic analgesics/combinations that were used as the dependent variable
in the multiple regression. The first seven states in each table are states with a PMP
operating during the study period. The other eight states did not have a PMP in place
during those years.
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Table 2
1998 ED Visits for States—Selected Controlled Substance DAWN Categories:
Psychotherapeutic Agents and Narcotic Analgesics/Combinations
1998
mentions/
100,000
popMSA only

1998 pop/
100,000state

California (SF, LA, SD-averaged)

106

326.83

Illinois (Chicago)

104

Massachusetts (Boston)
Michigan (Detroit)

mentions
ID
="Visits"
1998

Visits X C
= total
visits for
state 1998

1.55

68.82

22,492

120.70

1.84

56.52

6,822

189

61.44

1.82

103.85

6,381

138

98.20

1.87

73.80

7,247

69

181.59

1.70

40.59

7,371

Texas (Dallas)

141

197.12

1.86

75.91

14,944

Washington (Seattle)

167

56.88

1.67

100.00

5,688

State

New York (NY & Buf-averaged)

TOTAL

Colorado (Denver)

1998
mentions/
episode

1,042.76

70,945

105

38.91

1.76

59.66

2,321

Florida (Miami)

82

149.08

1.67

49.10

7,320

Georgia (Atlanta)

136

76.36

1.88

72.34

5,524

Louisiana (New Orleans)

156

43.63

1.90

83.68

3,651

Maryland (Baltimore)

152

51.30

1.71

88.89

4,560

Minnesota (Minneapolis)

107

47.26

1.87

57.22

2,704

Missouri (St. Louis)

118

54.38

1.88

62.77

3,413

Pennsylvania (Philadelphia)

204

120.02

1.89

107.94

13,256

TOTAL

580.94

Note. Emergency Department Trends from DAWN. Final Estimates 1998-2001.
Source: SAMHSA DHHS-OAS D-24
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Table 3
1999 ED Visits for States—Selected Controlled Substance DAWN Categories:
Psychotherapeutic Agents and Narcotic Analgesics/Combinations
1999

mentions/
State

100,000
pop - MSA
only

1999 pop/
100,000state

1999
mentions/
episode

mentions

Visits X I

/D
1999

= total
visits for
state 1999

="Visits"

California (SF, LA, SD-averaged)

113.33

331.45

1.51

75.05

24,875

Illinois (Chicago)

107.00

121.28

1.83

58.47

7,091

Massachusetts (Boston)

163.00

61.75

1.82

89.56

5,530

Michigan (Detroit)

133.00

98.64

1.87

71.12

7,015

81.50

181.97

1.72

47.38

8,622

Texas (Dallas)

123.00

200.44

1.58

77.85

15,604

Washington (Seattle)

159.00

57.56

1.64

96.95

5,580

New York (NY & Buf-averaged)

TOTAL

Colorado (Denver)

1,053.09

74,317

121.00

40.56

1.71

70.76

2,870

82.00

151.11

1.70

48.24

7,290

Georgia (Atlanta)

137.00

77.88

1.91

71.73

5,586

Louisiana (New Orleans)

141.00

43.72

2.00

70.50

3,082

Maryland (Baltimore)

164.00

51.72

1.75

93.71

4,847

Minnesota (Minneapolis)

110.00

47.76

1.93

56.99

2,722

Missouri (St. Louis)

121.00

54.68

1.85

65.41

3,577

Pennsylvania (Philadelphia)

194.00

119.94

1.87

103.74

12,443

Florida (Miami)

TOTAL

587.37

Note. Emergency Department Trends from DAWN: Final Estimates 1998-2001.
Source: SAMHSA DHHS-0AS D-24
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Table 4
2000 ED Visits for States—Selected Controlled Substance DAWN Categories:
Psychotherapeutic Agents and Narcotic Analgesics/Combinations
2000
mentions/
100,000
pop - MSA
only

2000 pop/
100,000state

California (SF, LA, SD-averaged)

112

338.72

Illinois (Chicago)

113

Massachusetts (Boston)
Michigan (Detroit)

mentions
/D
="Visits"
2000

Visits X O
= total
visits for
state 2000

1.64

68.29

23,131

124.19

1.83

61.75

7,669

183

63.49

1.74

110.47

7,014

141

99.28

1.92

73.44

7,291

93

189.76

1.74

53.45

10,143

Texas (Dallas)

131

208.51

1.83

71.58

14.925

Washington (Seattle)

219

58.94

1.71

128.07

7,548

State

New York (NY & Buf-averaged)

TOTAL

2000
mentions/
episode

1,082.89

77,721

Colorado (Denver)

117

43.01

1.73

67.63

2,909

Florida (Miami)

101

159.82

1.74

58.05

9,278

Georgia (Atlanta)

127

81.86

1.97

64.47

5,278

Louisiana (New Orleans)

153

44.69

1.97

77.66

3,471

Maryland (Baltimore)

155

52.96

1.73

89.60

4,745

Minnesota (Minneapolis)

121

49.19

1.94

62.37

3,068

Missouri (St. Louis)

137

55.95

1.93

70.98

3,971

Pennsylvania (Philadelphia)

204

122.81

1.90

107.37

13,186

TOTAL

610.29

Note. Emergency Department Trends from DAWN: Final Estimates 1998-2001.
Source: SAMHSA DHHS-0AS D-24
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Table 5
2001 ED Visits for States—Selected Controlled Substance DAWN Categories:
Psychotherapeutic Agents and Narcotic Analgesics/Combinations
2001
mentions/
100,000
pop - MSA
only

2001 pop/
100,000state

California (SF, LA, SD-averaged)

126

345.33

Illinois (Chicago)

150

Massachusetts (Boston)

mentions
ID
="Visits"
2001

Visits X U
= total
visits for
state 2001

1.68

75.00

25,900

125.17

1.77

84.75

10,608

233

64.00

1.77

131.64

8,425

Michigan (Detroit)

193

100.05

1.93

100.00

10,005

New York (NY & Buf-averaged)

116

190.75

1.69

68.64

13,093

Texas (Dallas)

122

213.41

1.86

65.59

13,998

Washington (Seattle)

255

59.93

1.72

148.26

8,885

State

TOTAL

2001
mentions/
episode

1,098.64

90,914

Colorado (Denver)

118

44.28

1.72

68.60

3,038

Florida (Miami)

103

163.55

1.79

57.54

9,411

99

83.94

1.88

52.66

4,420

Louisiana (New Orleans)

182

44.66

1.89

96.30

4,301

Maryland (Baltimore)

211

53.83

1.79

117.88

6,345

Minnesota (Minneapolis)

145

49.85

1.88

77.13

3,845

Missouri (St. Louis)

167

56.36

1.94

86.08

4,851

Pennsylvania (Philadelphia)

239

122.98

1.87

127.81

15,718

Georgia (Atlanta)

TOTAL

619.45

Note. Emergency Department Trends from DAWN: Final Estimates 1998-2001.
Source: SAMHSA DHHS-0AS D-24
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The above data were used to calculate the dependent variable, the proxy for
drug diversion. The total number of visits for each category of states for each year is
presented in Table 6.

Table 6
Visits for Each Category of States Per Year
1998

1999

2000

2001

PMP States

70,945

74,317

77,721

90,914

Non-PMP States

42,749

42,416

45,906

51,929

Category o f States

The numbers in each column represent the estimate o f total state ED visits for
psychotherapeutic agents and narcotic analgesics and narcotic analgesic combinations
as defined previously. The seven PMP states have a greater population than the eight
non-PMP states, which might explain the raw increase in number of visits and which
also supports the literature and the assumption that more people equals more drug
diversion. For example, the seven PMP states had an estimated total population of
approximately 110 million people in 2001 and a corresponding 90,914 ED visits in the
selected categories. For the non-PMP states, the population for 2001 was
approximately 62 million, with 51,929 ED visits.
It was necessary to make the following assumptions in using the DAWN
statistics for the dependent variable:
1.

Each episode or visit is unique. No individual visits the ED more than once

per year for drug-related reasons. There are no statistics available that would identify
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repeat visits by individuals in any given year for drug-related reasons. Intuitively,
there are probably some repeat visits, but an additional assumption is made that repeat
visits are small in number, are not significant, and would not significantly affect the
conclusions of this study.
2. DAWN statistics are collected by “reporters” at the selected hospital EDs.
Much of the information is collected by observation or review o f records. Although
patients can be interviewed for the reports, in general they are not; thus, the drugs
mentioned in the selected categories may not be “diverted” to recreational use. Drugs
found in the body at the ED could be there for legitimate medical reasons. Reports on
patients who are unconscious or dead upon arrival at the ED can be obtained only
from the medical records. Such records are subject to accurate recording by medical
personnel. For this portion of the research, it is assumed that such records are
accurate, and that the selected drugs as identified are present illicitly.
3. DAWN limited the number of drug mentions reported to four drugs plus
alcohol during the period of this study. For this study, it is assumed that these drugs
caused the ED visit. Furthermore, it is assumed that the prescription drugs that
caused the visit were diverted from approved medical uses—either they were
obtained illegally or used in larger doses than prescribed.
4. DAWN collects data only from selected MSAs, which are large urban
areas. It is assumed that conclusions drawn for DAWN data also apply to the rural
areas of the states in the study, and at the same levels.
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Independent Variables—Population, New Cancer Cases, and PMP
Three categories of data were used as independent variables for the regression
equation: population, new cancer cases, and the presence or absence of a PMP.
Population figures were obtained from the U.S. Census Bureau and can be accessed
from the Bureau’s website, www.census.gov. Population estimates were used for the
years 1998, 1999, and 2001, with actual census count figures used for 2000.
Estimates were used as calculated by the Census Bureau for July 1 of the study years.
An assumption was made that the mid-year estimates and the actual numbers for the
census count year of 2000 were statistically similar for use in this study.
The variable, New Cancer Cases, was obtained from the American Cancer
Society’s (ACS) publication, Cancer Facts & Figures for the selected years. This
statistic was chosen over the Centers for Disease Control’s (CDC) statistics on cancer
case counts by state, because it was assumed that New Cancer Cases would not be
duplicated in subsequent years, and that each new cancer case represented one new
person. The CDC data would include cancer cases that continue to be counted over
several years, with the inclusion of some of the same cancer patients in more than one
year. The ACS cancer data include all new cases for all sites, except non-invasive
cancers such as basal and squamous cell skin cancers and in-situ carcinomas except
urinary bladder. Chronic pain conditions often accompany cancer; thus, this variable
was added to the regression equation to measure the effect of changes in disease
prevalence in the diversion of the selected medications. Unlike other chronic diseases,
cancer statistics were available for the years of the study, on a state-by-state basis.
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New Cancer Cases thus becomes the proxy for increases or decreases in disease
conditions that require the use of controlled substances.
Table 7 on the next page contains the population data and New Cancer Cases
by state for each of the years o f the study.
The presence or absence of a PMP was included to measure the effect of this
type of prescription monitoring policy on the changes in drug diversion. Each of the
PMP programs for the seven PMP states in the study was considered to equally
influence drug diversion in its state, even though the parameters of the programs
differed somewhat from state to state. The primary differences were the controlled
substance category or categories that were covered by the state’s PMP, along with
the years the PMP had been in place. During the period of the study, the covered
drugs for the PMP study-states are as follows:
California:

Schedule II, since 1939

Illinois:

Schedule II since 1961

Massachusetts:

Schedule II since 1992

Michigan:

Schedule II since 1989

New York:

Schedule II and Benzodiazepines since 1972

Texas:

Schedule II since 1981

Washington:

Schedules II, III, IV, V since 1984 (for disciplinary
purposes only)

In the regression model, a state with a PMP was given a value of 1, and a non-PMP
state was given a value of 2.
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Table 7
Population and New Cancer Cases
1998-2001, by State
1998
Population

1998 New
Cancer Cases

1999
Population

1999 New
Cancer Cases

PMP States
California
Illinois
Massachusetts
Michigan
New York
Texas
Washington

32,682,794
12,069,774
6,144,407
9,820,231
18,159,175
19,712,389
5,687,832

113,300
58,100
31,500
44,900
83,600
77,500
24,100

33,145,121
12,128,370
6,175,169
9,863,775
18,196,601
20,044,141
5,756,361

112,300
56,800
31,700
44,200
83,100
77,400
23,800

Non-PMP States
Colorado
Florida
Georgia
Louisiana
Maryland
Minnesota
Missouri
Pennsylvania

3,891,293
14,908,230
7,636,522
4,362,758
5,130,072
4,726,411
5,437,562
12,002,329

13,200
88,100
28,300
20,500
22,900
19,600
28,100
68,800

4,056,133
15,111,244
7,788,240
4,372,035
5,171,634
4,775,508
5,468,338
11,994,016

13,300
88,000
29,100
20,300
22,600
19,400
27,900
66,600

2000
Population

2000 New
Cancer Cases

2001
Population

2001 New
Cancer Cases

PMP States
California
Illinois
Massachusetts
Michigan
New York
Texas
Washington

33,871,648
12,419,293
6,349,097
9,928,444
18,976,457
20,851,820
5,894,121

113,200
55,100
30,100
41,400
81,500
76,100
23,600

34,533,054
12,517,168
6,399,869
10,005,218
19,074,843
21,340,598
5,992,760

117,400
56,800
31,300
45,300
83,200
78,900
24,800

Non-PMP states
Colorado
Florida
Georgia
Louisiana
Maryland
Minnesota
Missouri
Pennsylvania

4,301,261
15,982,378
8,186,453
4,468,976
5,296,486
4,919,479
5,595,211
12,281,054

13,400
88,100
29,400
20,800
22,600
19,900
27,000
66,600

4,428,786
16,355,193
8,394,795
4,466,001
5,383,377
4,985,202
5,636,220
12,298,363

14,300
91,600
31,100
21,700
23,500
20,600
28,400
68,400

Note. Population data from U.S. Census, 1998-2001. New Cancer Cases from
American Cancer Society, 1998-2001.
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The statistical analysis of the variables was done using a multiple regression
format, using the SPSS computer program. Tests of statistical significance were run
to determine the effect of a PMP on drug diversion and to identify correlation issues
and reliability of the regression and the variables used. The results and their
implications are presented in the next chapter.
Qualitative Methodology
In addition to the quantitative analysis of the levels of diversion of controlled
substances, using DAWN statistics for the selected states, this research also includes a
qualitative case study to identify perceived effects of controlled prescribing laws on
drug diversion and pain management in Michigan and Florida. Michigan has operated
with controlled prescribing laws from 1989 to the present, with its laws modified in
2002. Florida has been without such laws, but the state’s legislature has considered
passage of a PMP for at least the last 3 years. In addition, the Florida Office of the
Governor includes an Office of Drug Control, which is focusing many of its resources
on the drug diversion issues in the state.
Seeking and comparing the opinions of professionals within these two states
with distinctly different policies for addressing diversion was considered a necessary
component of the study, to determine if the opinions and experience of those who
deal with these topics were consistent with the regression results from the quantitative
analysis. Additionally, the literature review indicated that the perceptions of barriers
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to pain management, addiction potential, and attitude towards drug abuse were a
factor in how these issues studied were addressed by clinicians in the states with and
without PMPs. Although it was beyond the scope of this study to conduct interviews
in all 15 states, the case study analysis provides some interesting insights and relevant
suggestions for further study.
The qualitative study consists of interviews with physicians, pharmacists, and
law enforcement officials in the two states. Thirty interviews were conducted over the
months of July through December 2004, with 15 subjects interviewed in each of the
two states. Of those subjects, 3 were pharmacists, 8 were physicians, and 4 were law
enforcement professionals in each state. Seven of the interviews were conducted by
phone, and 23 were conducted in person.
Subjects were selected based on my personal knowledge of the subjects, as
well as for access and credibility reasons. Subjects who were sought and not known
personally were referred to me by mutual professional friends. This method of
selecting the participants was considered important in obtaining frank opinions and
encouraging free discussion of the research subject matter. Nearly all of the originally
contacted subjects agreed to be interviewed, and the interviews were conducted at
times and places selected by the participants. The interviews generally lasted 30-45
minutes, with a few lasting over an hour. Participants were asked a series of openended questions, a copy of which they received prior to the interview. During the
interviews, additional questions were often added to the list, based on the comments
and responses provided. The interviews produced some very rich information on the
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subject of drug abuse and pain management, and allowed for the addition of many
insights from the perspective of those who deal with the issues on a daily basis as a
part of their jobs.
The general questions that were either asked of each participant or answered
by the participant without raising the question are provided below:
1. (For physicians and pharmacists) What, in your opinion, is the state
of pain management in your state?
(For law enforcement) What, in your opinion, is the state of drug diversion
in your state?
2. (For physicians and pharmacists) What influences prescribing
patterns for pain conditions—both chronic and terminal?
(For law enforcement) What influences prescribing that results in drug
diversion?
3. (For physicians and pharmacists) What factors influence the quality
of pain management in your state?
(For law enforcement) What factors influence the amount of drug
diversion of Scheduled drugs in your state?
4. (For physicians and pharmacists) How do laws and policy affect
drug diversion in your state, especially that of Schedule II drugs?
(For law enforcement) How does the activity to control drug diversion
affect pain management in (Florida) (Michigan)?
5. How do you think a PMP will affect drug diversion and pain
management if enacted in Florida?
OR
How does Michigan’s PMP affect drug diversion and pain
management in Michigan?
6. What can be done to decrease the diversion of legal drugs to illegal
use?
7. What can be done to improve pain management in (Florida)
(Michigan)?
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8. What data do we need to have available to address drug diversion
and measure the quality of pain management?
9. Would you like to add anything else?
Physicians were included as interview subjects because they are the primary
prescribers o f controlled substances and are the main resource for those seeking
treatment for pain. Physicians are thus prime contacts for the diversion of prescription
medicines, and with the exception of drugs that are lost or stolen, are a key access
point for drugs that are used illicitly. That may be innocent or intentional on the
physician’s part, but either way, they play an important role.
Pharmacists were interviewed to include perspectives on their role in helping
their customers understand pain medications, and advise on use. These participants
are also the final decision makers in filling prescriptions. Pharmacists are often in a
position to determine whether a prescription is legitimate, or is likely to fall into the
wrong hands, or is being obtained for illegal use. They can also tell whether a
physician’s prescribing patterns have changed significantly. One pharmacist with
whom I spoke during the early development of this research stated that he had been in
business long enough to know intuitively the prescribing patterns o f physicians who
sent patients to his pharmacy. If a prescription or a series of prescriptions were
presented that were significantly out of the ordinary for a particular doctor, the
pharmacist would be alerted, and either call the doctor or consider reporting him or
her. Pharmacists were also important to this research because they are likely to help
identify other issues that may affect diversion activity and good pain management.
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Law enforcement officials are included in the case study, because they brought
a perspective on the need to control drug diversion that was unlikely to be voiced by
the physicians and pharmacists. The law enforcement community sees the effects of
drug diversion much more frequently than most physicians and pharmacists, not only
on the users, but also on the friends and families of the users and indeed on the entire
community. The inclusion of law enforcement officials as participants brought an
additional perspective to the research, necessary to balance the perceptions of the
practitioner community concerned with restrictions on prescribing.
During the participant scheduling and interview process, only 2 subjects
declined to participate, and 1 other did not return phone calls. Nearly all of the
subjects willingly extended their comments beyond the 30-minute time frame
requested for the interview, and all expressed interest in the results of the research.
Analysis o f Interviews

The interviews were in-depth interviews of experts in their fields. The
interviews were recorded and transcribed by the researcher herself, to lend additional
understanding to the comments and perspectives provided. The transcribed interviews
were reviewed several times in the process of analysis of the information. Categories
of analysis based on the questions asked were used to group responses, as were
emergent categories that resulted from the interviews. The second edition of
Designing Qualitative Research by Catherine Marshall and Gretchen Rossman (1995)
and the second edition of Case Study Research Design and M ethods by Robert Yin
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(1994) were consulted to help organize the data and structure the analysis of the
interviews. The interviews were conducted as required by the Human Subjects
Institutional Review Board (HSIRB) of Western Michigan University.
The results of the qualitative research are considered together with the
quantitative findings in drawing conclusions from the research. The qualitative study
results provide a perspective on pain management and drug diversion from
professionals who work in PMP and non-PMP states. The results are presented
anonymously as required by HSIRB protocols.
A limitation of the qualitative research is that the participants were selected by
the researcher rather than randomly selected. Although this assured that participants
had knowledge of the topics and were able to address the research questions, it may
have created a bias. Another limitation, already mentioned, is that participants were
selected from only 2 of the 15 states in the study, so the results of the case study
cannot be projected to the other states.
Results of the quantitative and qualitative parts of this research are presented
in the next chapters, as separate analyses and in combination to provide reinforcement
and add credibility to the research conclusions.
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CHAPTER IV
FINDINGS, QUANTITATIVE ANALYSIS
Development of Regression Components
In reviewing the results of the data analysis, it is important to note again that
there are no data that accurately measure the level of drug diversion in any state or
the country as a whole. Drug diversion is hard to quantify using currently available
information. The definition of drug diversion is also repeated as a reference in
reviewing the results of the quantitative analysis. For the purposes of this study, drug
diversion is defined as the illegal use of legal prescription drugs. This activity is not
easy to quantify, since much happens in clandestine settings which are never known,
much less investigated. Data on the abuse of legal prescription drugs—even
controlled substances—are not collected in a consistent manner across the country.
There are many cases where legal drugs are used illegally that are not captured and
may never be captured in any reasonably accessible manner, and it is logical to assume
that there are cases of suspected and possibly prosecuted drug diversion that are in
fact the legal use o f a controlled substance that went awry due to drug interaction or
other environmental or individual circumstances. Because of the difficulty in
collecting data to measure drug diversion, the statistical analysis used to test the
influence of independent variables on the proxy used for drug diversion did not
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produce substantial conclusions. However, it did provide some interesting insights
that were reinforced by the qualitative analysis that is also a part of this research.
The multiple regression mode of analysis was used to determine the potential
influence and functional relationship of selected data on the prevalence o f drug abuse
in the 15 states chosen for the study. This type of analysis uses mathematical methods
to determine the extent of such relationship between variables. Correlation analysis
was also employed to determine possible associations between two sets of data.
Correlation differs from regression analysis in that the finding of a correlation
between sets of data or factors does not imply a functional relationship. This is an
important distinction, because a functional relationship implies a “cause and effect”
environment, which then suggests the possibility of control of that environment. On
the other hand, data or factors that are correlated may not create an influence; they
are just frequently found together. Using professional football as an illustration, great
fan support is often associated with a winning football team. However, great fan
support does not make a football team win. So even though the two factors are
usually associated with each other, a high level of fan support does not function to
make a winning team. There is no cause and effect of significance.
In the search for data to address the research question, it was hypothesized
that there would be no significant difference in the amount of drug diversion in the 15
study states during the years of the study, regardless of the presence or absence of a
prescription monitoring program (PMP), and that in fact the increase or decrease in
drug diversion was not caused by the presence or absence of public policy designed to
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influence diversion activity. The data search included a review of numerous variables
and data sources, as already discussed in depth in the methodology section. The
selected data for the 15 states over the 4 years of the study were entered on a table
using the statistical analysis program SPSS version 8.0. They are presented in Table 8
on the following pages. The dependent variable entitled “visits” in the table is the
proxy value for drug diversion, and was calculated from DAWN (Drug Abuse
Warning Network) statistics for the 15 states during the years of the study (19982001). Visits refers to the number o f drug-related individual visits to emergency
departments during the time period of the study. Only drug-related visits for the
specific, controlled substance categories of psychotherapeutic agents, narcotic
analgesics, and narcotic analgesic combinations as described in the methodology
chapter were used. Statistical analysis was done using a multiple regression program
within the SPSS software program.
The initial regression computation was run using all three of the final selection
of independent variables—population, new cancer cases, and the presence or absence
of a PMP. Population was selected as one of the independent variables to determine
the effect of a growth in population on an increase or decrease in prescription drug
diversion. There is a belief by some that drug diversion is primarily a function of the
number of people in the country. This will be discussed in the section which reports
the findings from the interviews conducted as a part of this research. New cancer
cases were selected as a proxy for an increase or decrease in disease prevalence. The
treatment of cancer is likely to include strong pain medications, so an increase in
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Table 8
Values—Dependent and Independent Variables,
15 Study States, 1998-2001 (N= 60)
Visits
(Dependent
Variable)

Population1

New Cancer
Casesb

PMP°

State

22,492
6,822
6,381
7,427
7,371
14,944
5,688
2,321
7,320
5,524
3,651
4,560
2,704
3,413
13,256

32,682,794
12,069,774
6,144,407
9,820,231
18,159,175
19,712,389
5,687,832
3,891,293
14,908,230
7,636,522
4,362,758
5,130,072
4,726,411
5,437,562
12,002,329

113,300
58,100
31,500
44,900
83,600
77,500
24,100
13,200
88,100
28,300
20,500
22,900
19,600
28,100
68,800

1.00
1.00
1.00
1.00
1.00
1.00
1.00
2.00
2.00
2.00
2.00
2.00
2.00
2.00
2.00

California-1998
Illinois
Massachusetts
Michigan
New York
Texas
Washington
Colorado
Florida
Georgia
Louisiana
Maryland
Minnesota
Missouri
Pennsylvania

24,875
7,091
5,530
7,015
8,622
15,604
5,580
2,870
7,290
5,586
3,082
4,847
2,722
3,577
12,443

33,145,121
12,128,370
6,173,169
9,863,775
18,196,601
20,044,141
5,756,361
4,056,133
15,111,244
7,788,240
4,372,035
5,171,634
4,775,508
5,468,338
11,994,016

112,300
56,800
31,700
44,200
83,100
77,400
23,800
13,300
88,000
29,100
20,300
22,600
19,400
27,900
66,600

1.00
1.00
1.00
1.00
1.00
1.00
1.00
2.00
2.00
2.00
2.00
2
2.00
2.00
2.00

California-1999
Illinois
Massachusetts
Michigan
New York
Texas
Washington
Colorado
Florida
Georgia
Louisiana
Maryland
Minnesota
Missouri
Pennsylvania
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Table 8—Continued
Visits
(Dependent
Variable)

Population8

New Cancer
Casesb

State

PMPC

23,131
7,669
7,014
7,291
10,143
14,925
7,548
2,909
9,278
5,278
3,471
4,745
3,068
3,971
13,186

33,871,648
12,419,293
6,349,097
9,928,444
18,976,457
20,851,820
5,894,121
4,301,261
15,982,378
8,186,453
4,468,976
5,296,486
4,919,479
5,595,211
12,281,054

113,200
55,100
30,100
41,400
81,500
76,100
23,600
13,400
88,100
29,400
20,800
22,600
19,900
27,000
66,600

1.00
1.00
1.00
1.00
1.00
1.00
1.00
2.00
2.00
2.00
2.00
2.00
2.00
2.00
2.00

California-2000
Illinois
Massachusetts
Michigan
New York
Texas
Washington
Colorado
Florida
Georgia
Louisiana
Maryland
Minnesota
Missouri
Pennsylvania

25,900
10,608
8,425
10,005
13,093
13,998
8,885
3,038
9,411
4,420
4,301
6,345
3,845
4,851
15,718

34,533,054
12,517,168
6,399,869
10,005,218
19,074,843
21,340,598
5,992,760
4,428,786
16,355,193
8,394,795
4,466,001
5,383,377
4,985,202
5,636,220
12,298,363

117,400
56,800
31,300
45,300
83,200
78,900
24,800
14,300
91,600
31,100
21,700
23,500
20,600
28,400
68,400

1.00
1.00
1.00
1.00
1.00
1.00
1.00
2.00
2.00
2.00
2.00
2.00
2.00
2.00
2.00

California-2001
Illinois
Massachusetts
Michigan
New York
Texas
Washington
Colorado
Florida
Georgia
Louisiana
Maryland
Minnesota
Missouri
Pennsylvania

Population is total population for the state for the years indicated, per the U.S.
Census figure. '’New Cancer Cases for the year, per the American Cancer Society.
Existence (1) or non-existence (2) of a PMP.
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number of cancer cases was assumed to cause an increase in the amount of controlled
substances in use. The variable PMP (prescription monitoring program) represents the
presence or absence of specific public policy that is implemented with the belief that it
will decrease drug diversion.
This model with three independent variables produced an R Squareof 85.1,
indicating the model explained 85.1% of the variance in the dependent variable. This
indicates that 85.1% of the variation in drug diversion is explained by the three
independent variables. The relationship between the dependent variable and the
independent variables was thus highly significant, indicating the variance is not likely
to be due to sampling error. The results of the three-variable regression model are
presented in Table 9, which reports the R Square and the standard error of the
estimate of 2,225, which is the amount of predicted error in the estimate of the
dependent variable, drug diversion, that the regression equation produces. Table 9
below contains the model summary.

Table 9
Model Summary and Change Statistics, 1998-2001 ( N - 60)

Model

R
Square

R
Square

Adjusted
R
Square

1

0.922

0.851

0.842

Standard
Error of
the
Estimate

R
Square
Change

F
Change

d j\

d fl

Sig. F
Change

2,224.66

0.851

106.2

3

56

0

Note. Predictors: (Constant), PMP, New Cancer Cases, Population per U.S. Census
figures.
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Table 10 was developed to identify statistics for the independent variable
coefficients and a value for the constant or ^-intercept for the model. This analysis
provides numerical coefficients for each o f the three independent variables and assigns
a positive or negative value to each variable’s influence on the estimate of the
dependent variable, drug diversion. Using the data provided in Table 10, the following
regression equation was determined.
Visits (Drug Diversion) = 2189.928 + 7.134(POP/10,000) 2 225(Newcan/100) - 504.166(PMP),
where “visits” is the proxy for measuring drug diversion in each of the states in the
study.

Table 10
Coefficients and Standard Error Calculations, 1998-2001 (N= 60)
Model

Unstandardized
Coefficients
B

Std. Error

Standardized
Coefficients
Beta

t

Sig.

1.635

.108

2189.928

1339.257

Population, per
U.S. Census figures

7.134E-04

.000

1.012

6.000

.000

New Cancer Cases

-2.225E-02

.030

-.120

-.746

.459

-504.166

671.861

-.045

-.750

.456

(Constant)

PMP

Note. Dependent Variable: Annual Visits to ED departments per DAWN stats, for
selected drug mentions. Predictors: (Constant), PMP, New Cancer Cases, Population
per U.S. Census figures.

Review of the raw data showed that the number of new cancer cases generally
increased when population increased, which means that the influence of population
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and new cancer cases on drug diversion may overlap, with their individual influence
being questionable as well as creating uncertainties with the regression equation as a
whole. Therefore, the correlation of independent variables to each other and to the
dependent variable were calculated, to test for multicollinearity and singularity
concerns. Multicollinearity occurs when variables are highly correlated (0.90 and
above) and singularity is when they are perfectly correlated. When multicollinearity
exists in a regression matrix, the independent variables are interrelated, which makes
the regression coefficients unreliable. The test for multicollinearity and singularity
were run using the SPSS software, and are presented in Table 11.
The analysis shows that population and new cancer cases are indeed highly
correlated, as might be expected. The correlation between population and new cancer
cases is .946, verifying the very high interrelationship between the two variables. With
this level of multicollinearity, the model does not allow for a determination of the
separate effects of population and new cancer cases. With a multicollinearity over
0.70 statistical problems occur, with the independent variables interrelated, and yet
affecting the dependent variable differently (Wulder, n.d.). The regression coefficients
are unstable and unreliable.
In consideration o f this finding, the regression was re-run twice. The variable
population was removed from the first run, and new cancer cases from the second run
to determine if the results would thereby improve. Both new runs thus contained two
independent variables, one run with just population and PMP as the independent
variables, and the other with new cancer cases and PMP as the two independent
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Table 11
Correlations, Dependent and Independent Variables, 1998-2001 (N= 60)
Dependent
Variable:
Annual Visits to
ED departments
per DAWN stats,
for selected drug
mentions
Pearson
Correlation

Population,
per U.S. Census
figures

New Cancer
Cases

PMP

1.000

.920

.855

-.493

Population, per
U.S. census
figures

.920

1.000

.946

-.492

New Cancer
Cases

.855

.946

1.000

-.416

-.493

-.492

-.416

1.000

Dependent
Variable:
Annual Visits to
ED departments
per DAWN
stats, for selected
drug mentions

PMP

variables. Both new runs provided less reliable results than the first run with all three
variables. In both additional runs, the R Square value was reduced but not
significantly reduced, and the standard error o f the estimate was increased. Thus,
neither of the new runs was determined to be an improvement. Interestingly, new
cancer cases as a variable is negatively correlated in the three-variable regression, but
positively correlated in the two-variable analysis (Newcan and PMP). This confirms
the concerns over instability in the three-variable equation and the strong and
unreliable relationship between population and new cancer cases.
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Some Observations

Although no significant conclusions can be drawn from the multiple regression
results, there appears to be a positive association between an increase in a state’s
population, an increase in new cancer cases and an increase in controlled substancerelated visits to selected metropolitan area emergency departments. Such a connection
makes sense. Importantly, the fact that drug diversion and population are positively
related was suggested by several of the participants in the qualitative portion of this
research. Comments such as “drug abuse will always be here” and “more people” or
“more availability of drugs,” meaning an increasing supply of drugs available to more
people, were mentioned in various interview contexts as predictors of drug abuse. At
least some of the subjects interviewed for this research believed that drug abuse is
simply a function of the number of people in an area. More information on that topic
will be included in the interview results chapter. However, for statistical analysis
purposes, the high correlation value suggests that the variables are redundant and may
bring the same issue to the analysis. For that reason, although there is a clear
association between variables, no functional relationship has been proven.
It would also seem logical that an increase in new cancer cases would be
associated with an increase in population. Cancer is the second leading cause of death
(CDC website, 2005, National Center for Health Statistics-Fast Stats) and a disease
modality that requires extensive use of strong pain medications such as the controlled
substances that are the subject of this study. The use of new cancer case statistics was
thus considered a reasonable proxy for diseases that promote more extensive use of
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the subject medications and as a proxy for measuring increases and decreases for such
need from a medical perspective. Unfortunately, the correlation with population is too
high to make it a reliable variable, since the high correlation suggests that both
variables are measuring much of the same thing. Stated another way, new cancer
cases appear to also be associated with a growth in population, so population growth
is probably included within the cancer variable as well as the population variable.
Limitations of DAWN Data as a Proxy for Drug Abuse
Some limitations of the use of DAWN data were mentioned in the
methodology chapter. It is important to emphasize that “although DAWN is capable
o f detecting certain drugs of abuse before their appearance in other data systems,
findings from DAWN alone cannot define an emerging drug abuse problem or
quantify precisely the abuse potential of prescription drug products. Instead, DAWN
identifies sentinel events—indications of a potential drug abuse problem . . .” (U.S.
Department of Health and Human Services, 2003, p. 111).
In its review of the usefulness of DAWN data as a measure of drug abuse,
SAMHSA (the Substance Abuse and Mental Health Services Administration) analysis
provides some commentary as both limitations and in defense of DAWN as a tool
(U.S. Department o f Health and Human Services, 2003, pp. 106-111). Limitations
include:
1.

DAWN data were intended to be reported where “intent to abuse” was

present. In reality, it is hard to distinguish such intent since intent is usually
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inconsequential to care, subjective, and not a priority when an individual presents for
treatment. Thus, intent was impossible to collect in all cases, and some visits may be
missing from the DAWN data.
2. Some people may visit the ED more than once per year with a drug abuse
problem. DAWN does not distinguish visits by person, so the numbers o f individual
visits may be overstated because of the research assumption that each visit is one
different person. However, the extent of such overstatement was assumed to be
insignificant for purposes of this study.
3. A report of opiates can include either narcotic analgesics (prescription
opiates) or heroin, which cannot always be distinguished from a prescription analgesic
due to chemical actions. Thus, the statistics for prescribed narcotic analgesics may
include some use of illegal drugs.
4. DAWN statistics show only one dimension of drug abuse—those presenting
at the ED departments of selected hospitals. Only a fraction of abuse cases are a part
of DAWN statistics, which would imply that DAWN statistics understate the
prevalence of prescription drug abuse. However, the DAWN statistics have been used
over the years to verify claims of increases in drug diversion and abuse of prescription
medications.
In defense of the use of DAWN statistics, SAMHSA offers these comments:
1.

The DAWN data show an increasing trend in the abuse of “other

substances”—the drugs that are the subject of this research. Over the period of 19952002, the use of narcotic analgesics increased 260%, and the use of benzodiazepines
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increased 38%. Both categories are included in the controlled substance schedules.
Thus, it was concluded, for purposes of this study, that the DAWN data’s ability to
show increases and decreases provide a sufficient case for use as the dependent
variable and proxy for drug abuse o f controlled substances.
2. Although only 21 metropolitan areas are included in the DAWN
information used for this study, those 21 areas are located in states that comprise the
majority o f the U.S. population.
3. SAMHSA analysts themselves state that “ED visits are one useful indicator
o f the drug abuse in communities” (U.S. Department of Health and Human Services,
2003, p. 110).
Conclusions
Although the quantitative model is not as reliable as desired, some conclusions
can be proposed.
First, there does not appear to be a significant correlation between the
presence or absence of a PMP and the number of controlled substance drug abuse
cases, using DAWN statistics as the proxy for such abuse. In fact, the presence of a
PMP is negatively correlated to the number of DAWN cases as presented in the
analysis. This means that a policy such as a PMP may actually increase the recorded
incidences of abuse. From an analysis perspective, this could mean a number of
things. For example, on one hand it could be interpreted to mean that a PMP causes
more attention to be placed on the potential for abuse, with more cases brought to the
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ED and more attention to determining abuse by the DAWN reporters because o f the
heightened awareness that a state law would generate. On the other hand, it could
mean that a PMP does not have anything to do with the incidences of abuse and the
absence of such a policy may in fact be better for a state. One could speculate that law
enforcement activity directed at identifying abusers is stronger in states without PMPs
because there is no such law that can be relied on, thus “street” enforcement must be
more focused. Or maybe less public attention is paid to abuse issues in states without
PMPs; thus, it is not a publicly reinforced activity, or is not a priority for reporting.
Regardless, this result of the regression does suggest the need for further study, since
the implementation and annual costs of PMP policies can be substantial and are not
justified if PMPs are ineffective.
Secondly, there is a clear connection between a sheer increase in numbers of
people and the DAWN trends. This reinforces most instinctive and anecdotal
evidence, but leaves policy makers with a dilemma. As the population of a state
increases, should the government dedicate more resources (money and people) to the
prevention of prescription drug abuse, or should it try to stem the trend by creating
policies that might provide law enforcement with additional tools that would make the
existing resources more efficient? And if additional policies are a choice, do they
really work, or just create additional costs for the citizens? There are other issues that
would need consideration before a simple answer is offered, such as public education
needs, additional training for health care professionals, and a number of prevention
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programs that might make a bigger impact on stemming abuse than the presence of
additional policies targeted only at the law enforcement dimension o f the problem.
The primary conclusion that can be drawn from the extensive efforts to
quantify a response to the research question is that there is just not enough data
available to justify or not justify the presence of a PMP. In all of the data that were
analyzed for possible use in the regression, and in the limited data that were finally
included in the regression, there is no evidence that PMPs have anything substantial to
do with the trends related to abuse of controlled substances in the United States.
Without further study, it would be unwise to recommend that state governments incur
the costs of such policies, and it might be suggested that such activity would take the
focus away from activities that might actually have more of an impact on reducing the
illegal use of controlled substances, thereby delaying the implementation of a better
solution.
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CHAPTER V
THE CASE STUDY
Overview
The application of public policy and the delivery of health care services related
to pain management happen at the point of service, when professionals incorporate
their personal values and their interpretation of such policies into their interaction
with the people they serve. When regulations differ between states, it is theorized that
behaviors and perceptions would also be different. The purpose of including a case
study in this research was to learn such behaviors and perceptions from the
professionals involved in pain management and drug diversion issues, and to compare
differences between two states. The case study includes direct interviews with 30
individuals, 15 working under Michigan laws and 15 working under Florida laws. The
people selected for the interviews were grouped into three categories: law
enforcement, pharmacists, and physicians. There were four law enforcement
professionals, three pharmacists, and eight physicians interviewed in each state.
Interviews were conducted between July 15 and December 31, 2004. Twentythree interviews were conducted in person and seven over the phone.
The 30 subjects had significant knowledge of the issues surrounding pain
management, drug diversion, and prescription monitoring policies in their respective
states, both individually and as a group. During the period o f the study, Michigan had
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a PMP, and Florida did not. However, legislators in Florida were considering the
implementation of such a program as a means to control drug diversion. The PMP in
Michigan was known as the Michigan Official Prescription Program (OPP) and during
the time period o f this study, required physicians to write all prescriptions for
Schedule II drugs on a special prescription pad. This meant that physicians licensed to
prescribe controlled substances had to carry two prescription pads if they wanted to
prescribe Schedule II drugs. Those prescription forms were required to be forwarded
after dispensing to a state agency for use in review of prescribing patterns and as
potential evidence for investigation and prosecution of suspected drug crimes.
This caused an additional paperwork burden and created some fears of
oversight, which caused much discontent within the physician community. Michigan
eventually repealed the OPP program, and replaced it with the Michigan Automated
Prescription System (MAPS), which eliminated the special prescription pad and
requires electronic submission of prescriptions for drugs in Schedules II-V. Among
other features, the MAPS allows physicians to query the MAPS database to
determine the number of drugs a patient is obtaining from Michigan pharmacies.
Florida legislators have considered passing laws to implement programs with
characteristics o f the OPP and MAPS for at least 3 years. Thus, the environment for
prescribing and therefore for the availability of strong drugs was different in the two
states. This case study was designed to identify how those differences translated into
practice.
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It is important to note that persons selected for the interviews were not
chosen because of any particular national expertise in the research topic; rather,
subjects were selected because they were able to speak on the issues from a point of
service perspective. Individuals selected were either known to the investigator or
selected based on recommendations by people who were familiar with the research
topic.
The general interview structure and questions are presented in the
Methodology Chapter. Early in the interview process, it was determined that some
participants wanted to talk about the role of pharmaceutical representatives and
companies in the delivery of medications for pain management, as well as the impact
of internet pharmacies on the availability of Scheduled drugs. Thus, queries were
added to the basic interview structure to assure that all participants were given an
opportunity to discuss internet pharmacy and pharmaceutical representative influence,
if such topics were not voluntarily mentioned. Nearly all of the subjects spoke
passionately about the topics, with clear differences in emphasis depending on the
profession of the participant. Distinctions in attitude or opinion between Michigan and
Florida were not so clear. All of the interviews were 30 minutes or longer, with
several individuals’ participation much longer, in several cases up to an hour. The
results of the interviews are presented by professional category, with differences
between the two states noted.
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Law Enforcement
Law enforcement participants included a sheriff from each state; two
government bureaucrats, one from each state; one DEA representative; and three
officers from state law enforcement divisions. Responses are reported by category of
inquiry.
On Drug Diversion
One of the queries made of all interview participants was their opinion on the
severity of the problem of drug diversion in their state. With one exception, all
individuals in the law enforcement category indicated that drug diversion had
increased in their respective state and continues to be a growing problem. Those
interviewed in Florida made comments such as, drug diversion is “growing at an
exponential rate,” “prescription drug abuse is far more of a problem than realized,”
“illicit drug diversion is the most critical problem we have (in the area o f drug
abuse),” and “Florida is one of the most rapidly growing states for drug diversion—
worse than other states.” One Florida participant made the strong statement that “It is
a runaway problem, becoming an epidemic.” Comments from the Michigan
participants included: “Drug diversion is a significant problem,” “has gone up quite a
bit,” “Michigan has a larger than average problem with drug diversion than the rest of
the country,” and (the exception) “drug diversion in Michigan has stayed the same for
at least the past 3 years.”
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Participants were asked how they formed such opinions. The responses were
more varied, with some respondents making general statements o f perception, and
others actually citing some statistics. Florida law enforcement participants reported an
increase in the number of cases “being made,” increased advertising by
pharmaceutical companies which increases supply, population growth which also
increases the supply, and an increase in the number of deaths with controlled
substances in the deceased’s blood. A Michigan respondent stated he compared the
current diversion o f legal drugs to similar problems when he first began his law
enforcement career, and reported that he felt there was much less diversion activity in
the past. Other Michigan respondents used information from law enforcement activity
such as jail bookings. Data sources cited by one respondent included ARCOS data
and DAWN data, plus “general information” from coroners. There were two
mentions (one from each state) of the dilemma caused by the presence of multiple
drugs in the identification of actual cause of death.
Thus, while there appeared to be agreement that drug diversion was a growing
problem, the information used to reach that conclusion was extremely varied, from a
“gut feeling” based on experience and anecdotal evidence to an interpretation o f
actual statistics.
Respondents were questioned on what influences a physician to divert drugs
or put a physician in a position where prescriptions are diverted. Interestingly, law
enforcement participants from both states cited money as the primary influence—
comments included “pure greed,” “it’s big money,” and “money for scripts kind-of
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atmosphere.” A dose second was addiction o f the physician, with six of the subjects
indicating that as an influence. Two participants cited instances o f trading drugs for
sex.
On Influencing Choice o f Drugs
Of note here was the discussion centered around physicians who are perceived
to be fooled by their patients into providing drugs that are then diverted, or who are
not felt to be up-to-date on drugs. Some of the respondents talked extensively about
physicians who are “duped” by their patients, or “too soft,” or victims of time
pressures that prevent the needed interactions with patients—“production line
medicine” was a phrase that was used. Two of the subjects talked extensively about
the responsibility of the physician in learning more about available new drugs before
prescribing, and one person stated that physicians should not be allowed to prescribe
controlled substances without additional, post-medical school training.
Five of the subjects (four from Florida and one from Michigan) cited the
influence of pharmaceutical companies on prescribing patterns and choice of drugs.
Those who commented were not overly critical of pharmaceutical company
representatives, recognizing the natural business activities of such companies.
However, comments like “oversell new drugs,” “gonna make as many as they can
sell,” and a discussion of company marketing techniques used were a part of the
conversations.
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On the State o f Pain Management

Respondents were queried on how they felt pain management was affected by
law enforcement activity. In general, the four participants from Florida have stronger
feelings than Michigan respondents about the existence of a “chilling effect” on
proper prescribing as a result of such activity. One stated that we “cannot let patients
suffer because of diversion,” a comment that was supported by others in the study.
However, he also stated, “by the same token, some doctors need to be arrested.” One
felt a PMP would provide doctors with more information and thus reduce the chilling
effect on proper prescribing. Another acknowledged that “many doctors are now
stating [that they are] leery to prescribe certain medications . . . ” However, an
interesting statistic presented by one of the participants was that only 50 physicians
had been arrested in the entire country in the previous year (2003).
Three o f the four Michigan subjects did not acknowledge a chilling effect on
pain management. The other stated that he had not seen any such effect on physicians
who were pain management specialists. Another stated he never did get a lot of
information on the failure of physicians to provide adequate pain management, and in
fact Michigan had seen an increase in the prescribing of Schedule II drugs since
Michigan’s new electronic prescription system (MAPS) went into effect, thereby
indicating to him that pain management had improved. (A chilling effect could
theoretically reduce the prescribing of strong, Schedule II drugs.) This same person
felt that pharmacists should have a bigger role in the final choice of prescriptions for
the patients. Another stated that a chilling effect, if one existed, might be beneficial
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and said, “Yeah, we may have a chilling effect on some of these doctors that are just
borderline, but maybe that’s good.”
All of the law enforcement study participants talked about addiction problems
at some time during their interviews, and all expressed a concern over such addiction
and the physician’s role in addressing addiction to prescription drugs. Several
incidences were cited in the course of the interviews, some describing physicians who
prescribe without doing a medical exam or only a feeble attempt at an exam (“taking
blood pressure through a winter coat”).
There was a clear concern over the wide reach of drug addiction, with one
sheriff stating, “I ’m o f the belief that everything comes back to drugs. Anything to do
with crime

It always seems to get back there somehow.” He cited several crimes

including homicides, all o f which were committed over drug needs, but noted that
such connection was not made on the arrest report. He said, “Unfortunately, when it
comes time for sentencing, they’re sentencing the guy for armed robbery, for car
jacking, or whatever. They’re looking at that as the violent crime.” He felt that such
reporting diluted the statistics on the extent of drug crimes. It should be noted that he
was referring to all drugs, both legal and illegal.

On Influencing Prescribing-Pharmaceutical Issues
Some commented on the role that pharmaceutical companies and pharmacies
play in drug diversion. Two of the subjects indicated that pharmacy company
representatives unduly influence some physicians’ choice of pain medications, but one
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stated that the education provided to physicians by these representatives was good.
Six of the eight law enforcement officials indicated that criminal activity in pharmacies
was also a concern. In both states, laws were cited that require pharmacies to report
suspicious prescriptions; however, those laws are difficult to enforce. The concept
that pharmacies are in business to sell prescriptions, which can discourage such
reporting (by turning away business) was mentioned, but one Michigan respondent
did state that more pharmacists turn in drug diversion leads than physicians— about
four times as many. Two Florida respondents and two Michigan respondents reported
cases of illegal pharmacy activity and pharmacy thefts. One respondent referred to the
temptation to “Mom and Pop,” or locally owned operations, where the owners turn a
“blind eye” to a questionable prescription, as opposed to a chain operation where
databases and prescription histories can be reviewed, and financial incentives are not
as personal.
Four participants, two from each state, talked about the growing drug
diversion problems that are connected to internet pharmacies. Both states have laws
that make it illegal to sell drugs over the internet without a defined examination, but
again, those laws are hard to enforce. Although such pharmacies must be licensed in
the state of sale, comments included “hard to track,” “only catch by complaint,”
“running different websites,” a source of “dangerous diversion o f prescription drugs,”
and “not enough investigators in Florida alone to handle internet pharmacy (activity).”
When asked about the role of pharmaceutical companies and their
representatives’ influence on diversion activity, none of the participants indicated they
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felt the sales approach by pharmaceutical company staff encouraged criminal activity.
Mentions were made o f strong marketing techniques and the use of gifts to influence
the use o f their company’s drugs, but no culpability was perceived.
Effect o f Public Policy, Regulatory and Law Enforcement Activity
During the period o f time assigned to the quantitative study (1998-2001),
Michigan had an active prescription monitoring program, which was eliminated in
2003 in favor of an electronic database for Scheduled drugs. The prescription
monitoring activity moved from a reporting of Schedule II prescriptions through a
special prescription pad, to the electronic reporting of prescriptions for all legal
Scheduled drugs, with no special form or pad required. This eased the administrative
burden on physicians, but still captured prescribing patterns. Florida has never had a
PMP or anything similar, but has attempted to pass legislation to implement a similar
program during at least three legislative sessions. Comments on laws, policies and
PMPs differed between the two states in this case study, because of the difference in
the regulatory climate.
However, there was consistent appreciation for the benefits that a PMP would
bring to the efforts against drug diversion. All eight law enforcement participants
supported a monitoring program or some additional data collection that would assist
in the identification of illegal prescribing. Interestingly, the Michigan respondents
(where a PMP—the MAPS—is operating) were less passionate in their responses,
with two of the four Michigan participants not even familiar with Michigan’s MAPS.
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One Michigan respondent stated that the laws on the books were fairly effective, but
enforced inconsistently. That comment about inconsistent enforcement was supported
by another participant who also stated that such laws should not be created to address
specific events or specific drugs, but to prevent bad outcomes. The Michigan subjects
were also more likely to feel the real beneficiaries of a PMP are the physicians and
pharmacists who are able to use the MAPS to track prescription activity of their
patients and those wanting to become their patients. However, those “real time”
benefits are limited, because prescription records are generally not available on the
database sooner than 30 to 45 days from the date of the sale, which means an
inquiring physician can learn what drugs a patient obtained 30 to 45 days ago, but not
last week.
The Florida participants were very supportive of implementing a PMP, making
statements such as PMPs are “a fantastic tool,” and would “bring down the death
rate” from illicit use of prescription drugs. Two others felt that a PMP would not
exert a chilling effect on pain prescribing, but would actually make proper prescribing
more possible, since physicians would be able to obtain a patient’s prescription history
before finalizing treatment. (However, with the 30- to 45-day lag time that Michigan
reported, the PMP would be unlikely to be of assistance during a patient’s visit.) One
of the Florida participants also stated he would support a mandated special
prescription pad for controlled substances, regardless of the passage of a PMP.
Florida law enforcement participants were not optimistic about the passage of a

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

128
Florida PMP, stating that legislators, physician groups, and consumer rights
organizations had opposed such laws when introduced in the past.
With one exception, all participants cited other problems with the environment
that hindered the anti-drug diversion activity in their state. One from each state
expressed concern over the cost of additional laws. Other issues included a concern
over abuse o f illegal drugs and of alcohol, which would not be addressed by a PMP;
the need for more accountability; need for a national drug database as opposed to just
state by state records; more physician education; more drug abuse treatment funding,
more law enforcement officials; and better communications. There was no perceived
indication that a PMP was or would be a key factor in the prevention o f abuse of legal
drugs. Rather it is a complicated problem, with no solution in sight.
On Decreasing Drug Diversion and Improving Pain Management
All participants provided ideas on activities and programs that would be likely
to reduce drug diversion, outside of a PMP, and also what else can be done to
address the perceived pain management problem. Comments were made regarding
mandating forgery-resistant prescription pads, a need for more law enforcement
investigators—“We’re so far behind the eight ball now that it wouldn’t help us if we
got 100 more investigators throughout this county,” a need forjudges to be tougher
in their sentencing, and more funding and better access to treatment for those who are
users. Four of the participants indicated a need for more education. Interestingly, one
felt the public needed the education, another thought education was lacking for law
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enforcement officers, and the other two thought the education gap was with the
physicians. One comment was made regarding the inevitability of crimes o f drug
diversion, given human nature, regardless of education and government activity to
address the issue.
Nearly all of the participants were unable to provide additional solutions for
the improvement o f pain management. In general, most felt that pain management was
taken care of already, and that skills and tools were in place to assure that needed
pain treatments would be available. The implication was that improvements in pain
management were the responsibility of the physicians, and that the medical profession
needed to better apply the opportunities that were already in place. One participant
did discuss the need for a specialty license for pain management physicians.
On Data Needs

There was no specific data identified by the eight law enforcement participants
for collection, but there was agreement that additional statistical information would be
helpful in their jobs. The need to connect data sources was mentioned at various
points in the interviews, with participants stating that a central database of
prescription activity would be helpful. When specifically questioned on data needs at
the conclusion of the interviews, four of the participants mentioned the need to
provide the available data in a more timely fashion. Examples of 1- and 2-year old
data were mentioned as not being very helpful in investigations. O f note is that a need
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for more and better data was mentioned by law enforcement participants in both the
PMP (Michigan) and non-PMP state (Florida).

Pharmacists
Six pharmacists were interviewed for this study, three each in Michigan and
Florida. Two of the Michigan pharmacists were with rural pharmacies, one being an
owner. The other Michigan pharmacist was the head pharmacist for a small chain
store operation. In Florida, one pharmacist practiced in a rural setting in a grocery
store, one managed a drug chain store in an urban setting, and the other worked in
private practice for a clinic.
On the State o f Pain Management
All six of the pharmacists stated that pain management is not what it should
be, with pharmacists from both states indicating that pain management specialists do a
better job than general practice physicians. Florida participants did not agree on
causes for the state of pain management in their areas, citing some physician concerns
with aggressive investigations, patient fears of addiction and side effects of medicine,
and lack of adequate training at the university level for clinicians. One respondent
talked about the “warring factions”—law enforcement and physicians—that may have
created further prescribing concerns on the part of physicians. This respondent also
encouraged the use of alternative therapies with non-Scheduled drugs that may be
appropriate for many pain patients.
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All three Michigan participants stated that the quality of pain management
depends on the individual practitioner. One stated that acute pain is better treated
than chronic pain, which is “a lot of trial and error.” Another indicated that hospice
patients are better treated for pain than other pain patients. Another talked extensively
about the cost o f inadequate pain treatment: more time off work, can lead to
depression, more clinical visits, and the family structure suffers. This Michigan
participant also talked about the tendency o f physicians not to prescribe outside of
what they learned “years ago.” She stated, “I see them using drugs like Darvocet and
Demerol that basically in current standards of practice, you don’t use them anymore.”
On Influencing Choice o f Drugs

The pharmacy participants were asked their opinion on what influences a
physician to prescribe certain drugs for pain management. Four of the six expressed a
need for more education ranging from medical school training to better education
from drug company detailing. One Florida subject talked extensively about the
responsibility of drug companies to discuss the risks of controlled substances for
certain patient populations, as well as the benefits. She stated the pharmaceutical
companies “go out o f their way to downplay the negatives and to up-play the
positives.” She also indicated that the marketing is skewed toward patient norms, but
pain patients are not the norm, and patients that have a history of substance abuse are
not the norm, implying that education on treatment of these patient populations needs
to be different. A Michigan participant also discussed the lack of clinical studies by
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drug companies, to prove the long-range effectiveness of treatment for chronic pain
patients who use their drugs.
All six subjects stated they felt that pharmaceutical companies, through their
various retail and direct-to-physician marketing efforts are a major influence on
physician prescribing patterns. The influence was perceived as both good and bad,
with some concerns over aggressive marketing, but equal appreciation for the
education that is provided. A Michigan subject commented, “The drug reps present
them [physicians] with a clear, concise evaluation o f their product, and if the doctor
feels it’s appropriate, they’ve got dosing information, indications, and everything right
there given to them. A big time saver for the doctor.”
Two of the participants (one from each state) felt the biggest influence on
choice of drugs was the payer, or insurance company, and one other participant
included that as one of his top three influencing factors in choice of drugs. Fear of
prescribing certain drugs was mentioned by one subject in each state. Addiction
concerns were discussed at length by a Florida participant.
The learning process for the use of Scheduled drugs was discussed in various
ways, with one participant stating “peer to peer conversations,” another citing “trial
and error,” another that the use of Schedule II drugs was not taught in medical
schools, and another that continuing education is negatively affected by regulatory
scrutiny.
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Perspectives on D rug Diversion
All six pharmacists acknowledged drug diversion as being a problem in their
respective states, and there was general agreement that drug diversion was also a
problem throughout the country. Two of the Florida participants did not think more
laws would cause drug diversion to decrease, with one stating that additional
regulations would “just make the diverter more sophisticated.” The other Florida
participant thought a PMP would help to reduce drug diversion, but at the expense of
pain management. Two Michigan pharmacists stated the elimination of the special
prescription pad for Schedule II drugs (repealed in 2003) makes drug diversion easier,
but those same two individuals were more concerned over the diversion caused by
addiction, and the lack o f funding for addiction programs. One of the Florida
participants also talked extensively about the need for addiction treatment, pointing to
the significant reimbursement barriers to such treatment, but that is “where anti-drug
diversion activity has to start.” A Michigan pharmacist called addiction treatment a
“bigger bang for the buck” citing the alternative and perceived greater cost of
repeated incarceration if diverters are not treated.
Several issues related to time constraints were mentioned by participants in
both states, with involvement in arresting someone for drug diversion being very
time-intensive from both a law perspective as well as a privacy perspective. Subjects
gave examples o f the many calls they would make (if they had time) to determine if a
suspected prescription was legitimate, the need to catch someone actually exchanging
drugs for money or the timing necessary to arrest someone at the point of sale. Other
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comments included a concern for the safety of the pharmacist in such a process, and
the refusal to fill a suspected prescription as the safest and most expedient solution for
a pharmacist who suspects diversion. There also appeared to be some liability
concerns over possible violation of HIPAA regulations if patients’ names and their
medications were released.
On Laws, Policies, and PMPs (Prescription M onitoring Programs)
The responses to questions regarding the effect that laws and regulations had
on pain management and drug diversion were very similar, in spite of the fact that
Florida does not have a prescription monitoring program in place, and Michigan does.
None of the six respondents felt that such programs were the solution to either issue,
and all six also had policies within their own operations to address suspected drug
diversion and interact with physicians on medication issues.
Florida participants in general felt that a PMP or similar laws would decrease
the diversion of prescription drugs, but would have a corresponding negative effect
on proper prescribing with the additional regulatory scrutiny. One pharmacist stated
the solution to both issues needs to start with the physicians, as they “drive the care.”
Another stated that more laws would increase the workload for already busy
pharmacists. He also said, “The tighter and the more laws you pass, the less able
health care professionals and patients are to work together to get what they need.” A
third stated that monitoring laws can have a “great positive effect” if designed and
implemented right, as such design would help physicians feel safer in their prescribing.
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However, such design has to be done collaboratively with both health professionals
and law enforcement, and then all who have access to such monitoring programs need
to be “perfectly educated” on its use. Although this pharmacist supported a properly
designed PMP, she was not optimistic that Florida could create such a program. She
stated:
Right now, there’s only negative impact, because of the independence of
everybody doing their own thing, everybody’s blaming the other person for
their problems. The DEA, law enforcement, say it’s the physicians’ problems,
they’re the ones at fault. The physicians are saying, well you know, if the DEA
would stay out o f it, we could actually manage pain. So there’s a lot of
pointing fingers, I think right now with the legislators, with the law
enforcement, and they come together only when they’re forced. And when
they’re forced, there’s not much positive outcome—to date anyway.
Michigan participants talked about the PMP that is in place in their state, but
did not feel that the PMP or other laws were significant in the efforts to decrease drug
diversion or improve pain management. Two of the subjects felt the elimination of a
special prescription pad for Schedule II drugs might make it easier to divert drugs.
One participant stated that the necessary education that was promised with
Michigan’s PMP change did not appear to be happening; thus its usefulness was
limited. Another stated that such laws are more of a tool for state officials than health
professionals. A third stated he had “no strong opinion” on PMPs and the information
available; however, this participant did not know that the database was accessible for
health care practitioners, which exemplified the lack of sufficient education this issue.
Michigan participants had fewer comments regarding laws such as PMPs than the
Florida participants, with little interest in the subject, and more interest in their
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internal policies to deal with drug diversion and pain patients. None o f the three
indicated the PMP was a good tool for their operations.
On Decreasing Drug Diversion and Improving Pain Management
The pharmacists were asked what else could be done to decrease drug
diversion and improve pain management, if they did not bring up the topic on their
own. Three (two from Florida and the other from Michigan) specifically mentioned
the need to treat addiction as a part of the war on drugs, with two of the three other
participants mentioning addiction treatment issues when queried earlier in the
interviews. A Florida pharmacist reported health insurance barriers to addiction
treatment. One Michigan pharmacist stated she felt emphasizing education and
addiction treatment was the key, but the system was “self-defeating,” stating that law
enforcement “counts convictions. That’s how they look good, is how many
convictions they’ve had, not on how many people they’ve sent to treatment. So
there’s no incentive for them to get people into treatment. They want that conviction,
because that’s how they’re funded.”
There was a sense that both drug diversion and improved pain management
could be better addressed with more collaboration—between physicians, pharmacists,
law enforcement officials, patients and others, depending on the respondent. Although
stated a number of different ways, there was interest in more involvement between
physician and pharmacists. Pain management improvement was felt to be a function of
more education by two participants and a direct responsibility of physicians by two
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others. One subject from each state talked extensively of the need to develop a shared
or joint practice for chronic pain management, with many types of practitioners
available for patient analysis and screening, and with the development of a joint
treatment plan. One commented on the difficulty of treating pain, since it is hard to
measure and thus assess the effectiveness of treatment. Another discussed the need to
find treatment for chronic pain as early in the diagnosis as possible, since “Once that
pain starts, that cycle of pain starts, it’s harder to get it under control.”
On the diversion-for-business subject, there was a general feeling that there
was too much money involved in diverting prescription drugs to ever close down such
activities.
On Data Needs
Five of the six pharmacists mentioned additional data that would be helpful in
addressing drug diversion and under-treatment of pain conditions. One Michigan
participant would like to compare Michigan before and after the MAPS to determine
if the change in the laws actually changed anything in practice. Another thought
outcomes would be helpful. The Florida participants discussed data needs a bit more
in depth, citing the need for a central database on statistics ranging from knowing
which patients are receiving a “large amount of narcotics,” to arrest data so clinicians
would know of prior drug arrests when a patient visited their practice, to a PMP of
some sort. One Florida pharmacist spoke at length about the need to identify the
extent of diversion, so that can be compared with statistics on the extent of pain, to
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determine the real effect on society of the two issues. She also suggested that families
of patients who are arrested or overdose be interviewed to determine the existence of
underlying causes such as addiction, unmanaged pain, and related psychiatric issues.
Physicians
Sixteen physicians were interviewed, using the same basic set of questions
asked o f the pharmacists and law enforcement participants. Eight physicians from
Michigan and eight physicians from Florida were included in the interviews. Although
not specifically asked, it was determined during the course of the interviews that all
16 had been practicing medicine for at least 10 years, with some practicing much
longer. Their medical specialties included oncology, family practice, hospice and
nursing home medical directors, pain management specialists and internal medicine.
There was significant experience among these physician participants in dealing with
patients in pain.
On the State o f Pain Management

Florida physicians ranked their state’s health care professionals as providing
poor to just average pain management. Michigan physicians were a little more
positive, ranking Michigan as providing average to above average treatment for pain
conditions, with one exception. Physicians based their opinions on their own
experiences and that of their patients. One Florida physician stated that he felt the
closer a pain patient lived to a major medical center, the more likely he or she was to
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receive good pain management. He stated, “I think the farther you move away from
universities and major treatment centers, the worse it gets.” Physicians in large
centers “understand the risks better.” Another Florida physician commented that pain
management is a little easier to provide than in the past; however, a lot of people are
living in a state of pain. Three of the Florida doctors felt the state of pain treatment
was poor—one even called it “horrible, simply horrible.” One physician spoke
passionately about the limitations imposed by the failure of the medical profession and
the managed care companies to define and utilize pain specialists, which limits
referrals to their expertise. He stated the reimbursement system favors certain
treatments for pain conditions (such as physical therapy but no psychological
counseling to help determine cause). He also stated that malpractice insurance rates
for those who include pain treatment as a specialty of their practice are prohibitive,
discouraging many physicians from extensive treatment of pain patients.
Michigan physicians were much more comfortable with the level of pain
management in their state than Florida physicians, with some agreement that it was
getting better. Michigan physicians talked more at length about the need for
comprehensive pain management and a more holistic approach to the treatment of
pain. One physician stated that “pain management isn’t just about prescribing drugs
but that’s where it always starts and always ends.” Although this physician ranked
Michigan as average in pain management, he stated that if he were to consider the
lack of access to treatment with alternative therapies, Michigan would be rated much
lower. Another physician agreed, saying that doctors are much more comfortable
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prescribing stronger medications now than in the past, but that the treatment of pain is
“mish-mash.” She stated that there is no structured approach to pain management,
that “they understand that good pain care might be important, but they’re not sure
how to get there.” Another talked at length about the need to provide multi
disciplinary care if we are to really improve the lives of those in pain. However, this
physician reported that the reimbursement system does not support such care, so
there is and will be a “continual deficiency” in pain treatment.
Some physicians from both Florida and Michigan felt that pain management is
much better within a hospice setting. A similar comment heard more than once was
that terminal pain was treated better than chronic, non-malignant pain.
On Influencing Choice o f Drugs
The 16 physicians were asked what factors influenced a physician’s choice of
medications for their patients. If the participants did not mention sources of influence
that were mentioned by a number o f other physicians, they were asked for their
opinion on those factors also. Seven of the Michigan physicians and four of the
Florida physicians stated that education they received in medical school and
continuing education under CME is a strong influence. Some talked about a “comfort
level” with certain drugs, prescribing what they are “used to.” “They teach you in
medical school (that) you can’t know everything, but know a few drugs well.” A
Michigan physician elaborated on the education issue, stating that the residency
program is key to the practice of pain management. He said:
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Because the best chance we have at changing practice patterns is not catching
them at CME lectures after they’re out in the community; it’s affecting their
practice patterns while they are still impressionable, while they’re in training.
And it’s very hard to change practice once they’ve finished. Because most
physicians practice what they learned in their residency programs.
Michigan physicians put education and knowledge at or near the top of the list
of influencing factors in their prescribing. Another major influence for the Michigan
contingent was managed care (MCO) company related. A variety of MCO policies
such as drug formularies, incentives to treat with medications rather than more
expensive therapies, and the cost o f drugs to patients due to MCO rules was
discussed by four of the Michigan physicians.
All Michigan physicians either mentioned pharmaceutical companies as a
factor or were asked that questions directly. Interestingly, none of these physicians
felt that pharmaceutical company representatives negatively influenced a physician’s
choice of medications, and most felt that the knowledge gained from pharmaceutical
representatives was acceptable to good. One stated, “Without their detailing, most
drugs wouldn’t be used.” Another said that “leader docs” are not influenced by
pharmaceutical marketing; another observed that such marketing exerted no influence
on a doctor’s choice of drugs. Two Michigan doctors indicated they also considered
what drugs are available in their patient’s geographic area, since not all drugs are
stocked at every pharmacy. Two also felt that a fear of prescribing strong medications
could influence some choices of drugs.
Among the Florida physicians interviewed, the commentary on influencing
factors was less cohesive. Four Florida physicians had more concerns over addiction
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and “risky patients,” with one stating, “They’ll tend to avoid using drugs that have a
potential for addiction if they think that they’re going to have a whole bunch o f drug
addicts on their hands.” Pharmaceutical company influence was also inconsistent, with
comments ranging from “little or no influence” to one doctor stating that many
physicians rely solely on the knowledge dispensed by the pharmaceutical industry.
Comments by others included reference to doctors being too busy to research drugs
on their own and appreciating the studies done by drug companies. Two Florida
physicians mentioned reimbursement and cost issues as a factor in selection of drugs
for their patients.
Only one physician, a Florida participant, mentioned fear of DEA activity,
stating DEA agents provoke pain physicians and monitor them excessively.
On What Affects the Quality o f Pain Management

In addition to conversation on what influences prescribing patterns, physicians
were asked what influences the quality of pain management for patients in their
respective states. Education, training, and knowledge were mentioned again by nearly
all physicians as the primary factor. One Florida physician commented on how
difficult it is to handle pain patients, that pain is a difficult problem to diagnose and
treat, and time consuming. He stated, “It’s not hard to practice medicine without
doing pain management,” and inferred that any barriers will affect quality. Another
Florida doctor said, “I don’t know that many of my colleagues know the first thing
about pain management.”
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Seven participants, four from Michigan and three from Florida mentioned
fears and misconceptions about addiction and the use of strong medicines again when
asked questions on this topic. Commentary included lack of understanding of the
difference between addiction, physical dependence, and tolerance, and the fact that
someone classed as an addict can also have a legitimate pain problem. Many of the
participants talked at length regarding how they would handle a patient who was
perceived or known to have an addiction problem, with some choosing to drop the
patient, and others continuing to treat, but with limitations and even the use of
“contracts” where the patient must make certain promises regarding treatment in
order for the doctor to agree to continue to treat him or her.
Six physicians specified that the health insurance industry is a major influence
on the quality of pain management, five from Michigan and one from Florida.
Michigan doctors commented on the lack o f earlier referrals to pain specialists, lack
o f reimbursement for some treatment procedures being limited or lacking, and
inadequate payment for a full assessment, diagnostic testing and a comprehensive plan
of care. A Michigan physician pointed out the cost inefficiencies of delayed pain
management. He stated:
Reimbursement is still not coming forth from insurers or managed care
organizations for comprehensive pain services.. . . And what managed care
and health care reimbursers and businesses at this point have not yet come to
understand is that in a high cost chronic illness such as pain, you’re not gonna
save money by limiting services early in the course of treatment.
He also commented on the development of more health problems—which he
called preventable—if early treatment was not available for pain management, and
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warned that the cost was not only a financial one, but also a social cost to the patients
and their families as well. Another Michigan doctor talked about the limitations o f a
primary care physician in the treatment of chronic pain. He stated, “y ° u know, what’s
in the average doctor’s armamentary? Well, it’s primarily drugs and physical therapy.
When that doesn’t work they do one of two things. Either they continue to write the
patients drugs, or they punt.” This same physician commented at length on the system
that encourages drug use as the least expensive treatment route, rather than allowing
physicians to fully diagnose and identify appropriate care. He gave this example:
We do have technologies now that can be done percutaneously to deal with
certain types of disc problems, or some of the other structures in the back that
generate pain, but yet because they’re more expensive than writing 120
Vicodin a month, it oftentimes becomes difficult to get that stuff approved.
. . . So the influence that HMO’s have had on the one hand have probably
increased the use of narcotics by the primary care doctor and it slows down
the referral. . .
The lone Florida physician, a practicing pain specialist who commented on the
role of health insurers in the quality of pain management, supported the Michigan
comments on the influence of managed care companies. He stated that late referral to
pain specialists is the common practice of health plans; that the pain specialist is the
“doc of last resort.” He commented on many workers compensation cases where
patients were referred to chiropractic treatments and physical therapists and treatment
by medication alone, and “when nothing else works,” they are referred to his practice,
when the funding has been exhausted. Based on his experience, he felt the poor pain
management reimbursement and late referral systems of health plans are key factors in
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the low quality o f pain management, and the collateral damage is that this encourages
drug diversion, as some patients seek their own solutions.
E ffect o f Public Policy, Regulatory and Law Enforcement Activity
Participating physicians were asked their opinion on the effect of policy and
enforcement activity on pain management. At the time of the interviews, Michigan
had just ended a decade-long prescription monitoring program, which started in the
late 1980s as a triplicate prescription program for Schedule II drugs requiring
physicians to create three copies of each such prescription, with one copy going to the
state. Later, the triplicate requirement was repealed and replaced with a special,
numbered prescription pad for Schedule II prescriptions, which meant that physicians
who wrote such prescriptions had to carry two prescription pads. Because the
numbered sheets could be monitored, many physicians kept those pads in a safe place,
which created a prescribing barrier for physicians who practiced in a variety of
settings outside of their office. The special pad was eliminated in 2003, when an
electronic system call MAPS (Michigan Automated Prescription System) was passed
into law.
There has been no prescription monitoring system in place in Florida, but
there have been several attempts by the legislature to implement an electronic
monitoring system, efforts that have been resisted by the medical community and
others. Thus, the regulatory climate in the two states differs significantly. In spite of
that, the majority of physicians in both states agreed that regulatory oversight and fear
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of practice sanctions produce a “chilling effect” on prescribing for pain management
purposes, regardless of the reality that very few physicians are prosecuted for drug
diversion.
Michigan physicians commented on the MAPS system now in place, and there
was a general feeling that the program is a good one to have available, but only one of
the physicians has ever used the MAPS to get information on a patient. One physician
indicated he was relying on the pharmacy (rather than MAPS) to alert him if anyone is
filling multiple prescriptions from his practice. Another stated that, although the
MAPS program eliminated the special prescription pad barrier to good pain
management, it still contains monitoring of all Scheduled drugs, which might tempt
“doctors who don’t want to be watched” to prescribe older, less effective drugs. He
compared the experience in New York, when physicians were required to report
prescriptions of Schedule IV drugs, and stated, “so you saw patients getting old drugs
like Miltown and other things like that, that were horrible drugs, because they
wouldn’t be scrutinized.” Another Michigan physician liked the inclusion o f all
Scheduled drugs, as this allowed a more comprehensive analysis of a patient’s
medications. A Michigan physician who spoke strongly in favor of the MAPS stated
that the change in Michigan “enhances pain management” because a barrier (the
special pad) has been eliminated. She stated that the data available through the MAPS
allow for better decision-making.
However, education on MAPS for the physician and pharmacist community
has not been done well, so the new system is still not used by many. The other
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concern with the program, expressed by two physicians, was that the program could
not handle volumes o f requests (which may be a factor in the limited education that
has occurred). One stated, “There’s two problems though. One is, nobody seems to
know it exists, outside o f a very few of us. And the second thing is, if people were to
use it the way it is supposed to be used, the people in Lansing told me it would crash
the system.” Another physician complained that, while he can obtain medication
history for his patients, the MAPS system will not provide him with his own
prescribing history, so he cannot check to determine if anyone is forging his name to
obtain medications.
In general, physicians felt that the MAPS program could be a tool to improve
patient care, without being as burdensome as former Michigan regulations. They did
not, however, look upon the program as a tool in fighting drug diversion. One
physician specifically commented that such programs do not have an effect on drug
diversion. He said, “I think people who really want to get the drugs figure out a way
to do it. It may have made people who really wanted to get at the drugs work harder
to do it, but I don’t think that it made that much difference.”
Florida physicians had a much greater concern over the possibility of more
regulations, including the development of an electronic database PMP, similar to
MAPS. Florida physicians were more likely to view a PMP as a tool to fight drug
diversion, and to create treatment access barriers for pain patients. One stated:
So to implement this type of legislation (a PMP) without any input from pain
physicians is going to be an act to secure prosecutions. Pain physicians view
this legislation as handing the DEA on a silver platter exactly what they’re
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looking for. Unrestricted monitoring, information at their fingertips, to target
whomever they wish at whatever time they wish.
Another stated that regulatory activities in Tallahassee and Washington keep
pain management from getting better. However, this same physician said that more
prescription data in an easily accessible database would be very helpful in the practice
o f pain medicine. She said, “You could almost cut it (diversion) out—99% o f it
overnight—if you just had that computer data tabulated and reviewed and enforced.”
Another felt that the movement to a PMP in Florida was not supported by evidence.
He said, “the legislative response seems to be driven, as it often is, by horror stories
and anecdotes that may or may not have anything to do really with the bulk o f
concerns and issues that we have.” This same physician would strongly support
centrally maintained electronic medical charts available for medical care only, but
would not support such electronic systems if the primary focus was on decreasing
drug diversion. That feeling was supported by other Florida physicians, with three of
them also stating that a PMP or other electronic tracking system would not solve the
drug diversion problem.
One physician from Florida did not believe the cost of such a system was
worth the benefits, stating:
I wonder about it [cost], I mean, what’s the magnitude of the problem and the
cost of catching that one person. What did we accomplish? To go through this
expense, the prescribing, to check everybody, and 1 in 700—is it 1 in lCt—I
don’t know. I don’t know. I don’t know what the value is here.
Another commented on a related issue, the lack of knowledge of the actual
extent of drug diversion:
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I don’t think we know—we hear about these spectacular cases, we don’t hear
about the huge problem of inadequate pain management nearly as often as the
few cases o f a few people selling drugs in the parking lot at doctors’ offices
and that seems to be what drives public policy more than the bulk of the
experiences.
Thus, there was some concern over cost-benefit issues related to the
development of a PMP in Florida. Another physician summed up his feelings that the
solution to drug diversion is far more complicated than passing laws can fix—“that
just puts more people in jail.”
Interestingly, none of the physicians interviewed had any personal experiences
with DEA or law enforcement investigations of their practice, and few had even
received an inquiry from any government agency about their prescribing patterns. In
addition, none of them recalled any colleague who had been investigated, other than a
cursory and rare call or letter. Their knowledge of such instances came from reading
and hearing about cases from TV and radio coverage.
Perspectives on Drug Diversion

Study participants were asked for their perceptions about drug diversion in
their state. Michigan physicians were not as sure that there was a big problem with
drug diversion, although all acknowledged that drug diversion exists. Florida
physicians as a group felt drug diversion was more serious. Several general comments
were made about the need for more data to determine the true extent of the drug
diversion problem. In lieu of good data, the perceptions of drug diversion varied from
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not being sure there was a problem, to a sense that there is “a lot more diversion than
we know about.”
Three Michigan physicians stated that drug diversion happens primarily for
monetary reasons, and made no comments on any other motivators. Four of the
Michigan doctors stated that drug diversion will always be with us, with one stating:
But the amount (of prescription drugs) that slips out into the drug community
is minor compared to what’s already out there. So if you stopped all narcotic
prescriptions, you’d have essentially the same amount of narcotics out on the
street as you already have.
This same physician went on to state that it was not a prime concern o f his to
stop drug diversion. He said:
My job is to take care of the patient, and if I think the patient’s being deprived
because their family is selling some of their drugs, then we’ll take care of it
without stopping the care. Because my responsibility is really to the patient,
not to the drug enforcement people.
Another commented that regulatory activity monitoring prescribing of one
Schedule of drugs has only served to move drug diversion from that Schedule to
another (such as from diverting Schedule II to diverting Schedule III drugs, if II’s are
being monitored). This just changed the drug of choice, not the amount of diversion.
Two Michigan physicians commented on other sources of drug diversion—
pharmacy theft from all sources (pharmacy staff as well as outside thieves) and by
nurses in nursing homes. The opportunity for medication theft is particularly
tempting, since many patients are not as cognitively able to monitor their own
medications. One other Michigan physician stated that the “incidence of drug
diversion is much smaller than the hype,” and compared the one third of Michigan

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

151
residents who have pain problems to the less than 1% of residents with a drug
addiction problem (based on diagnostic codes for addiction treatment).
Florida physicians not only felt that drug diversion was more of a serious
problem than Michigan physicians, but a couple of them even warned that the
problem will get worse, that we are seeing the “tip of the iceberg.” Three of these
physicians talked about drug abuse among other health care professionals—those that
serve the patients. One indicated he had been involved in “four or five cases” of staff
diverting drugs from patients. Another mentioned the diversion that occurred in two
of her cases, where older relatives were used to obtain legitimate prescriptions, and
the drugs were then stolen and sold or used. One commented on the statistics that
report polydrug use, where more than one drug is identified, and the most common
other “drug” is alcohol. She stated that using such statistics to support statements
about the extent o f drug abuse are wrong, since mixing alcohol with drugs is not drug
diversion—it is non-compliance with medication instruction. Two physicians
volunteered that money was the prime motivator for diversion, with one stating that
diverting for sex was also an issue.

On Decreasing Drug Diversion

Participants were asked how they would suggest drug diversion be addressed.
Both Michigan and Florida physicians commented again on the belief that improper
drug use and thus drug diversion will always be present. There will always be a
certain percentage of the population that is unable to control drug use. A Florida
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physician stated, “I don’t think the drag problem has probably changed in a century.”
A Michigan doctor, different from the one mentioned in the preceding paragraph,
stated that we need to address the more serious drag problems of alcohol abuse and
illegal drag abuse first, and that has not happened for “a couple of thousand years.”
His point was that extraordinary attention to diversion of prescription drags would be
ignoring the real drag problem in this country.
Another Michigan participant talked at length about the relationship that the
media, regulators, and general public have drawn between strong medications and
addictions. She stated, “So we need the federal government to look at the true
positive and negative effects of medications. And none of these medications are
addicting, there’s nothing addicting about any substance, there is the ability to be
addicted.” She urged a change of mindset to get rid of the myths that opioids are
addicting. And she stated, “there are fewer opioid addicts in the state of Michigan
than there are benzodiazepine and alcohol and other medication addicts.”
Michigan participants mentioned a need for greater general and unbiased
education on drag diversion. They also indicated that better record keeping and
information on use of drags be developed so that the extent of the problem can be
identified before perceived solutions are put in place. There was a general belief that
the MAPS system might help drag diversion a little bit, but no strong statement that
the MAPS has or will have a major impact.
Four Florida physicians indicated they thought more data, even a central
database such as a PMP or something similar to the Michigan MAPS program would
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help decrease drug diversion. One even called the concept “awesome,” but only if law
enforcement officials had very limited access. Another talked about the data that were
already available by computer (Medicaid data, chain pharmacy data, and health plan
data) but were not merged in any central database so that all the data could be used
effectively by physicians and others. The issue of merging already existing databases
was mentioned at other times in the interviews by most of the physicians in the study.
Two Florida doctors made a case for better use of pain specialists, who are
believed by them to be better able to identify drug diverters because o f their multi
disciplinary approach to pain management, which also equips them to identify and
treat addicts. Two mentioned more education as key to decreasing drug diversion,
with one physician advocating for a change in culture, starting with the very young,
so that people will grow up understanding what causes addiction and the
consequences, as well as what promotes good health. One Florida physician echoed
the Michigan statement regarding the bigger problem of alcohol abuse, stating that
diversion of legal prescription drugs is a small problem in comparison.
On Improving Pain Management

The study participants were asked what could be done to improve pain
management in their respective states. Nine physicians, five from Michigan and four
from Florida, stated that education was the key, with several stating that all providers
(physicians, pharmacists, nurses were mentioned) need more education in what makes
good pain management. The educational setting varied between the study subjects,
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with some emphasizing medical school, another supporting a role model program, and
another nursing school. Three of the Florida physicians favored mandated CME
courses on pain management, even though mandated education is usually resisted by
physicians. He said:
I hate to do this because I don’t like to be mandated—but you will get the
most bang for your buck if it’s mandated.. . . So I think in order to get
physicians to change how they treat pain, sorry to say, much as I don’t like it,
to be mandated to take education, would have a big impact.
Education of the general public on their right to pain management was
mentioned by one Florida physician and one Michigan physician. A Michigan
physician also thought that legislators and the “drug enforcement establishment”
needed more education about pain management. Four Michigan physicians talked
about things that could be done to improve the practice of pain management. One
favored the development of country-wide clinical practice guidelines, available on
computer for point of care use. Two others discussed the importance of proper
diagnostics, and three talked about the proper place for strong medications in the
treatment plan. One of these participants emphasized that physicians should avoid
treating pain just with drugs, while another stated that pain management doctors also
need to deal with “getting people off opioids,” and instead develop a comprehensive
plan of care with a variety of treatments, depending on the identified or perceived
causes of the pain.
In addition to emphasizing education, Florida physicians had other suggestions
for the improvement of pain management. One stated that the environment for
treating pain needs to change, that access to pain specialists must occur earlier in
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treatment. Another agreed, stating that there is a need for good, thorough pain
management specialists and specialties in Florida, and that there are good examples
which can serve as models. One Florida physician was pessimistic and could not offer
any suggestions for the improvement of pain management, stating that, absent any
significant changes, there would be no effective pain management in five to ten years.
On Data Needs
The final question posed to the physicians was about data needs. They were
asked what additional data and statistics are needed to better manage pain and to
address drug diversion. Three of the Florida physicians had no suggestions. Three
talked about the creation of a prescription-oriented database, with one mentioning
that the data should be standardized first. One thought the database should contain
information on known diverters, much like the information maintained on pedophiles.
Another suggested doing a cost-benefit analysis of arresting and prosecuting diverters
to determine if the benefits justify the costs. One suggested that patients be surveyed
at the point of service in the physicians’ offices and in hospital settings to determine
their perceptions and needs.
Michigan participants took a different approach to this question without
exception. Those who offered suggestions for additional statistics and data were very
research-oriented, rather than database specific. Six of the seven physicians
responding to this question talked about the need for much more research, with three
citing the need for outcomes identification. Two stated that research is needed to
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identify best practices so they can be imitated, and another recommended that the
Support Study be done again, to determine if any improvements have been made.
(The SUPPORT Study was conducted in the early 1990s to measure, among other
things, the state o f pain management in institutions.) One physician described the
research he felt was needed. He stated:
There has to be honest data collection o f consequence, diversion, addiction in
the traditional sense, abuse, non-compliance, and long term value that’s
matched by observable changes in life. In other words, I don’t want to just
hear that it makes people feel better, I want to see that it’s made them feel
better. I want to see that they’ve not just become couch potatoes that feel
better. I’d like to see some improvement in their ability to function at home,
their ability to function as a partner in marriage if that’s where they are, or
perform in school or get a job.
Summary

As a general statement, there were some important differences in the opinions
of al three categories of professionals and between the professionals in the two states
and some interesting areas of agreement. The Tables 12 and 13 on the following
pages summarize the findings. These tables summarize 30 interviews conducted in
2004 and 2005 in Michigan and Florida. The individuals participating in the interviews
included 16 physicians, 8 law enforcement officers, and 6 pharmacists. It should be
noted that the summaries contain the opinions, perceptions, and attitudes of only 30
individuals. However, those participating had extensive knowledge of either drug
diversion or pain management issues, or both.
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Table 12
Comparison o f Key Points by Profession
and Categories o f Discussion

Drag Diversion

Influencing
Choice of Drags

State of Pain
Management

Physicians

Pharmacists

Law Enforcement

All expressed a
concern over drag
diversion. Diversion
control not their issue.
Reasons for diversion
by physicians were
money, sexual favors,
and with some,
physician addiction
problems.

General
acknowledgment of a
drag diversion
problem. Need more
funding for addiction
treatment. New
policies addressing
diversion concerns
are time consuming
to implement.

Drag diversion
increasing and the
problem is
significant. Drag
company advertising
direct to consumers is
part of the problem.
Physician involve
ment motivated
primarily by money,
also their own
addiction and for
sexual favors.

Drag use knowledge
learned during
medical school and
from CME courses
was major factor.
Drag company reps
influence, but not
negatively. Addic-tion
concerns with certain
drags. Payer
formularies influ-ence
prescribing.

Physicians need more
education to make
good choices.
Pharmaceutical
company reps exert a
major influence—
good and bad. Payer
formulary also exerts
strong influence.

Pharmaceutical
companies exert
strong influence (but
not necessarily bad).
Lack of physician
expertise on use of
strong medicines—
more education
needed.

Ranked from poor to
average—none above
average. Pain
management is a
function of educa
tion. Addiction fears
are a barrier. MCO
formularies and late
referrals to special
ists a problem.

Pain management is
poor. Based on
knowledge of
individual practi
tioners and on
perception of barriers
in regulatory
environment.

Not much knowledge
of pain management.
Some acknowledged
a chilling effect due
to regulatory activity,
but some disagreed.
All expressed
concerns over
addiction.
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Table 12—Continued

Effect of Public
Policy

Decreasing Drug
Diversion and
Improving Pain
Management

Data Needs

Physicians

Pharmacists

Law Enforcement

Regulatory
oversight produces a
prescribing barrier.
PMPs not a tool in
fighting drug
diversion. Lots of
databases in place,
need to be merged
and reviewed for
gaps before new
policies are created.

Laws and policies are
not a solution to drug
diversion. All
pharmacies had
internal policies to
address diversion
issues

All supported a
monitoring program.
All felt drug
diversion is a
complicated problem
that a PMP would
not solve. PMP
would provide
another tool in the
war on drugs.

Drug diversion will
always be present:
address more
serious problems of
alcohol abuse and
illegal drug use first.
Education of all
providers is needed.
Earlier access to
pain specialists
needed to improve
pain management.

Treating addiction
must be a part of the
solution to diversion.
Pain management
needs more
collaboration between
pharmacists and
physicians.

Education gap on
diversion exists for
public, providers and
law enforcement, but
there will always be
drug diversion. Pain
management not a
concern of officers
interviewed.

Need for more data
was supported:
should be researchoriented,
emphasizing
outcomes and best
practices. Quality of
life improvement is
an important
outcome.

More data are
needed, outcomes
oriented. Use data for
decision-making, not
anecdotal information
or arrests.

Unable to identify
specific data needs,
but should be
consistent when
collected. Also needs
to be timely, to be
useful to law
enforcement.
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Table 13
Comparison o f Comments by State and Subject Area

Drug Diversion

Influencing
Choice of Drugs

State of Pain
Management

Michigan Physicians, Pharmacists,
and Law Enforcement

Florida Physicians, Pharmacists,
and Law Enforcement

Drug diversion is a problem,
physicians not as concerned about
prescription drug diversion. Drug
theft a concern, addiction
treatments needed. Internet
pharmacy concerns expressed.
Money is prime motivator for
diversion activity among health
care professionals.

Felt drug diversion a growing to
serious problem. Internet
pharmacies are a factor. More
laws not a solution. Addiction
treatment attention needed.
Diversion/theft of drugs by
healthcare professionals a
concern. Money is prime
motivation, sexual favors
second.

Acknowledged pharmaceutical
company influence, aggressive but
not problematic. Direct advertising
to consumers, education, experience
and payer influence all cited as
influencing physician drug choices.
Medical school and CME education
very important in choosing
medications.

Acknowledged pharmaceutical
company influence; aggressive,
but only two expressed
concerns. Education in medical
school and CME offerings are
major factors. Payer formularies
also an influence. Addiction
concerns over some drugs.

Average to above average rating for
pain management, in Michigan and
depends on practitioner, and his/her
education and expertise. No one
stated that enforcement activity
created a barrier. Expressed
concerns over addiction with strong
drugs. Need more comprehensive
treatment plans. MCO policies limit
pain treatment choices.

Poor to average pain
management rating for Florida.
More education needed on pain
management and addiction
potential. Enforcement and
regulatory activity can create
barriers, but that is overstated to
the public. Need to use pain
management specialists more.
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Table 13—Continued

Effect of Public
Policy: PMPs

Decreasing Drug
Diversion and
Improvement
Pain
Management

Data Needs

Michigan Physicians, Pharmacists,
and Law Enforcement

Florida Physicians, Pharmacists,
and Law Enforcement

Varied between professions
interviewed, but some in all
categories did support a PMP.
Perception that PMP benefits
physicians and pharmacists more
than law enforcement. None
interviewed believe PMPs were the
solution to drug diversion activity not timely enough. No personal
investigations of physicians by law
enforcement cited.

Law officers disagreed with
physicians in Florida, with law
enforcement supporting a PMP
for drug diversion control, and
physicians supporting them only
if used for medical charts and
records. All felt that PMPs are
not the key to preventing drug
diversion. Physicians and
pharmacists also felt a PMP
would create another barrier for
pain patients. No personal
experience with investigations
were cited.

The need for better education on
both issues was cited by all.
Sentencing, addiction treatment,
and collaboration also very impor
tant. However, drug diversion won't
be eliminated. Need more clinical
practice tools for pain management
improvement: pain patients deserve
treatment even if they have a
substance abuse problem. Law
enforcement felt skills and tools
were available for pain manage
ment, and responsibility of
physicians, while physicians
expressed concerns about education
gaps in those skills and tools.

Need for more education on
drug diversion expressed by law
officers and physicians.
Physicians also cited need for
more pain management
education—perhaps mandated
CMEs.. Treatment of addiction
needs to be addressed, and more
collaboration between
professionals has to occur. Drug
diversion will always be a
problem. Need more pain
specialists. Pain patients deserve
treatment even if they have a
substance abuse problem.

More data needed: physicians only
group to define type of data, calling
for research-based data collection,
including outcomes and best
practice identification. Should be
timely and accessible. More interest
in use of data for pain management
than diversion control.

General desire for a PMP, with
some physician exceptions. Data
that would be helpful are beyond
what a PMP can provide. Data
collection comments were more
oriented to diversion control
than pain management from
Florida participants.
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There were differences and similarities in opinions expressed between
professionals and between Michigan and Florida participants, and related comments
are presented in detail in the Conclusions section o f this report. Some key findings are
noted below.
• Physicians and pharmacists were very supportive of a prescription database,
as long as law enforcement did not have access to the information, and as long as it
was used as a patient care tool. Law enforcement believed they should have access
for drug diversion cases, and would not support a database for health care purposes
only.
• Physicians were more concerned about PMPs as a barrier than either
pharmacists or law enforcement officers.
• Michigan physicians rated the quality of pain management higher in
Michigan than Florida physicians did in Florida.
• Data needed to address drug diversion and pain management were not easy
to define, with physicians seeking outcome and best practices data, and law
enforcement more concerned with timely data for oversight and investigations.
• Physicians in Florida seemed more concerned over diversion control than
did Michigan physicians, who were more focused on patient care, as such concern
related to data needs.
• All interviewed agreed that more education was needed for all professional
who deal with pain management and drug diversion issues.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

162
• There was emphatic agreement that much more attention needs to be paid
to addiction treatment, in order to begin to address the growth of drug diversion.
Surprisingly, there was not much difference of note between the states, even
though they were operating under different drug monitoring policy environments at
the time o f the interview.
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CHAPTER VI
SUMMARY AND CONCLUSIONS
The purpose o f this research is to test the belief that prescribing of controlled
substances in the Schedule II federal classification o f drugs is affected by state-based
public policy that falls under the category o f prescription monitoring programs.
Schedule II drugs are the strongest category of drugs that can be obtained legally.
Drugs are placed in this schedule because they are the most potent and have the
highest potential for addiction. The research questions addressed two possible effects
of public policy that imposes prescription monitoring controls: whether such
monitoring has the power to decrease illegal diversion of prescription drugs, and
whether such laws lower the quality of pain management.
Summary

The study was conducted using two methodologies. Data were gathered and
analyzed for the 15 states in the study to determine if any conclusions could be drawn
after conducting a quantitative analysis. Seven of the states operated with a
prescription monitoring program (PMP) in place during the time period of the study,
and 8 o f the states did not have such laws in effect during that time. A case study
analysis consisting of interviews of physicians, pharmacists, and law enforcement
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officials in Michigan and Florida was also carried out to identify any differences in
practice patterns and perceptions between a PMP and non-PMP state.
The research questions were:
1. Do state controlled substance laws referred to as prescription monitoring
programs (PMPs) help to contain drug diversion activities of Scheduled drugs,
particularly Schedule II drugs?
2. Do PMPs and the regulatory climate limit access to good pain
management?
Drugs classified as Schedule II drugs were identified as the specific
pharmaceuticals of interest in order to make the best connection to prescription
monitoring programs in effect during the study period. Schedule II drugs are often the
drugs of choice for treating chronic, severe pain. During the time of the study, there
were 15 states with PMPs in place. All of those programs monitor Schedule II drugs,
with 7 also covering Schedule III drugs, and 6 monitoring Schedule IV drugs as well.
The research included both drug diversion, a law enforcement issue, and pain
management because they are connected, a fact supported by the literature. They are
two different issues, but as stated by one of the physicians interviewed for the study,
they are “intimately related.” In general, public policy has had an impact on the
delivery of medical care for decades, with Medicare and the Social Security Act
(1935) as benchmark laws along with Medicaid (1969) and the Controlled Substances
Act (1970) being national policies that have had an influence in every state. States
have also implemented additional controls over the practice of medicine through many
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different government programs such as professional licensing requirements,
professional boards, required education, and public policies such as the prescription
monitoring programs which are addressed in this research. Noting the influence that
laws, policies, and programs have on health care, it is clear that the practice of
medicine is controlled to a great extent by such public policy. Thus, any analysis of
public policy such as PMPs for law enforcement purposes should also study the effect
o f PMPs on the delivery of health care to the affected citizens.
As the research progressed from literature review and informal initial
discussions with experts in the field and the actual research began, it became apparent
that the public policy issues surrounding prescription drug diversion and the quality o f
pain management treatment relating to those issues were much more complicated than
initially perceived. In fact, it became evident that diversion of Schedule II drugs does
not exist in isolation from a number of other factors, such as the equally pursued
diversion of drugs in other federal controlled substance Schedules, particularly
Schedules III and IV. For example, in the two states where case studies were part of
the research, Lortab and Vicodin are the most prescribed drugs, and were therefore
believed to be the most diverted drugs. Both of these are brand names for
hydrocodone combinations, generally Schedule III drugs which have a high potential
for abuse and diversion. Other contributing factors include the use of legal and illegal
drugs at the same time (poly-drug use), the role that alcohol plays in combination
with other drugs, and the government’s way of handling addicts who become
criminals. In fact, it was not possible to collect data on drug abuse for drugs
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contained in only one controlled substance schedule; thus, the analysis of information
and subsequent conclusions of this study generally relate to all legal controlled
substances, not just those in Schedule II of the federal Controlled Substances Act.
The states with PMPs were compared to the states that have DAWN data
available in order to help identify a set of states with both DAWN and PMPs, and a
set with only PMPs. The DAWN program collects data on drug abuse episodes and
drug mentions, drawn from cases that present at emergency departments in selected
major metropolitan areas around the country. Although less than ideal, DAWN data
as projected statewide for the states in the study were chosen as the proxy for drug
diversion in the quantitative study because they were the best data available for all
those states during the study period.
SAMHSA (the Substance Abuse and Mental Health Services Administration),
the federal agency responsible for collecting data from emergency department (ED)
visits related to drug abuse, also acknowledged the complicity in collecting data on
drug diversion. Identifying single controlled substances for any study is difficult, since
drug diversion and abuse range from poly-drug use (any combination of legal or
illegal drugs), drug use in combination with alcohol, illegal drugs (Schedule I
substances such as heroin and marijuana), and prescription drugs (Schedules II - IV
and non-scheduled drugs). To illustrate this complexity, the breakdown of emergency
department drug mentions for 2002 reveals that 81% of the drugs identified are from
seven categories, only one of which contains legal controlled substances. SAMHSA
reports:
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Eight out o f every 10 ED drug mentions (81%) come from only 7
categories: alcohol-in-combination, cocaine, heroin, marijuana,
benzodiazepines, antidepressants, and analgesics. In 2002, alcohol-incombination was a factor in 31 percent of ED drug episodes (207,395
mentions), cocaine in 30 percent (199,198) marijuana in 18 percent
(119,472) and heroin in 14 percent (93,519). Collectively, the
benzodiazepines, antidepressants, and analgesics constituted 359,266
ED mentions in 2002, or nearly 30 percent of total ED drug mentions.
(U.S. Department o f Health and Human Services, 2003, p. 25)
Since DAWN reports drug mentions and episodes in different drug categories
than the Schedules in the federal Controlled Substance Act, it became apparent early
in the search for data for the quantitative portion of the study that the research data
could not be restricted to Schedule II drugs. The other salient issue affecting data
collection was the realization that drug diversion would not be easy to quantify.
Extensive data review, foiled requests for information that was not available on a
consistent and comparable basis in the 15 states in the study, and many months of
effort attempting to obtain drug theft data from the DEA forced a change from the
original plan. The decision was made that research could not be restricted to the
diversion o f only Schedule II drugs. The conclusions and recommendations here thus
refer to drug diversion in controlled substance Schedules II-IV.
Data were accumulated to quantitatively test the relationship between drug
diversion, using DAWN data as the proxy for drug diversion as well as other
independent variables. These independent variables, finally selected as a result of an
extensive search for meaningful and consistent data across all 15 states in the study,
were population, new cancer cases, and the presence or absence of a PMP. “New
cancer cases” was used as a proxy for the prevalence of diseases that are likely to
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require the use o f controlled substances. States selected for the quantitative study
included 7 with PMPs and 8 without PMPs. All 15 states had DAWN data and new
cancer cases data available.
The other part o f the study included a number of interviews with physicians,
pharmacists, and law enforcement officials in both Michigan and Florida to determine
differences in attitudes and perceptions in those states. During the study period,
Michigan had a PMP for the monitoring of Schedule II drugs. Michigan has since
replaced its triplicate PMP with an electronic PMP that covers all legal controlled
substances, Schedules II-V. Florida has never had a PMP in place. Michigan and
Florida were selected as the states of comparison because of the author’s familiarity
with those states and ability to identify individuals for the interviews. Thirty
interviews were conducted, 16 with physicians whose practice included a significant
amount of pain management, 6 with pharmacists, and 8 with law enforcement
officials. The interviews were designed to be 30 minutes in length, though several
went longer. Some subjects expanded on their answers during the interview time
voluntarily, providing specific examples of related issues from their own or a
colleague’s practice, or venting their frustration with the system.
Analysis o f the quantitative data was conducted using SPSS software. The
interviews were recorded, transcribed, and then analyzed. In addition, key words were
searched to identify similarities and differences in the responses to the interview
questions.
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Conclusions

In analyzing the research results and preparing conclusions of the study, it is
noted that the qualitative results which are considered with the quantitative results
were obtained from a small sample of professionals, as noted earlier in this chapter.
The interview sample for the case study was limited to 30 individuals. However, the
participants selected all had considerable expertise in drug diversion, pain
management, or with both issues. The following seven conclusions may be drawn
from this study.
1.

There does not appear to be a significant correlation between Prescription

M onitoring Programs and an increase or decrease in drug diversion in the 15 states
in the study. The multiple regression analysis indicated that PMPs had no effect or
may even be negatively correlated to instances of drug diversion as quantified using
DAWN statistics. Although there are some concerns with the regression analysis, this
conclusion was also supported during the interviews conducted for the case study.
The limitations of the regression analysis include the small number of
independent variables and the presence of mutlicollinearity between two of those
variables. Since there were only three independent variables in the regression, the
extensive correlation between two of them generates concern over the results. While
the regression suggests the above conclusion, such concerns support the need for
additional study and more extensive availability of evaluation data. The regression
equation was limited to three independent variables because there was a lack of
consistent and reliable data from other sources to include other variables.
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Interviewed subjects were asked their opinion on the causes of drug diversion
in their state. The majority of those interviewed in all three professional groups
acknowledged a concern with drug diversion. In general they stated that there was a
problem, with law enforcement officials more likely to view diversion as a major
problem. The extent of the problem was substantiated when the increase in drug
episodes and mentions in the DAWN data were compared to the increased size of the
general population. During the 4 years of the study, the population for the country
increased by 5.4%. Drug diversion, as measured by the DAWN data, increased 28%
for the seven states with a PMP and 21% for the eight non-PMP states. Although
such statistics were not tested for other influencing factors, the increase in reported
data from drug-related visits to emergency departments would suggest that there has
been a sizable increase in diversion. The data support the belief that such diversion is
a growing problem.
There was unanimous agreement among the 30 participants that the primary
motivation for drug diversion activity was money—with one subject referring to it as
“big money.” There was also a general acceptance of the view that drug diversion
“will always be with us.” This was a majority opinion of those interviewed and
supported the conclusion that public policies such as prescription monitoring
programs were not likely to be the solution, and indeed there may be no solution.
There was general consistency among the doctors, pharmacists, and law enforcement
officers on these points. They agreed that PMPs are at best a tool that can be used in
the war on drugs, but should not be considered a major factor in such activity.
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Comments from the four Florida law enforcement participants were an exception to
this response, with those individuals stating that a PMP would be of significant help in
addressing drug diversion in Florida.
There is support for this conclusion in the literature reviewed. A study by the
U.S. Department o f Justice (2000) alleged a connection between PMPs and the level
of drug diversion, but admitted that such a connection could not be quantified. A
study by Brushwood (2003) referred to the inconsistencies between data available in
different states, further implying an inability to verify any influence of PMPs on drug
diversion. He stated that such lack o f consistent data makes program evaluation
difficult, further confounding the ability to make a correlation. Data also used by a
USDOJ report from states with PMPs to correlate the existence of a PMP with a
reduction in drug diversion were not conclusive and very assumptive. For example,
that report used statistics such as the decline in arrests for drug diversion to make a
case for a decrease in drug diversion, without addressing other factors that might
influence the arrest numbers. In fact, one source, Reasononline.com, reported that
arrests for drug diversion in the country remained stable (not in decline) over a 3-year
period of this study, even though the number of PMPs increased during that time.
Based on such inconclusive information and lack o f a reliable connection between
PMPs and a decline in drug diversion, the American Alliance of Cancer Pain
Initiatives recommended that no new PMPs be implemented until “existing
information sources have been frilly utilized” (American Alliance of Cancer Pain
Initiatives, 2002).
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There is also some logic to this statement, upon reflection. PMPs collect data
that are retrospective. Data are reported after the diversion has occurred, which
questions the effectiveness o f PMPs as a preventive tool. Law enforcement officials
claim that PMPs do have a preventive role, but no such quantifiable evidence was
presented in any study. In the case o f the Michigan PMP, even in the preferred
electronic program, the data could have a lag time of up to 45 days. This might render
the data useful in investigations, but does not suggest that PMPs have a strong
influence on prevention o f drug diversion.
2. Drug diversion problems and drug abuse are not likely to be eliminated.
The data compiled for the regression analysis indicated an increase in drug diversion,
and the participants in the case study as a whole were resigned to the continuing
existence of diversion and drug abuse. The regression results suggested that drug
diversion may simply be a function of the number of people and the prevalence of
diseases that require the use of controlled substances in the treatment plans. The cycle
of more people, a corresponding increase in chronic diseases with the consequent
production of more drugs and thus the presence of more controlled substances in the
marketplace was mentioned by several study participants. These trends would lead to
an inevitable increase in diversion. When participants in the case study were asked
their opinions on possible activities that could slow the growth of illegal use of
prescription drugs, education and addiction treatment were mentioned most often,
along with the need for more law enforcement resources dedicated to the entire drug
abuse problem. This could imply that public policy to address diversion would be
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better directed towards developing and funding programs that address education
needs, addiction treatment funding, and putting more diversion-trained officers on the
street. These issues are covered in other recommendations.
There was no indication from any of the research efforts that drug diversion
can be eliminated, even with an expansion of public policy such as PMPs. Regardless
o f the professional category o f those interviewed for the qualitative portion of this
research, there was universal agreement that diversion of legal drugs would always be
an issue and a sub-category of the larger problem of drug abuse. This belief was also
supported by the literature. An extensive DEA Report for 1998-99 made that
conclusion, as do ongoing reports on the DEA website. Members of the pain
community also acknowledge the ongoing nature of drug diversion and its growth,
but stop short of suggesting that PMPs are the solution or that there is any solution.
The NSDA surveys report a continuing increase in abuse and diversion, in spite of an
increase in the number of PMPs.
There was, however, some optimism among those interviewed that the growth
in drug diversion and drug abuse could be slowed, but current policies were not
identified as a major weapon in that effort. Rather, the bigger issue of drug abuse
probably needs to be addressed from a global perspective, with other causes—theft,
Internet pharmacies, border access and others—incorporated into the search for an
effective resolution.
The entire subject of how much drug diversion could be attributed to
physician involvement needs a full assessment. It appears that a very small percent of

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

174
physicians are knowingly involved in drug diversion, with one source stating that only
50 physicians had been arrested in the country in 1 year (averaging 1 per state).
Furthermore, the study by Brushwood confirmed the small number o f physician
prosecutions over a 6-year period—less than one-thousandth o f a percent of all
physicians. However, those physicians who are arrested often make national headlines
and prosecutions are very public, so the extent of the drug diversion problem as it
relates to physician involvement may seem larger than it is.
Of consideration here is the cost of programs such as PMPs. If indeed they are
not proven effective, then the cost to taxpayers of such programs is wasteful. A study
by the GAO reported such programs cost state governments up to a million dollars
per year, funds that are clearly better spent elsewhere until the effectiveness of
policies to stem the growth of drug diversion is better identified.
3.

Prescription Drug Programs or related policies may be desirable and very

useful to physicians and pharmacists in patient care design and delivery. This
conclusion was based on interview discussions and a few studies of the effectiveness
of information available through prescription databases. It was also an unanticipated
conclusion, given the widespread concerns over the “chilling effect” on prescribing
controlled substances that is reported by several articles and reports. Students of the
chilling effect phenomenon such as Brushwood, Johnson, and Skelly believe that
PMPs that allow access to law enforcement will serve to limit physician willingness to
prescribe controlled substances. However, databases similar to PMPs may be
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supported by the medical community if their purpose does not include oversight and
investigation of medical professionals.
Of note in the discussions regarding drug diversion was an interest on the part
of the physicians in the study to have access to a prescription database that could be
used exclusively for patient care, with availability only to physicians and perhaps other
clinicians. In fact several participants, including some pharmacists, lamented that there
are current prescription drug databases (private insurances, pharmacy chains, and
Medicaid) that could and should be merged and “talk to each other” so that providers
can get a better picture of the prescription drug history of their patients. Several study
participants indicated that the databases available within pharmacy chains were
already used on an informal basis as pharmacists and physicians stayed in touch
regarding patients considered potential risks for drug diversion. These participants felt
the available information was very useful, but not extensive enough. Pharmacists
within a chain operation have access to their own company’s database, so useful
prescription history is available from within their operations. Physicians who were
dealing with a suspicious patient but were committed to his or her care sometimes
called several local pharmacies in an attempt to determine whether prescription
problems were present.
Using the sources currently available, providers of health care are already
using existing databases to help make good treatment decisions for their patients.
Thus the availability of a comprehensive database on prescription drug use would be a
significant improvement on the informal sharing system already in place. The
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difference between that informal system and the typical PMP is that only providers
can access the informal system, but PMPs are generally accessible to law enforcement
too.
Michigan physicians felt the electronic prescription program that replaced the
original PMP in Michigan (the Michigan Official Prescription Program or MOPP) was
more useful or potentially more useful to the care of their patients than the previous
policy, but it is still a monitoring program, accessible to law enforcement. Few had
used it for patient care as of the date of their interview. Physicians did feel that public
policy intended primarily to monitor physician prescribing was a potential barrier to
good pain management. Michigan physicians were less concerned about such policy
than Florida physicians. However, at the time of the interviews, Michigan had just
replaced its PMP with a “softer” law, and Florida physicians were reacting to the
potential for such a proposal in their state. The political environment was thus felt to
be a factor in the divergent responses. Also in another study, physicians in Utah and
Nevada reported their state’s PMP alerted them to potential diverters, and that was
deemed valuable.
Pharmacists talked more about their own internal checks and balances, and the
ability of their payers’ databases to check for multiple prescriptions from various
providers. More data rather than less were deemed to be important, but the use of the
data should be identified and agreed upon before new programs or policies are
implemented.
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In spite o f deep concerns from clinicians regarding the presence o f a PMP or
related regulatory policy, there was support from both physicians and pharmacists for
a patient database that could be used by the medical community to obtain information
about a patient’s prescription drug history and physician encounters. The physicians
interviewed indicated that they would not be inclined to use such a database very
often due to time constraints, but it would be valuable for patients of concern,
especially if the data were timely. None of the providers felt that such a database
should be accessible to law enforcement. If such a database were to be most useful, it
should produce information that fills an important gap in the health care system. As
one physician so clearly stated, it was his job to take care of patients, not to fight the
war on drugs. If a database becomes a tool solely to improve patient care, it would
likely be welcomed.
4.

Addiction to prescription drugs and the lack o f adequate attention to

addiction treatment were identified as major drug diversion issues by the
participants in the case study. There was a general and strong expression of support
for much more in the way of addiction treatment, if drug abuse is to be effectively
addressed. Study participants from both Michigan and Florida stated that treatment
for addiction, education regarding addiction, and better management of addiction
from a health care perspective are probably a better way to slow the growth of drug
diversion and drug abuse in general. As one pharmacist put it, “a bigger bang for the
buck.” Although examining the effect of greater attention to addiction treatment was
not a part of this study, there was a fairly clear message from the study participants
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that the war on drugs needs to include more in the way o f identification and adequate
treatment of drug addicts, whether they are addicted to prescription drugs, illegal
drugs or alcohol.
Discussion included the need for such care in all settings, not just the
physician’s office. A Florida law enforcement officer and a Michigan sheriff talked
extensively about untreated addiction problems for jailed individuals, who are denied
drugs while in jail but with no treatment are likely to commit drug-related crimes
upon release. Recidivism here is virtually inevitable, according to the law enforcement
officers interviewed. Physician participants were also concerned with the ability of the
medical community to adequately treat patients in pain when the patient might also
have addiction problems. For some, it may be easier to avoid prescribing the right
drugs, rather than deal with addiction or the potential for addiction in their patients.
Addiction to strong medicines was recognized as a potential problem long
ago, with the Controlled Substances Act of 1970 categorizing drugs into Schedules
partially based on their potential for addiction. Unfortunately, addiction is not well
understood as reported in studies such as those by Savage and Zickler, where reduced
prescribing of strong medications was a consequence of such misunderstandings.
More attention to treatment for those addicted to prescription drugs or any
other drug makes sense, since any decrease in drug-seeking behavior is likely to
decrease prescription drug diversion. In addition, adequate reimbursement for
addiction treatment should improve access and encourage such care. Greater
awareness and improved access may also remove some physician fears over treating
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what one referred to as “risky patients,” and thus foster a climate for improved pain
management. Although it was outside the scope of this research to test the effect of
good addiction treatment resources on the incidence of drug diversion and abuse, the
issue was mentioned and discussed enough by several study participants to suggest
further study.
5.

There is a needfor more education o f health care professionals on both

drug diversion issues and the treatment o f patients with chronic pain conditions. This
conclusion was expected, based on the literature, especially the literature on the
quality of pain management. A lack of sufficient knowledge of strong medicines,
addiction issues, and the treatment of chronic pain conditions were mentioned most
often by the case study participants from the two states, both in the context of what
needs to be done to decrease diversion and what needs to be done to improve the
quality of pain management. Many of the participants felt that medical school training
on the use of controlled substances was not sufficient to address the treatment of
patients with severe, chronic pain conditions that they might see during the years of
their professional practice. This was supported by an Institute of Medicine study
(Kaplan, 2004), which reported that specific education on pain management is not
routinely included in medical school training. The same dearth of education was
reported for nursing schools and schools of pharmacy. According to Fishman and
Gallagher (2004), no state licensing boards mandate CMEs in either pain management
or drug abuse, so additional knowledge on these subjects is optional for physicians
and other medical professionals. Several of the interviewed physicians stated that the
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drugs learned in medical school become the primary medication choices, with
additional knowledge of new drugs obtained mostly through interaction with
pharmaceutical company representatives and perhaps some voluntary CME courses.
The physician education obtained through pharmaceutical company
representatives was determined to be an important source of knowledge of the
benefits of new pain management drugs. However, concerns were expressed that such
education was limited in scope most of the time to accentuate the positive and to limit
education on the dangers o f new medicines. None of the participants felt that drug
company education should be eliminated, just expanded in its scope. In particular,
several of those interviewed said that pharmaceutical company education would be
much more valuable if the presentations included full information on the medication
risks, and provided assistance in identifying those populations of patients who are not
suited for such new drugs. Nearly all of the subjects in the case study felt that
pharmaceutical company information and education was extremely valuable, and there
appeared to be no good substitute or alternate source for that knowledge. The
concern was that the presentations were not comprehensive enough.
Education of the general public on the use of certain brand name prescription
drugs using TV, radio commercials, and other media was not viewed as education by
anyone in the study. Very little information can be delivered in a 30-second
commercial, and public advertising is designed solely to increase demand for a
product. Public advertising of new medicines was actually reported to be a problem
by some of the physicians in the study, since patients demanding prescriptions for
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advertised new drugs did not appear to be isolated incidents. It is important to note
that continuation of such advertising, although a part of the fabric of business, is not
considered health care education and is not a part of the conclusions related to
education that are contained in this research.
Interestingly, a report by the OIG called for “more adequate training” of DEA
agents. EDA head Dr. Donald Meyer also called for more physician education on
drug diversion. Overall, there appears to be a significant gap in education and training
on the related subjects of pain management and drug abuse.
6.

Among those interviewed, PMPs and other related public policies were

more o f a concern as a potential barrier to good pain management to physicians
than pharmacists or law enforcement officers. The majority of the physicians in both
Michigan and Florida felt that regulatory oversight and fear of practice sanctions
generated greater concern within the physician community than prescribing certain
drugs that help to control pain. This perception is supported in the literature
(Joranson, Angarola, Brushwood). This “chilling effect” was the subject o f much
discussion during the interviews, in spite of the fact that very few physicians are
actually prosecuted for their involvement in drug diversion.
There did not appear to be a difference in that concern between physicians in
the two states in the study. However, the Michigan contingent rated the quality of
pain management somewhat higher than the Florida contingent. This might suggest
that public policy does not, in practice, affect the quality of pain management, as
Michigan has a controlled prescribing program and Florida does not. This was a
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surprising finding, since the Michigan medical community had complained long and
loudly in the past about the diminished quality of pain management due to the
presence of a PMP. Perhaps the change in the PMP policy that went into effect in
2003 improved the treatment of pain, or at least the perception o f such treatment.
Michigan physicians did state that there was more of a chilling effect before its
monitoring program was modified to an electronic tracking system. It was not
determined if this change in policy improved the treatment of pain, and in fact nothing
in the interviews would suggest that such improvement had happened. No data were
available, and no research is evident in Michigan to determine if the quality o f pain
management has improved since the change in policy.
Florida physicians, practicing in a state without a PMP, actually rated the
quality of pain management lower than Michigan physicians. Certainly that could be
due to issues other than policy, but what it suggests in this study is that policies such
as PMPs are not a primary factor in the quality of pain management. That indeed was
supported by the results of the multiple regression.
In fact, physicians from both states, many of the pharmacists, and even some
o f the law enforcement officials were more concerned with the lack o f a
comprehensive approach to pain management, the scarcity of pain management
specialists, and the payer reimbursement barriers to the use of pain specialists. Payer
concerns include late referrals to pain specialists and lack of reimbursement for the
medications and therapies of choice early in the course of treatment for a chronic pain
condition.
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7.

There is a lack o f sufficient, accessible, consistent and reliable data to

define and measure both the extent o f drug diversion and the quality ofpain
management. Without such data, it is difficult to determine the magnitude o f either
problem, and impossible to know if activities to address such issues are of benefit. As
noted earlier, months were spent trying to collect data that better measured
prescription drug diversion than the DAWN statistics. A variety of data was collected
from state to state and even county by county, but on an inconsistent basis, so
combining data for analysis purposes was not possible. Access to some data, most
notably drug theft data, was denied even after several months of contact with the
DEA and proper application for such data through the Freedom of Information Act.
Subjectivity in data collection was identified, particularly in the case of data related to
causes of death.
Difficulties were also encountered when attempting to measure the state of
pain management. Most of the information to measure the incidence of pain was
collected through surveys that asked general questions about pain, rather than trying
to quantify the consequences of poor pain management. There are inconsistencies
with those studies that affect credibility. For example, a Florida survey of pain
(MacManus & Schuler, 2003), reported that as many as 75% of Floridians suffered
from unmanaged pain; a survey in Michigan (EPIC MRA, 1997) reported 20%, and a
national survey (Office of Applied Studies, 2005a) reported 57%. Regardless of
differences in the way the surveys were structured, the reported numbers are those
stated which are too inconsistent to be useful. According to research conducted by

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

184
Dean (2004), pain was only recognized as a complicated medical problem in the late
20th century, so gathering data on the treatment of pain is a fairly contemporary and
thus an evolving activity. Some studies such as the JCAHO pain assessment module
for institutionalized patients and the SAGE study o f pain in nursing home patients
provide good information, but those studies are targeted at a small percent of the
population, and rely to an extent on observations rather than improvements in quality
of life. As one of the interview subjects stated, he doesn’t want to see “couch
potatoes that feel better,” rather the measure of successful pain treatment is
improvement in the ability to function at home, at school, on the job, as a partner in
marriage or in other personal, social settings.
Physicians interviewed stated, in a number of different ways, that trusting
what patients tell them about the state of their pain condition is simply not possible,
much as they would like it to be.
So there needs to be good data collection including statistics on diversion,
addiction, abuse, non-compliance, long-term life style improvements and good health
outcomes to truly asses the state of pain management and determine improvements.
Without such data, finding solutions will continue to be a trial and error effort.
Without benchmark data on both drug diversion and the state of pain
management, there is no reliable way to make a case for any program or policy to
change the current state of either issue. If drug diversion and the quality of pain
management cannot be defined and measured, then the success or failure of a policy
cannot be measured. Benchmark data also allow for the setting of goals for new
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programs, such as targeting a 10% reduction in lost workdays due to pain, or a 5%
reduction in hospitalizations due to uncontrolled pain, or an 8% reduction in thefts of
controlled substances over a 2-year period, or a 5% reduction in deaths with
controlled substances present. Without reasonable data, those who fund policies and
programs to address drug diversion and improvements in the care of pain patients will
never know what success should look like, and they are likely to eliminate funding
after a short while. Worse, they could continue to fund programs that may be
perceived to address the issues but do not, thereby preventing the identification of
meaningful solutions.
Lack of good data is an insurmountable barrier to the identification and
implementation o f programs that work well. It is addressed as a recommendation of
the research.
The research was designed to find answers to the following questions.
1. Do state controlled-substance laws referred to as prescription monitoring
programs (PMPs) help to contain drug diversion activities of Scheduled drugs,
particularly Schedule II drugs? In particular, did the existence of these laws in seven
states significantly reduce such diversion as compared to eight other states, which do
not have such laws in place?
2. Do PMPs and the regulatory climate limit access to good pain
management? Is access to pain management greater in Florida than Michigan? Did
Michigan’s PMP pose a significant barrier to adequate pain management?
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The research found nothing to indicate conclusively that PMPs either help or
hinder drug diversion activities. There is, however, some evidence that they are at
best a minimal tool in such activity, but perhaps are not worth the cost of
implementation and maintenance. Further, there was no evidence that the amount of
prescription drug diversion in these states was a function of the presence or absence
of a PMP.
It is likely that PMPs may create a barrier to good pain management for some
physicians, but there is no way to measure the extent of such a barrier. Access to
good pain management was not considered a function of laws or public polices—
PMPs or other policies—in either Florida or Michigan.
Recommendations
In light of the conclusions in response to the research questions, four major
recommendations are offered. The recommendations that follow all have an effect on
public policy and its place in the war on drugs and the war on pain, with one
exception. The education recommendation has an indirect effect on public policy, as
mandated education is included in the commentary. There are also policy implications
in the seven conclusions. Public policy has a cost, so there are costs connected to the
recommendations that are a result of this research. However, there are also
tremendous costs to implement policies that are not effective. The recommendations
and conclusions are directed at containing additional costs for current policy while
seeking better answers.
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There were no research results which suggested that the current PMP policies
are an effective use of public funds or human resources. In fact, there is some
evidence that such policies may negatively affect pain management even if they do
reduce drug diversion. Thus, there is no recommendation that additional states should
implement PMPs, given the current level of information available on their
effectiveness. The recommendations instead discuss a means o f obtaining the
information that can be used to make decisions on what policies will play a significant
role in reducing diversion of legal drugs to illegal use, while doing no harm to the
treatment of pain patients.
The four recommendations follow.
1.

States should not implement a PMP or related public policy to address

drug diversion until information is available to assure that such a p o licy’s purpose is
clear and that implementation is cost-effective. The goals of such a policy should be
established and accepted by the public before implementation. The costs to start and
maintain a PMP should be publicized to insure that the results justify the costs. In
general, there was not sufficient evidence in this research to defend the creation of a
PMP for drug diversion control purposes.
However, states may wish to consider proceeding with a PMP or related
policy that is limited to assisting health care professionals in the delivery of good
patient care. There was support for prescription databases that help physicians and
pharmacists with information on patient prescription history, with no access by law
enforcement except by subpoena. Such a prescription database would allow
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physicians and pharmacists to access prescription drug information for patients who
are a part of their practice, providing them with additional information to help identify
problems or potential problems for treatment purposes. For example, a prescription
history for a pain patient might indicate that the patient had seen several doctors for
the treatment of his or her pain in the past few months, but after review o f that history
with the patient, it might be learned that the use of multiple doctors was a result of no
relief for the pain. Or the physician might learn that the patient had a drug diversion
or addiction issue, but still suffered from a pain condition, and needed more intense
management of the treatment plan, such as prescribing smaller quantities of drugs,
requiring a doctor-patient contract on the use of drugs, or including required drug
testing as a part of the treatment plan. The physician might also decide after review
that the patient’s condition cannot be treated at his or her office, and thus justifies an
earlier referral to a pain specialist.
Thus, for purposes of earlier identification of the entire medical issue which
should foster earlier comprehensive and preventative treatment, it is recommended
that state governments considering PMPs do so for medical treatment reasons only,
and not for drug diversion investigations. PMPs that go beyond such medical purpose
should be thoroughly researched, not only for cost-effectiveness but also for their
implications in the treatment of pain patients and to determine their real effect on
decreasing diversion of prescription drugs.
2.

Data identification and collection needs to be implemented on a large

scale to better address both drug diversion and the quality o f pain management. This
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should include benchmark data to set the stage for measuring the level of
effectiveness of activities designed to address problems in these two areas. The need
for better data and a means of measuring the extent of diversion of prescription drugs
and o f measuring pain management efficacy was evident in both the search for useful
data in the development of the regression equation and with the subjects interviewed
for the case study. “Better” data were described by the physician community and
some of the pharmacists as needing to be research-oriented, with attention to best
practices and outcomes.
Suggestions for research went far beyond mere surveys or small focus groups,
and certainly extended beyond a few isolated incidences that might gamer public
attention. They included research to identify best practices in both pain management
and addiction treatment, and the development of evidenced-based care plans as a
result of the research. Behavior studies were suggested, especially to better
understand the psychological bases for pain that is hard to control and also to better
understand addiction. More extensive research on the consequences of poor pain
management and lack of access to pain specialists and addiction treatment was
mentioned, along with studies of what earlier treatment of chronic pain means from
both a personal and economic perspective. A system to translate the research into
practice was mentioned as a critical component of any studies.
In the effort to collect data for the multiple regression in this study, the lack o f
consistent information, the lack of accurate information, and sometimes the sheer
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absence o f data was the single most critical issue preventing a better look at how
policies such as PMPs can change drug diversion patterns.
Interestingly, much of the data needed to improve the analysis of how policy
affects diversion activity appears to be available; it is just either not accessible or not
maintained in the same format. For example, it would have been enlightening to have
drug theft data for the years o f the study for all the study states. This information is
available (required to be reported to the DEA by each pharmacy), gathered quarterly
by DEA district offices, and then submitted to DEA headquarters in Virginia where it
is stored. I was able to obtain only one year of drug theft data from the DEA before
access was denied for such data for the other years in the study. An analysis of that
year’s data indicated that drug theft from pharmacies probably constitutes a major
proportion o f prescription drugs that are diverted. If drug thefts from pharmacies are
highly correlated with an increase or decrease in drug diversion, then it would be
logical to take action to decrease pharmacy theft as a primary step in decreasing drug
diversion. Public policy could then be directed at controlling pharmacy thefts, rather
than directed at diversion that might be the result of prescribing activities.
Similarly, it would have been helpful to include data on the number of drugrelated deaths in the states, with perhaps a reduction in such deaths suggesting a sign
of improvement. However, death statistics are maintained differently from state to
state, and there is no current way to take the death statistics for a number of states
and use them statistically in their present format. Causes of death and secondary
causes of death are sometimes verified and at other times not verified. It would be
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normal, for example, in a car accident for death to be recorded as death by accident,
rather than a drug overdose, even if drugs were the cause, because autopsies to
determine actual cause of death are the exception rather than the norm in most areas
o f the country.
Equally lacking is good data on the state of pain management and a means of
measuring whether pain management is improving. Information used to discuss and
quantify the state of pain management was generally available only through surveys
that queried individuals on their opinion of their own pairi and how they viewed its
effect on their lives. Such studies were one-time assessments, and some of the
questions used were of dubious value, since they often contained little that could be
measured. For example, one study asked subjects if they had experienced pain in the
past month, without clarifying the permanent or temporary nature of such pain (an
occasional headache is different from chronic back pain). In order to assess properly
the state of pain management and thus be able to determine the effect of public health
policy on the treatment of pain, a means of collecting data that measures the quality of
pain management must be identified. One of the physicians in the study said it well
when he stated that improved pain management means a better quality o f life:
employment, family relations, social activities, and involvement in the community
must be assessed to determine if there are barriers to effective treatment and when
such barriers are being removed.
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The need for better, more accurate, and accessible data is critical to making
good policy decisions. It is recommended that such data collection proceed before
any policies such as PMPs are implemented.
3.

Education on drug diversion and pain management should be a priority

fo r physicians, pharmacists, law enforcement officers assigned to anti-drug activity,
and managed care entities. Every participant in the case study commented on the
need for more and better education on pain management and drug diversion, with
some commenting extensively on the subject. Managed care entities should be added
to the list of those in need of additional education. Several of the case study
participants stated that the payer’s policies exert the final influence on prescribing
patterns and treatment plans for those in pain and those who may have a related drug
abuse problem.
Education goals should be established to increase provider and law
enforcement knowledge and understanding of drug diversion and addiction issues,
including how best to manage those individuals. Education for providers and payers
should be regularly available that will serve to increase the quality o f pain
management for those physicians and managed care companies who may have clients
with a chronic pain condition. Although only 30 individuals were interviewed for the
study, there was enough consensus on this issue to lend some credibility to the
proposals that professionals be required to take some CME courses on both subjects
in order to renew their licenses. Mandated education on specific topics is not
embraced by the health care community, and there is evidence that CME education
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does not change practice behaviors. However, with pain being one of the primary
reasons that people seek medical care and with the growth in drug abuse and drug
diversion, I believe a case can be made to require some type of regular, unbiased
education for health care professionals on both subjects.
4.

A better means o f addressing addiction should be identified that w ill

reduce the number o f individuals whose lives are controlled to some extent by the
need to use drugs in a way that is against medical advice. Dealing with drug addicts
in a positive way was the second most common topic of conversation among those
interviewed. In addition, the literature supports better attention to addiction concerns
as one of the critical components in any plan to reduce drug diversion. Although
outside the scope of this study, comments made in some of the interviews suggest
that data on addiction treatments available to the general public and to those addicts
who are incarcerated should be incorporated into future statistical analyses of what
influences drug diversion.
Improvement in addiction treatment will need additional funding from the
government and through private insurers and managed care companies. Addiction
treatment centers are often only available to those with private funds, or on a limited
basis to those with a health plan benefit. Treatment for addiction and the provision of
related support systems should continue for those affected for as long as necessary, as
such practice is cost-effective and in the long run helps to assure the safety of the
community and the individual, and improves quality of life.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

194
Suggestions for Further Research
The extensive search for relevant independent variables and the rich
conversations with the study participants revealed a number of areas that invite more
study. However, three topics seemed to surface in the research more often during the
months of the study, and are offered here as strong suggestions for further research.
1. Research should be conducted to identify a means of measuring drug
diversion (alone or as part of a full drug abuse agenda) so that activities to combat
these problems can be identified and then tested for effectiveness. The research should
identify a method or system that would assure consistent data collection across
regions and the entire country so that an accurate picture of the drug diversion
problem is available. The research should be designed to allow comparison o f drug
diversion problems to the bigger issue of drug abuse to determine the areas of most
concern. This will be very helpful in identifying priorities for public funding as well as
the assignment of human resources. Without such research and the consequent ability
to better define drug diversion, proposed solutions are not likely to be realistically
based, and the results of such solutions cannot be tested for effectiveness.
2. Similarly, research is needed to identify a means of measuring the quality of
pain management beyond general surveys of pain patients. Such research should go
beyond soliciting opinions regarding just pain intensity or just duration of the painful
condition. A higher quality of pain management will result in a better quality of life,
which means improvement in functional abilities at home and on the job, school
performance and social involvement—not just feeling better. Some studies have been
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done to measure days lost from work due to pain problems and to translate the lost
productivity into a cost to business. More such studies should be done to determine
the cost of untreated or under-treated pain, so that the frill effect on families and
communities can be measured. This would then provide a means to determine if
public or private activity was effective in improving the benchmarks.
3.

Research is suggested to determine the cost-effectiveness of addiction

treatment. Better attention to the medical treatment of drug addicts was mentioned
repeatedly as is discussed in the recommendations section. Importantly, research to
find a cost-effective means of treating addicts earlier in their disease is very critical, to
limit damage to their future health. Untreated, drug addiction sadly often results in an
early death. On the way, it can cause tremendous dysfunction in families and
relationships, and once the addiction becomes a part of life, it is very hard to bring it
under control. Addiction treatment research is particularly important for those who
are incarcerated, because untreated addictions encourage recidivism upon release.
Addiction research should thus be designed also to identify priorities for public
funding of addiction treatment.
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Alliance of States with Prescription Monitoring Programs
States with Prescription Monitoring Programs1
STATE

YEAR

“MONITORING

DRUG

~

MANAGING AGENCY- WEBSITE*"

ENACTED2 SYSTEM 1

SCHEDULES
AND GROUPS
MONITORED

TYPE

CALIFORNIA

1939

Triplicate + Electronic

C-ll

Justice Dept.

HAWAII

1943

Duplicate

C-ll

Public Safety Depl

Electronic

C-ll, III, IV

Duplicate

O-ll

Electronic

C-ll, III, IV

IDAHO

1967

Pharmacy Board

ILLINOIS

1961

Electronic

C-ll

Human Sendees Dept

INDIANA

1987

Single-copy +
Electronic

C-ll, III, IV, V

Public Safety Dept

KENTUCKY

1998

Electronic

C-ll, III, IV, V

Health Dept

MASSACHUSETTS

1992

Electronic

C-ll

Health Dept.

MICHIGAN

1988

Single-copy,
serialized + Electronic

C-ll

Consumer & Industry
Services Dept

NEVADA

1995

Electronic

C-ll, III, IV

Pharmacy Board

NEW MEXICO

1994

Electronic

C-ll

Pharmacy Board

NEW YORK

1972

Single-copy,
serialized + Electronic

C-il and
Benzodiazepines

Health Dept

OKLAHOMA

1990

Electronic

C-ll

Narcotics & Dangerous
Drugs Control Bureau

http://caag.state.ca.us
http://www.state.hi.u8/icsd/psd/ps
d.html
http://www.state.id. us/bop

http://www.state.ii.us/
http://www.state.in.us/safetynet
http://publichealth.state.ky.us/dru
g_control.htm
http://www.state.ma.us/dph/dcp/
http://www.cis.state.mi.us
http://www.state.nv.us/pharmacy/
frame.htm
http://www.state.nm.us/pharmacy
http://www.health.state.ny.us
http://www.state.ok.us/~obndd
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RHODE ISLAND

1978

Electronic.

C-ll, III

Pharmacy Board -

TEXAS

1981

Single-copy,
serialized + Electronic

C-ll

Public Safety Dept

UTAH

1995

Electronic

C-ll, III, IV, V

Professional Licensure
Division

WASHINGTON

1984

Triplicate

C-ll, III, IV, V

Pharmacy Board

WEST VIRGINIA

1995

Electronic

C-ll

Pharmacy Board

http://www.health.state.ri.us/hsr/p
harmacy.htm
http://www.txdps.state.tx.us
http://www.commerce.state.ut.us/
dopl/dopi1.htm
http://www.doh.wa.gov/pharmacy
http://www.state.wv.us/sos/corp/
proflicense.htm

1Information current as of March 2001.
2 Year original program enacted; does not reflect subsequent amendments.
3 May be different than original system type at time of original program enactment
4 Listed state websites do not necessarily have information on prescription monitoring programs.
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Controlled Substance Schedules > List of Controlled Substances > Schedule II

C on trolled S u b s t a n c e s in S c h e d u le II

This document Is a general reference and not a comprehensive list This list describes the basic or parent
chemical and does not describe the salts, Isomers and salts of Isomers, esters, ethers and derivatives
which may also be controlled substances.
Substance
1-Phenvlcydohexvlamine
1-PlDerfdinocvclohexanecarbonitrile
Mfentanil
Alphaprodtae
Amobarbital
Amphetamine
Anileridine
Benzoylecgonine
Bezitramlde
Carfentanil
Coca Leaves
Cocaine
Codeine
Dextropropoxyphena, bulk (non-dosage forms)
Dihvdrocodeine
Dihydroetorphine
Diphenoxylate
□iprenorphine
Ecgonine
Ethylmorphlne
Etorphine HCI
Fentanyl
Slutethimlde
Hydrocodone
Hydromorphone
Isomethadone
Levo-aiphacetylmethadol
Levomethorphan
Levorphanol
Meperidine
Meperidine intermediate-A
Meperidine intermediate-8
Meperidine intermediate-C

DEA
Number
7460
8603
9737
9010
2125
1100
9020
9180
9800
9743
9040
9041
9050
9273
9120
9334
9170
9058
9180
9190
9059
9801
2550
9193
9150
9226
9648
9210
9220
9230
9232
9233
9234

Narcotic
N
N
Y
Y
N
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y

Other Names
PCP precursor
PCC, PCP precursor
Alfenta
Nisentil
Amytal. Tuinal
Dexedrine, Adderall, Obetrol
Leritine
Cocaine metabolite
Burgodin
Wildnil
Methyl benzoylecgonine, Crack
Morphine methyl ester, methyl morphine
Propoxyphene
Didrate, Parzone
DHE
M50-50
Cocaine precursor, in Coca leaves
Dionin
M 99
Duragesic. Oralet Actiq, Sublimaze, innovar
Doriden. Dorimide
dihvdrocodeinone
Dilaudld, dihydromorphinone
isoamidone
LAAM, long acting methadone, levomethadyl acetate
Levo-Oromoran
Demerol. Mepergan. pethidine
Meperidine precursor
Meperidine precursor
Meperidine precursor
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Metazodne
Methadone
Methadone intermediate
Methamphetamine
Methylphenidate
Metopon
Morairide-intermedlata
Morphine
Uabilone
Opium extracts
Opium fluid extract
Opium poppy
Opium tincture
Opium, granulated
Opium, powdered
Opium, raw
Oxycodone
Oxymorphone
Pentobarbital
Phenazodne
Phencyclidine
Phenmetrazine
Phenylacetone
Piminodine
Poppy Straw
Poppy Straw Concentrate
Racemethorphan
Racemorphan
Remifentanil
Secobarbital
Sufentanil
Thebaine

9240
9250
9254
1105
1724
9260
9802
9300
7379
9610
9620
9650
9630
9640
9639
9600
9143
9652
2270
9715
7471
1631
8501
9730
9650
9670
9732
9733
9739
2315
9740
9333

Y
Y
Y
N
N
Y
Y
Y
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
N
Y
N
N
N
Y
Y
Y
Y
Y
Y
N
Y
Y

Dolophine, Methadose, Amidone
Methadone precursor
Desoxyn, D-desaxyephedrine. ICE. Crank, Speed
Concerts, Ritalin, Methytin

MS Contin, Roxanol, Oramorph. RMS. MSIR
Cesamet

Papaver somniferum
Laudanum
Granulated opium
Powdered opium
Raw opium, gum opium
OxyContin. Percocet, Endocet. Roxicodone, Roxicet,
Numorphan
Nembutal
Narphen, Prinadol
PCP, Sernylan
Preludin
P2P. phenyl-2-propanone, benzyl methyl ketone
Opium poppy capsules, poppy heads
Concentrate of Poppy Straw. CPS
Dromoran
Ultiva
Seconal. Tuinal
Sufenta
Precursor of many narcotics

B a c k io jo g

Registration Support
Toll Free Number 1-800-882-9539
ARCOS | Career Opportunities | Chemical Program | Controlled Substa n ce Schedules | Drugs and Chem icals of Concern
Electronic Commerce Initiatives I I Federal Register Notices I Import Export i Links I Meetings and Events | NFLIS
Offices & Directories | On-Line Forms & Applications | Program Description | Publications | Q uestions & Answers | Q uotas
Reports Required by 21 CPR | Title 21 Regulations & Codified CSA
Contact Us I Home | Hot Items | Site Map | Search | What's New
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Controlled Substance Schedules > List of Controlled Substances > Schedule III

C ontrolled S u b s t a n c e s in S c h e d u le III

This document Is a general reference and not a comprehensive list. This list describes the basic or parent
chemical and does not describe the salts, Isomers and salts of isomers, esters, ethers and derivatives which
may also b e controlled substances.
DEA
Narcotic
Other Names
Number
13Beta-ethvl-17beta-hvdroxvaon-4-en-3-one
4000
N
17AlDha-methvl-3alDha.17beta-cShvdroxv-5alDha-androstane
4000
N
17AlDha-metfivl-3beta.17beta-dhvdroxv-5alDha-androstane
4000
N
17Alpha-methvl-3beta.17beta-dlhvdraxyandrost-4-ene
4000
N
17Alpha-methyl-4-hydroxynandrolone (17alpha-methyl-4-hydroxy-17beta-hydroxyestr-4- 4000
N
sn-3-one)
17Alpha-methyl-delta1-dihydrotestosterone (17beta-hydroxy-17alpha-methyl-5alpha4000
N
17-Alpha-methyl-1-testo8terone
androst-1 -en-3-one)
19-Nor-4-androstenediol (3beta,17beta-dihydroxyestr-4-ene; 3aipha,17beta4000
N
cShydroxyestr-4-ene)
19-Nor-4-androstenediona (estr-4-en-3,17-dlone)
4000
N
19-Nor-5-androstenediol (3beta,17beta-dihydroxyestr-5-ene; 3alpha,17beta4000
N
Shvdroxveatr-5-ene)
19-Nor-5-androstenedione (estr-5-en-3,17-dione)
4000
N
1-Androstenediol (3beta,17beta-dihydroxy-5alpha-androst-1-ene; 3afpha,17beta4000
N
rShydroxy-5alpha-androst-1-ene)
1-Androstenedione (5alpha-androst-1 -en-3,17-cSone)
4000
N
3Alpha,17beta-dihydroxy-5alpha-androstane
4000
N
3Beta,17beta-dihydroxv-5alpha-androstane
4000
N
4-Androstenedlol (3beta.17beta-dihvdroxv-androst-4-ene)
4000
N
4-AD
4-Androstenedlone (androsM-en-3.17-dlone)
4000
N
4-Dihydrotestosterone (17beta-hydroxyandrostan-3-one)
4000
N
Anabolex, Andractim, Pesomax
Stanolone
4-Hydroxy-19-nortestosterone (4,17beta-cfhvdraxvestr-4-en-3-one)
4000
N
1-Hydroxytestosterone (4,17beta-dhydroxyandrost-4-en-3-one)
4000
N
5-Androstenediol (3beta.17beta-dihydroxy-androst-5-ene)
4000
N
5-Androstenedione (androst-5-en-3,17-done)
4000
N
Amobarbital & noncontrolled active ingred.
2126
N
Amobarbital suppository dosage form
2126
N
4000
Anabolic steroids
N
"Body Building” drugs
Androstanedione (5alpha-androstan-3,17-dione)
4000
N
Aprobarbital
2100
N
Alurate
Barbituric acid derivative
2100
N
Barbiturates not specifically list*
Benzphetamlne
1228
Didrex, Inapetyl
N
Substance
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Bdasterone (7alpha, 17alpha-dmethvl-17beta-hydroxyancfrost-4-en-3-one)
Bddenone (17beta-hydroxyandrost-1,4-diene-3-one)

4000
4000

N
N

Buprenorphine

9064

Y

Butabarbital (secbutabarbital)
Butalbital
Butobarbital (butethal)
Calusterone (7beta. 17alpha-dimethvl-17beta-hvdroxvandrost-4-en-3-one)
Chlorhexadol

2100
2100
2100
4000
2510

N
N
N
N
N

CHorphentermine

1645

N

Clortarmine
Clostebol (4-chloro-17beta-hydroxyandrost-4-en-3-one)

1647
4000

N
N

Codeine &iaoqulnoline alkaloid 90 mg/du

9803

Y

Codeine combination product 90 mg/du

9804

Y

Dehydrochloromethyltestosterone (4-chloro-17beta-hydroxy-17alpha-methylandrost-1,4den-3-one)
Deltal -dhydrotestosterone (17beta-hvdroxv-5alpha-androst-1 -en-3-one)
Dihydrocodeine combination product 90'mo/du
Dronabinol in sesam e oil in soft gelatin capsule

4000

N

4000
9807
7369

N
Y
N

Drostanolone (17beta-hvdroxv-2alpha-methyl-5al pha-androstan-3-one)
Ethylestrenol (17alpha-ethyl-17beta-hydroxyestr-4~ene)

4000
4000

N
N

Ethylmorphlne combination product 15 mg/du
Fluoxymesterone (9-(Iuoro-17alpha-methyl-11beta, 17beta-dhydroxyandrost-4-en-3one)
Formebolone (2-formyl-17alpha-methyl-11alpha, 17beta-dihydroxyandrost-1,4-den-3one)
Furazabol (17alpha-methyl-17beta-hydroxyandrostanof2,3-cl-furazan)
Samma Hvdroxvbutvric Add preparations
hiydrocodone &isoquinoline alkaloid <15 mg/du

9808
4000

Y
N

Anadroid-F, Halotestin, Ora-Tet

4000

N

Esidene, Hubernol

4000
2012
9805

N
N
Y

Hydrocodone combination product <15 mg/du

9806

Y

Ketamine
Lysergic acid
Lysergic add amide
Mestanolone (17alpha-methyl-17beta-hydroxy-5alpha-androstan-3-one)

7285
7300
7310
4000

N
N
N
N

Mesterolone(1alpha-methyl-17beta-hydroxy-5alpha-androstan-3-one)
Methandenone(17alpha-methyl-17beta-hydroxyandrost-1,4-diene-3-one)

4000
4000

N
N

Methandriol (17alpha-methvl-3beta.17beta-dihvdroxvandrost-5-ene)
Methendone (1-methyl-17beta-hydroxy-5alpha-androst-1-en-3-one)

4000
4000

N
N

Methyldienolone (17alpha-methvl-17beta-hydroxyestr-4.9(10)-den-3-one)
Methyltestosterone (17alpha-methvM7beta-hydroxyandrost-4-en-3-one)
Methyltrienolone (17alpha-methyl-17beta-hydroxyestr-4,9,11-trien-3-one)
Uethyprvlon
Mibolerone(7alpha,17alpha-dimethyl-17beta-hydroxyestr-4-en-3-one)
Morphine combination product/50 mg/100 ml or gm
Malorphine
'Jandrolone (17beta-hydroxyestr-4-en-3-one)

4000
4000
4000
2575
4000
9810
9400
4000

N
N
N
N
N
Y
Y
N

Norbolethone/13beta,17alpha-<Jethyl-17beta-hydroxygon-4-en-3-one)

4000

N

Equipoise, Parenaboi, Vebond,
dehvdrotestosterone
Buprenex, Temgesic, Subutax,
Suboxone
Butisot. Butibel
Fiorinal, Butalbital with aspirin
Sonervl (UK)
Methosarb
Mechloral, Mecoral, Medodorrn
Chloralodol
Pre-Sate, Lucofen, Apsedon,
Desopimon
Voranil
Alfa-Trofodermln, Clostene, 4 chlorotestosterone
Codeine with papaverine or
noscapine
Empirin,Fiorinal,Tylenol,ASA or
ftPAP w/codeine
Oral-Turinabol
1-Testosterone
Svnalgos-DC. Compal
Marinol, synthetic THC in s e sa r
ail/soft gelatin
Drolban, Masterid, Permastrii
Maxibolin, Orabolin, Duraboifn-i
Duraboral

Frazalon, Miotolon, Qu Zhi Shu
Zvrem .
Dihydrocodeinone+papaverine
noscapine
Lorcet, Lortab.Vicodln,
Ticoprofen.Tussionex, Norco
Ketaset, Ketalar, Spedal K, K
LSD precursor
LSD precursor
Assimil, Ermalone, Methybol,
Tantarone
Androviron. Proviron. Testiwop
Dianabol, Metabolina, Nerobol,
Perbolin
Sinesex. Stenediol. Troformone
Primobolan, Primobolan Depot,
Primobolan S
Android, Oreton, Testred, Viriloi
Metriboione
Noludar
Cheque, Matenon
Nalllne
Deca-Durabolin, Duraboiin,
Durabolin-50
Genabol
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Controlled S u b sta n c e S c h e d u les > List of Controlled S u b s ta n c e s > S c h e d u le IV

C ontrolled S u b s t a n c e s in S c h e d u le IV

This document Is a general reference and not a comprehensive list This list describes the basic or parent
chemical and does not describe the salts, Isomers and salts of Isomers, esters, ethers and derivatives
which may also b e controlled substances.
Substance
Alprazolam
Barbital
Bromazepam
Butorphanol
Camazepam
Cathine
Chloral betaine
Chloral hvdrate
Chlordiazepoxide
Clobazam
Clonazepam
Clorazepate
Clotiazepam
Cloxazolam
□eloiazepam
□exfenfluramine
Dextropropoxyphene dosage forms
Diazepam
□ichloralphenazone
Diethyl propion
Difenoxin 1 mg/25 ug AtS04/du
Estazolam
Ethchlorwnol
Ethinamate
Ethyl loflazepate
Fencamfamin
Fenfluramine
Fenproporex
Fludlazepam
Flunitrazepam
Flurazepam
Halazepam
Haloxazolam

DEA
Number
2882
2145
2748
9720
2749
1230
2460
2465
2744
2751
2737
2768
2752’
2753
2754
1670
9278
2765
2467
1610
9167
2756
2540
2545
2758
1760
1670
1575
2759
2763
2767
2762
2771

Narcotic
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
Y
N
N
N
Y
N
N
N
N
N
N
N
N
N
N
N
N

Other Names
Xanax
Veronal. Plexonal. barbitone
Lexotan. Lexatin. Lexotanil
Stadol, Stadol NS. Torbugesic. Torbutrol
Albego, Limpidon. Paxor
Constituent of "Khat" plant
Beta Chlor
Noctec
Librium, Ubritabs. Limbitrol, SK-Lvgen
Urbadan. Urbanvl
Klonopin. Clonopin
Tranxene
Trecalmo, Rize, Clozan, Veratran
Akton, Lubalix. Olcadil, Sepazon
Redux
Darvon. propoxyphene, Darvocet, Propacet
Valium. Dlastat
Midrin, dichloralantipyrine
Tenuate. Tepanil
Motofen
ProSom, Domnamid, Eurodin, Nuctaion
Pladdvl
Valmid, Valamin
Reactivan
Pondimin, Ponderal
Gacilin, Solvolip
Rohypnd, Narcozep, Darkene, Roipnol
Dalmane
Paxipam
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Norclostebol (4-chloro-17beta-hydroxyestr-4-en-3-one
Norethandroione (17alpha-ethyl -17beta-hydroxvestr-4-en-3-one)
Mormethandrolone(17alDha-methvl-17beta-hvdroxvestr-4-en-3-one)
Opium combination product 25 mg/du

4000
4000
4000
9809

N
N
N
Y

Oxandrolone (17alpha-methyM7beta-hydroxy-2-oxa-5alpha-androstan-3-one)

4000

N

Oxymesterone (17alpha-methyl-4,17beta-dihydroxyandrost-4-en-3-one)

4000

N

Oxymetholone(17alpha-methyl-2-hydroxymethylene-17beta-hydroxy-5alpha-androstan- 4000
3-one)
2271
Pentobarbital &noncontrolled active ingred.
2271
Pentobarbital suppository dosage form
Phendimetrazine
1615

N
N
N
N

Secobarbital & noncontrolled active ingred
Secobarbital suppository dosage form
Stanozolol (17alpha-methvl-17beta-hvdroxy-5alpha-androst-1-eno[3,2-cl-pyrazole)
Stenbolone (17beta-hvdroxv-2-methvl-5alpha-androst-1-en-3-one)
Stimulant compounds previously excepted
Suifondiethvlmethane
Sulfonethvlmethane
Sulfon methane
Talbutal
Testolactone (13-hvdroxv-3-oxo-13,17-secoandrosta-1.4-dien-17-oic add lactone)
Testosterone (17beta-hydroxyandrost-4-en-3-one)

2316
2316
4000
4000
1405
2600
2605
2610
2100
4000
4000

N
N
N
N
N
N
N
N
N
N
N

Tetrahydrogestrinone (13beta, 17alpha-diethvl-17beta-hvdroxygon-4,9,11 -trien-3-one)
Thiamylal
Thiopental
Tiletamine &Zolazepam Combination Product
Trenbolone {17beta-hvdroxvestr-4,9,11 -trien-3-one)
Vinbarbital

4000
2100
2100
7295
4000
2100

N
N
N
N
N
N

Anabol-4-19. Lentabol
Nilevar, Pronabol. Soievar
Lutenin. Matronal. Orgasteron
Paregoric, other combination
products
Anavar, Lonavar, Oxandrin,
Provitar, Vasorome
Anamidol, Balnimax, Orariaboi,
Oranabol 10
Anadrol-50, Adroyd, Anapolon,
Anasteron, Pardrovd
FP-3
WANS
Plegine, Prelu-2, Bontril, Mdflat
Statobex

Winstrol. Wlnstrol-V
Mediatrtc

Lotusate
Teolit, Teslac
Android-T, Androlan, Depotest,
□elatestrvl
THG
Surltal
Pentothal
Telazol
Finaplix-S. Finaiet, Parabolan
Delvinal, vinbarbitone

Back to Top
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Ketazdam
_oprazolam
Lorazepam
-ormetazeDam
Mazindol
Mebutamate
Medazepam
Mefenorex
Meprobamate
Methohexital
Methylphenobarbital (mephobarbital)
Midazolam
Modafinil
Nlmetazepam
Nitrazepam
Nordiazepam
Oxazepam
Oxazolam
Paraldehyde
Pemoline
Pentazocine
Petrichloral
Phenobarbital
Phentermine
Pinazepam
Pipradrol .
Prazepam
Ouazepam
Sibutramine
SPA
Temazepam
Tetrazepam
Triazolam
Zaleplon
Zolpidem
Zopidone

2772
2773
2885
2774
1605
2800
2836
1580
2820
2264
2250
2884
1680
2837
2834
2838
2835
2839
2585
1530
9709
2591
2285
1640
2883
1750
2764
2881
1675
1635
2925
2886
2887
2781
2783
2784

Back

N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N •
N
N
N
N
N
N

Anxon, Loftran, Solatran, Contamex
Ativan
Noctamid
Sanorex, Mazanor
Capla
Nobrium
Anorexic, Amexate. Doracil, Pondinil
Miltown. Eauanil. Micrainin, Equagesic. Meprospan
Brevital
IMebaral, mephobarbital
Versed
Provigil
Erimin
Mogadon
Nordazepam, Demadar, Madar
Serax, Serenid-D
Serenal. Convertal
Paral
Cylert
Talwin, Talwin NX. Talacen, Talwin Compound
Pentaervthritol chloral. Peridor
Luminal, Donnatal, Bellergal-S
lonamin. Fastin, Adpex-P, Obe-Nix, Zantryl
Domar
Detaril, Stimolag Fortis
Centrax
Doral
Meridia
1-dimethvlamino-1,2-diphenylethane, Lefetamine
Restoril
Myolastan, Musaril
Haldon
Sonata
Ambien, Ivadal, Stilnoct Stilnox
Lunesta

to Tor

R egistration Support

Toll Free Number: 1-800-882-9539
ARCOS | Career Opportunities | Chemical Program | Controlled S u b stan ce S ch ed u les | Drugs and Chem icals of Concern
Electronic Commerce Initiatives | | Federal Register Notices j Import Export | Links | Meetings and Events | NFLIS
Offices & Directories | On-Line Forms & Applications | Program Description | Publications | Questions & Answers | Quotas
Reports Required bv 21 CFR | Title 21 Regulations & Codified CSA
Contact Us | Home | Hot Items | Site Map | Search | What's New

http://www.deadiversion.usdoj.gov/schedules/listby_sched/sched4.htm

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

3/1/2006

Appendix D
DEA Offices of Diversion Control

218

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

219

j.s.

o h & a & t m e m t o f ju s t? c s

of=«Jt? sriir-crpJCH/viefVTjaaMJiviSTn’A T /arj

Offices and Directories > Field Office Locations

Field O ffice L o c a tio n s

To access information on Field Offices, select a particular
state on the map below or view the text list of states.

Legend
® Diversion Program Manager, Diversion Investigators, and
Registrant Assistants
° Diversion Investigators
® Diversion Investigators and Registration Assistants
ALABAMA
ALASKA
ARIZONA
ARKANSAS

NEBRASKA
NEVADA
NEW JERSEY
NEW HAMPSHIRE

http://www.deadiversion.usdoj.gov/offices_n_dirs/fielddiv/index.html
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CALIFORNIA (Northern)
CALIFORNIA (Central!
CALIFORNIA (San Diego & Imperial Counties
Only)

NEW YORK
NEW MEXICO
NORTH CAROLINA

COLORADO
CONNECTICUT
DELAWARE
DISTRICT OF COLUMBIA
FLORIDA
GEORGIA
HAWAII
IDAHO
ILLINOIS
INDIANA
IOWA
KANSAS
KENTUCKY
LOUISIANA
MAINE
MARYLAND
MASSACHUSETTS
MICHIGAN
MINNESOTA
MISSISSIPPI
MISSOURI
MONTANA

NORTH DAKOTA
OHIO
OKLAHOMA
OREGON
PENNSYLVANIA
PUERTO RICO
RHODE ISLAND
SOUTH CAROLINA
SOUTH DAKOTA
TENNESSEE
TEXAS (Central, Southern, & Western)
HXAS (Northern)
TRUST TERRITORY
UTAH
VERMONT
VIRGIN ISLANDS
VIRGINIA
WEST VIRGINIA
WISCONSIN
WYOMING
CARIBBEAN

Registration Support
Toll Free Number: 1-800-882-9539
ARC O S | Career Opportunities | Chemical Program | Controlled Substance Schedules | Drugs and Chem icals of C oncern
Electronic Commerce Initiative s | | Federal Register N otices | Import Export | Links | Meetings and Events | NFLIS
Offices & Directories | On-Line Forms & Applications | Program Description | Publications | Questions & Answers | Quotas
Reports Required bv 21 CFR | Title 21 Regulations A Codilied CSA
Contact Us | Home | Hot Items | Site Map | Search | What's New
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DIVERSION PROGRAMS
APPLICATIONS & ON-LINE
FORMS
ARCOS
CHEMICALS
CONTROLLED SUBSTANCE
SCHEDULES
IMPORT AND EXPORT
NFLIS
QUOTAS
REGISTRATION SUPPORT
REPORTS REQUIRED BY 21 CFR

O ffices & D irectories >

Diversion Program Managers

D iversion Program M an agers

Select a Field Office Location:
Atlanta
Newark
Boston
New Orleans
Caribbean
New York
Chicago
Philadelphia
Dallas
Phoenix
Denver
St. Louis
Detroit
San Diego
El Paso
San Francisco
Houston
Seattle
Los Angeles
Washington D.C
Miami

RESOURCES
CAREER OPPORTUNITIES
DRUGS/CHEMICALS OF
CONCERN
e-COMMERCE INITIATIVES
FEDERAL REGISTER NOTICES
MEETINGS & EVENTS
OFFICES & DIRECTORIES
PROGRAM DESCRIPTION
PUBLICATIONS
QUESTIONS & ANSWERS

DIVISION

Atlanta

REGULATIONS & CODIFIEDCSA

States

NW Georgia
North Carolina
South Carolina
Tennessee

LINKS
FEDERAL AGENCIES & RELATED
INDUSTRY RELATED
PUBLIC INTEREST

Name

Howard W. Davis

Address

75 Spring Street, SW, Room 800
Atlanta, GA 30303

Telephone

404-893-7165

Fax

404-893-7138 (Diversion Program Manager)
404-893-7096 (Diversion Group)
Back to Top

r? * s a- ' i

• jQ rtu
. ; r? r

. <'V

DIVISION

Boston

Stales

Connecticut
Maine
Massachusetts
New Hampshire
Rhode Island
Vermont

http://www. deadiversion, usdoj.gov/offices_n_dirs/prog_mngrs.htm
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To view PDF documents

External links included in this
website should not be construed
as an official endorsement o f the
views contained therein.

Name

Nancy Coffey

Address

JFK Federal Building
15 New Sudbury Street, Room 400E
Boston, MA 02203-0402

Telephone

617-557-2191

Fax

617-557-2130 (Diversion Program Manager)
617-557-2126 (Diversion Group)
B ack to Top

DIVISION
States

Name
Address

Caribbean
Barbados
Dominican Rep
Grenada
Guadeloupe
Haiti
Jamaica
DPM -Marcellino Sustache

Netherlands Antilles
Puerto Rico
Saint Martin
Trinidad and Tobago
U.S. Virgin Islands

Mailing Address:
P.O. Box 2167
San Juan, PR 00922-2167
Physical address:
Second Street Bldg 17
Suites 400 and 500
Guaynabo, PR 00968

Telephone
Fax

787-775-1716
787-775-1855
B ack to Top

DIVISION

Chicago

States

Illinois (north) and (central)
Indiana
Wisconsin
Minnesota & North Dakota

Name

Acting DPM - James K. Portner

Address

Kluczynski Federal Building
230 S. Dearborn Street, Room 1200
Chicago, IL 60604

Telephone

312-353-8227 or 800-478-7914
312-353-7875 or 800-478-7914

Fax

312-353-1476 (Diversion Program Manager)
312-353-1235 (Diversion Group)
312-353-1236 or 800-478-7642 (Minnesota)
Back to Top
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DIVISION

Dallas

States

Oklahoma
North Texas

Name
Address

Michael Lewis

Telephone

214-366-6900

Fax

214-366-6902

10160 Technology Blvd., East
Dallas, TX 75235

B ack to T op

DIVISION

Denver

States

Colorado
Montana
Utah
Wyoming

Name
Address

William C. Reinig
115 Inverness Drive, East
Englewood, CO 80112

Telephone

303-705-7300

Fax

303-705-7423
B ack to Top

DIVISION
States

Detroit
Kentucky
Michigan
Ohio

Name

Acting DPM - James Geldhof

Address

431 Howard Street
Detroit, Ml 48226

Telephone

313-234-4307

Fax

313-234-4041 (Diversion Program Manager)
313-234-4149 (Diversion Group)
Back to Top

DIVISION

El Paso

States

New Mexico
West Texas

Name

G/S Benjamin Vinson

Address

El Paso Federal Justice Center
660 South Mesa Hills Drive, Suite 2000
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El Paso, TX 79912
Telephone

915-832-6000

Fax

915-832-6302 (Diversion Program Manager)
915-832-6225
Back to Top

DIVISION
States

Houston

Name

Judett R. Black

Address

1433 West Loop South, Suite 600
Houston, TX 77027-9506

Telephone

713-693-3000
713-693-3634 (Group)

Fax

713-693-3661

South Texas

Back to Top

DIVISION
States

Los Angeles
Central California
Guam
Hawaii
Nevada

Name

Raymond Conner

Address

255 East Temple Street, 20th Floor
Los Angeles, CA 90012

Telephone

213-621-6711

Fax

213-894-5924 (Diversion Program Manager)
213-894-3946 (Diversion Group)
Back to Top

DIVISION

Miami

States

Bahamas
Florida

Name

Barbara A. McGrath

Address

8400 N.W. 53rd Street
Miami, FL 33166

Telephone

305-994-4704

Fax

305-994-4293
Back to Top
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DIVISION

New Orleans

States

Alabama
Arkansas
Louisiana
Mississippi

Name

Donald Hickman

Address

3838 N. Causeway Blvd., Room 1800
Lakeway III
Metairie, LA 70002

Telephone

504-840-1100
504-840-1100 (Group)

Fax

504-8401076
504-8401076 (Group)
Back to Top

DIVISION
States
Name
Address
Telephone
Fax

New York
New York
Margaret A. Brophy
99 Tenth Avenue
New York, NY 10011
212-337-1190
212-337-1575 (Group)
212-337-2895 (Diversion Program Manager)
212-337-2872 (Diversion Group)
Back to Top

DIVISION

New Jersey

States

New Jersey

Name

George Harbeck

Address

80 Mulberry Street, 2nd Floor
Newark, NJ 07102

Telephone

973-776-1100
973-776-1161/1171 (Group)

Fax

973-776-1215 (Diversion Program Manager)
973-776-1166 (Diversion Group)
Back to Top

DIVISION
States

Philadelphia
Delaware
Pennsylvania
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Address

Ann L. Carter
VUIIIiamJ. Green Federal Building
600 Arch Street, Room 10224
Philadelphia, PA 19106

Telephone

215-597-9540

Fax

215-597-3030

Name

Back to Top

DIVISION

Phoenix

States

Arizona

Name

G/S Barbara Roberts

Address

3010 N. 2nd Street, Suite 301
Phoenix, AZ 85012

Telephone

602-664-5813

Fax

602-664-5820
Back to Top

DIVISION St. Louis
Iowa
States
Kansas
Missouri

Nebraska
South
Dakota
South
Illinois

Name
Address

Acting DPM - Barbara Heath / Kansas City DO
317 South 16th Street
St. Louis, MO 63103
Telephone 913-825-4201 (KCDO)
314-538-4600 (Group)
Fax
314-538-4622
Back to Top

DIVISION

San Diego

States

South California

Name

G/S Valencia B. Abrams

Address

4560 Viewridge Avenue
San Diego, CA 92123-1637

Telephone

858-616-4100 (G/S)
858-616-4100 (Group)

Fax

858-616-4326
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Back to Top

DIVISION

San Francisco

States

North California

Name

William Davis

Address

450 Golden Gate Avenue, 14th Floor
P.O. Box 36035
San Francisco, CA 94102

Telephone

415-436-7900

Fax

415-436-7810
Back to Top

DIVISION
States

Seattle
Alaska
Idaho
Oregon
Washington

Name

Alfred C. Cheeseman

Address

400 2nd Avenue West
Seattle, WA 98119

Telephone

206-553-5443

Fax

206-553-1576
Back to Top

DIVISION

Washington D.C.

States

District of Columbia
Maryland
Virginia
West Virginia

Name

Donetta Spears

Address

Mailing Address:
Techworld
800 K Street, NW, Suite 500
Washington, DC 20001
Physical Address:
8011Street, NW, Suite 500
Washington, DC 20001

Telephone

202-305-8137
202-305-8800 (Group)

Fax

202-307-5823 (Diversion Program Manager)
202-305-8355 (Diversion Group)

http://www.deadiversion.usdoj.gov/offices_n_dirs/prog_mngrs.htm
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EXECUTIVE BRIEF
“STATE OF PAIN”
MICHIGAN PAIN STUDY - A STATEWIDE SURVEY
Sample:

Random stratified sample of 1,500 Michigan adults (Error margin +/- 2.5%)

The "pain" facts in Michigan are that one in five Michigan adults are experiencing some form
of chronic, ongoing or recurring pain, representing some 1.2 million people. This experience
is not a passing problem, since 77 percent of these sufferers have been experiencing pain for well
over a year, with 40 percent indicating the pain is "constant" and has a major impact on their lives.
Chronic pain not only impacts the lives of those suffering, but the rest of Michigan as well. Fortytwo percent of respondents reporting pain said their pain has affected their relationsh ipMrith
spouses, family and fellow workers. For employers this means lost productivity,
percent of pain sufferers missed some work last year. This accounts for some 400,00fr
workers; put another way, 12 percent of the Michigan work force did not show up for work some
time in the last year because of pain (35 percent missing more than 20 days).
Hospital emergency rooms saw 21 percent of these chronic pain sufferers (representing
approximately 252,000 adults) an average of four times, with two percent of these
patients, approximately 24,000 in-pain adults, receiving treatment for overdoses of medication.
Solutions for this problem will not come easy. Seventy percent of chronic pain sufferers said
they still experience pain after treatment. Thirty percent (representing approximately 360,000
adults) said they did not experience even a reduction in their pain after treatment; with 22 percent
saying treatment "only makes it worse."
Looking for solutions for their pain has lead to five percent of chronic pains sufferers
fC
(representing approximately 60,000 adults) to drink alcohol, including 18 percent of whom
admit to overdosing on their medication. Forty-eight percent report "getting depressed"
about their pain and 29 percent report "losing sleep."
i~
A final solution for some chronic pain sufferers is the contemplation of suicide. Ten percent of
respondents experiencing chronic, on going or recurring pain said they have thought about
committing suicide, representing 120,000 adults in Michigan.
Reduction in the number of chronic pain sufferers may come through education and access to
drugs, procedures, medical devices and referrals to other health care professionals and pain
centers. Thirteen percent of chronic pain sufferers said they have been denied such access.
Half of pain respondents are unaware that Michigan has several pain centers or that there
has been several advancements in the treatment of pain.
Currently, 42 percent of chronic pain sufferers either see no doctor on a regular basis or only
see a family doctor. Sixty-five percent of these respondents have never seen a specialist or a
professional who specializes in treating pain.
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MEN & WOMEN - PAIN
Men and women differ in their views of pain. While men appear to come to some form of
resignation to their pain, women appear to more successfully acknowledge and incorporate
pain into their daily lives. Twenty-two percent of men reporting pain and 34 percent of women
reporting pain rate their quality of life "the best it can be" as a result of the effects of pain
(on a scale of 0-10, with 8, 9 and 10 being considered "the best.")
Differences between men and women don't stop there. While 57 percent of men indicate they
"under report" pain, 47 percent of women say they do so, and women also more quickly
seek out help for their pain than do men. This difference can lead to dangerous consequences
because men are not coping with their pain; twice as many men (14 percent) as women (seven
percent) said they contemplate suicide because of their pain.
Men under age 50 were most likely to have pain that has persisted more than a year (86 percent),
compared to 75 percent for men over 50,79 percent for women over 50 and 69 percent for
women under 50. Men under 50 were most likely to "under report" their pain. Women over 50
are the least comfortable about discussing pain with their doctors and men under 30 are by far the
most likely to call in sick to work because of pain.

Experienced chronic pain

Men

Women

17%

23%

43%
50%
81%

20%
71%
75%

Men

Women

Pain has a major impact
Pain has a significant impact

38%
23%

42%
20%

Comfortable talking about pain
Under reporting

46%
57%

42%
47%

Recent pain severe/excruciating 29%

38%

Missed work due to pain

31%

27%

"Pain makes me depressed"
"Pain makes me suicidal"

48%
17%

48%
7%

SOURCE OF PAIN:
Injury or accident
Ongoing condition
Pain has persisted more than a year

WILL SEEK MEDICAL HELP:
If pain persists more than a day
If over-counter medicine doesn't work
Work impaired more than 20 days
When pain becomes unbearable

5%
8%
34%
29%

9%
7%
24%
32%
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ADDITIONAL COMMENTS
1. One-in-live Michigan adults (20 percent) may have "chronic" pain, representing some
1.2 million adults. These numbers appear to be conservative, since half the respondents (51
percent) said they "underreport" pain. If that is true, then a number of respondents
experiencing pain may not have made it through the survey screen, since they may have not
indicated they have pain and thus were not interviewed.
2. Telling others they are in pain does not come easily to the survey respondents. Only seven
percent report seeking help for pain "immediately," while 46 percent (representing
approximately 552,000 adults) wait until it's "unbearable" or "interferes with other activities."
Men more than women (26 percent to 16 percent) "wait for pain to pass on its own."
3. Above average numbers of people in pain can be found in Detroit and in northern
Michigan. This is not unexpected, as other data in the survey shows that people who are
older or of lower income status have higher reported incidents of chronic pain. Older women
rank the highest in reporting chronic pain, at 31 percent.
4. Younger men report the main reason for pain is "the result of an injury or accident" (56
percent), while the rest of respondents report "ongoing conditions" as the primary reason for
pain.
5. The reported pain is not short term, as 77 percent (representing approximately 924,000
adults) said their pain has been with them over a year and 85 percent saying over sixth
months.
6. Forty percent (representing approximately 480,000 adults) said their pain is "constant"
with another 27 percent indicating their pain is "daily." This totals to 67 percent of
respondents reporting pain experiencing it on a regular daily basis. These numbers hold true
across all generation groups.
7. A significant difference between those "under reporting" and those who don't, lies in
the result that those under reporting report having constant pain by 45 percent opposed to the
37 percent of those in constant pain who don't under report.
8. Sufferers in their 6th to 12th month of pain appear to go through some kind of resignation
or acknowledgment of their pain. This particular group attempts to "let pain pass on its
own," with 35 percent of these respondents waiting for it to pass versus 19 percent of all
respondents reporting pain. Further study is needed on this apparent phase of psychological
adjustment - i.e.: Does this adjustment lead pain sufferers to refuse to seek or accept
treatment? Is the success of treatment affected during this phase?
9. At risk respondents - the survey indicates that 10 to 15 percent of pain respondents
(representing approximately 120,000-180,000 adults) could be classified at risk.
Overdosing on medication, severe depression, drinking alcohol, working on the job impaired
by their pain and being unable to get help for their pain.
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NOTES OF INTEREST
• 22 percent feel uncomfortable talking about their pain with their doctors.
• 22 percent don't have faith that the medical professionals they see have the knowledge or
understanding needed to treat their pain.
• People with chronic pain spend about $1,118 out-of-pocket each year on medicine to relieve
the pain and average four emergency room visits per year. Twenty-one percent say they have
been hospitalized for their condition, for an average hospital stay of three days.
• 28 percent said their pain was severe enough to impair their ability to perform their job well
that on more than 20 work days in the past year.
• Complaints of chronic pain are most common among people earning less than $30,000 a year.
it IInfl
####
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Michigan Pain Study —News Conference Participants
Ed Sarpolus, Vice President, EPIC/MRA, Lansing, Michigan

Sarpolus is a leading pollster and public opinion analyst. His firm’s studies focus on a wide range
of social and political issues and receive national attention. Recent studies have addressed such
topics as assisted suicide, aggressive driving and a variety of health and public health issues.
Sarpolus is a frequent speaker and often-quoted source in interpreting public opinion.
Joel R. Saper, M.D., Chairman, Michigan Council on Pain
Director, Michigan Head Pain & Neurological Institute, Ann Arbor, Michigan

Dr. Saper is a board-certified neurologist recognized internationally as a leading pain expert and
educator, and founder of the world’s first comprehensive head pain treatment and research center.
He was appointed by the Michigan Legislature to chair the Michigan Council on Pain and speaks
nationwide on the causes and treatment of severe and chronic pain. Dr. Saper is chairman of the
National Coalition for Patients in Pain and past president of the American Association for the
Study of Headache. He is on the boards of the American Pain Society and American Association
of Pain Medicine and is also past national chairperson of the American Council for Headache
Education.
John Burrows, M.D.
Hospice Medical Director, Karmanos Cancer Institute, Southfield, Michigan

Dr. Burrows joined Karmanos Cancer Institute (the former Michigan Cancer Foundation) in 1973
and now directs one of the state’s largest hospice programs. He is also a practicing oncologist.
Dr. Burrows is responsible for establishing numerous cancer treatment and training programs at
St. John Hospital in Detroit and elsewhere around the state. He is a frequent speaker on cancer
patient care and is on the faculty of the Wayne State University School of Medicine.
John Jerome, Ph.D., Clinical Director, Sparrow Regional Pain Center, Lansing, Michigan

Dr. Jerome is a licensed psychologist with 23 years experience specializing in the treatment of the
emotional effects of chronic pain. He recently authored chapters on pain management for the
1997 medical text, Foundations o f Osteopathic Medicine, and is on the faculty of the College of
Osteopathic Medicine at Michigan State University.
Todd Lininger, M.D., Vice Chairman, Department of Anesthesiology and Medical Director
of Pain Management Services, North Oakland Medical Center, Pontiac, Michigan

Dr. Lininger is board-certified in anesthesiology and pain management with a special interest in
reflex sympathetic dystrophy and neuropathic pain. He is a frequent national speaker on new
advances in pain treatment and is on the faculty of the Wayne State University School of
Medicine, Department of Anesthesiology.
Susanne Homant, Executive Director, Michigan Hospice Organization, Lansing, Michigan

Homant is responsible for operations of this statewide organization which is a leading advocate
for quality hospice care in Michigan. She leads the organization’s efforts in lobbying on public
policy and legislative issues and manages the organization’s statewide educational programs.
Homant is a director and legislative chairperson of the Michigan Cancer Pain Initiative. She is
completing a doctorate in public administration at Western Michigan University.
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♦
Deanls C. Turk, Ph.t>.
John md Emma Bonita Proftuor
of AnaathMiotcjy & Pain Retearch
Department of Anesthitielogy

Septemb»r2, 1997
Tb* Honorable Joe Palamsra
SUte Representative
State Capitol, Rm . 315
Lansing, Michigan 48909-7514
Dear Rep. Palainara:
Dr. Joel Saper requested that 1 provide you with some information based on my research concerning the
effectiveness o f specialized treatment o t patients with chronic pain. I hope that what 1 will summarize in this
letter will be o f some use to your and your committee.
It has bean estimated that over 60 million Americans some from tom e type o f persistent or recurrent pain. Not
only does chronic pain adversely affect patients' physical and psychological well-being, chronic pain costs
billions o f dollars to society in lost productivity, health care expenditures, and disability compensation. In the
past quarter century, speeialiKd treatment facilities - Multidisciplinary Pain Centers (MPCs) - have been
established to treat patients with recalcitrant pain problems. A recent survey identified over 400 pain centers
and dinica dedicated to the treatment o f rehabilitation o f these patients. In 1995, it was estimated that over
175,000 were treated at MPCs (MarketData, 1995).
Despite the growing number of MPCs, persistent skepticism has been voiced by third-party payers who
frequently deny payment for treatment. The criticisms are of two general types: (1) it is suggested that there is
no evidence that MPCs a n successful in bring about important outcomes, namely, returning people to work
and other functional activities, reducing utilization o f the health care system, and closure o f disability claims;
and (2) it is asserted that MPCs are not cost-effective. Despite the skepticism, there is a substantial body o f
published evidence that runs counter these two criticisms.
It is important to note that the patients treated at MPCs have long histories o f pain (averaging over 7 years).
These are the most difficult cases. These patients are heavy utilizers of the health care system with over 83%
taking pain medication and the average patient having 1.7 surgical procedures prior to treatment an MPC (Flor
et al. 1992) and on average spent over 513,000 on health care in the year prior to treatment (Simmons et al.,
1988). In addition, over 30% of treated at MPC are receiving some form o f disability at the Initiation o f
treatment. (Flor et al., 1992). Even though the patients treated at MPCs are among the most difficult, the
results are quits impressive. I will highlight some of these.
Two meta-analyses (Flor et al., 1992; Cutler et at., 1994) concluded that MPCs are substantially more effective
in helping return patients to work than conventional medical and surgical interventions. Based on over 65
published itudies[3,089 patients], Plor et al. noted that from 45%-65% o f patients treated at MPCs return to
work following treatment. This can be compared to the 20% of patients who return to work. Following
treatment at MPCs. patients required 1/3 the number of surgical intervention and hospitalizations compared to
patients treated by conventional medical and surgical care. Treatment at MPCs resulted in closure of disability
claims for of those receiving disability at the time o f treatment.

1959 NB Pacific street, Rm BB1423/HSB, Box 355540, Seattle, Washington 98195-6540
Telephone: (206) 616-2626, PAX: (206) 543-295S, E-mail: Turlulc@u.w»»hing(on.e<Jti
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Representative Joe Palamara

September 3, 1997
Page 2

My colleagues and I (Turk St Gatchel, in press; Turk & Okifuji, 1997) have nude extrapolations from the data
included in the two meta-analyses cited above and more recent studies and concluded that not only are MPCs
clinically-effcetive they are cost-effective. Using the 3,089 patients included In the Flor et al. meta-analysis,
we estimated that even after factoring the cost of treatment at MPCs (average $8,100 based on a MarketData
Survey inl995) savings in excess o f 520 million would be achieved based on reduction* in health care
utilization and indemnity costs during the first year following treatment. Considering the average age o f the
patients treated in the Flor et al. meta-analysis was 45, the savings until age 65 would exceed $248 million. If
ws used the same assumptions for the estimated 175,000 patients treated at MPCs, then the financial savings
would exceed $11 billion in the first year following treatment alone. Of course these astronomical figures do
not take in to consideration the reduction in suffering and improvement in the quality of life of the patients and
their families.
The data I have presented supports the clinical and cost-effectivcness of MPCs. To my knowledge, no health
care intervention has been studies as extensively as MPCs nor have the outcomes for treatment been as great.
These results are significantly better than any reported for conventional medical or surgical trsatmsnts for
chronic pain. Yet, alternatives such as surgery are more readily covered by third-party payers. There seems
to be a disparity in the evidence that is acceptable. Third-party payers should give greater attention to the
available evidence as MFCs hold significant promise for reducing health care txpendimres and disability
compensation while improving the functioning and quality of life o f a substantial proportion of chronic pain
suffers.
I hope that the information I have provided will be of some value to you and your colleagues who are
examining the issue o f appropriate treatment and rehabilitation of people suffering from chronic pain. 1 have
Included a list o f references upon which I baaed my conclusions. Please let me know if I can provide any
additional information or be of any further assistance.
Sincerely,
Dennis C. Turk. Ph.D .
DCT/jb

enclosure
cc. Joel R. Saper, M .D ., FACP
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W e s t e r n M ic h i g a n U n iv e r sit y
Human Subjects Institutional Review Board

-e n te n m a l
1903-2003 C e le b ra tio n

Date: June 29,2004
To:

Peter Kobrak, Principal Investigator
SusanneHomant, Student Investigator

From: Mary Lagerwey, Ph.D., Chair
Re:

HSIRB Project Number: 04-05-26

This letter will serve as confirmation that your research project entitled “The War on
Drugs V. The war on Pain: Do Controlled Prescribing Laws Have a Role” has been
approved under the expedited category of review by the Human Subjects Institutional
Review Board. The conditions and duration of this approval are specified in the Policies
of Western Michigan University. You may now begin to implement the research as
described in the application.
Please note that you may only conduct this research exactly in the form it was approved.
You must seek specific board approval for any changes in this project. You must also
seek reapproval if the project extends beyond the termination date noted below. In
addition if there are any unanticipated adverse reactions of unanticipated events
associated with the conduct of this research, you should immediately suspend the project
and contact the Chair of the HSIRB for consultation.
The Board wishes you success in the pursuit of your research goals.
Approval Termination: June 29, 2005

W alw ood H all, K alam azoo, Ml 49008-5456
PH O N E : (269)387-8293 FAX: (269) 387-8276
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WESTERN MICHIGAN UNIVERSITY
Human Subjects Institutional Review Board
WMU Mail Stop: 5456

iim -t

Phone: (269) 387-8293

9n c
0 ^UUO

APPLICATION FOR CONTINUING REVIEW OR FINAL REPORT F O R M .S .f.R .g f^
In compliance with Western Michigan University’s policy that “the HSIRB's review of research will be conducted
at appropriate intervals but not less than once per year,” the HSIRB requests the following information:
I. PROJECT INFORMATION
PROJECT TITLE: The War on Drugs v. the War on Pain

HSIRB Project Number: 04-05-26
Previous level of review: □ Full Board Review X Expedited Review □ Administrative (Exempt) Review
Date of Review Request: 05/29/05
II. INVESTIGATOR INFORMATION
PRINCIPAL INVESTIGATOR OR ADVISOR
Name: Peter Kobrak, PhD
Department: PA&A
Mail Stop: N/A

Date of Last Approval: 06/29/04

Electronic Mail Address: Peter.kobrak@wmich.edu

(1) CO-PRINCIPAL OR STUDENT INVESTIGATOR
Name: Susanne F. Homant
Department: PA&A
Mail Stop: N/A
Electronic Mail Address: Suehospice@aol.com
(2) CO-PRINCIPAL OR STUDENT INVESTIGATOR
Name:

Department:

Mail Stop:

Electronic Mail Address:

III. CURRENT STATUS OF RESEARCH PROJECT
Please answer questions 1-4 to determine if this project requires continuing review by the HSlRB.
1. The project is closed to recruitment of new subjects.
XX Yes (Date of last enrollment: 12/5/04)
renewai.)

[UNo (Project must be reviewed for

2. All subjects have completed research related interventions.
XX Yes □ Not Applicable
QNo (Project must be reviewed for renewal.)
3. Long-term follow-up of subjects has been completed.
XX Yes
□ Not Applicable
renewal.)
4. Analysis of data is complete.
QY? s

ONo (Project must be reviewed for

XX No (Project must be reviewed for renewal.)

•

If you hive answered “No” to ANY of the questions above, you must apply for Continuing Review.
Please complete numbers 5-12 on page 2. If you need to make changes in your protocol, please submit a
separate memo detailing the changes that you are requesting.

•

If you have answered “Yes” or “Not Applicable” to ALL of the above questions, please check the Final
Report box below and complete questions 5-10 on page 2.

•

If your protocol has been open for three years and you still want to collect or analyze data, you must close
this protocol by filing a final report using this form and apply for approval of a new protocol using an
Application for Initial Review. Please make a Final Report on your project by completing numbers 5-10
on page 2.

IV. XX

A p plication for C ontinuing R eview

V. Q

Final Report

Revised 7/03
WMU HSIRB
All other copies obsolete.
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HSIRB Project Number: 04-05-26
5. Have there been changes in Principal or Co^Principal Investigators?
C]Yes
(If yes, provide details on an 'Additional Investigators’ form (available at the HSIRB w eb site,

XX No

http://www.wmich.edu/research/complianceyhsirb/hsirb_2.html).)
6.

H as the approved protocol b een modified or added to with respect to:

(If yes to any item below, provide the details on an attached sheet.)
a. Procedures
DYes
XX No
b.

Subjects

dY es

XX No

c.
d.

Design
Data collection

DYes
dY es

XX No
XX No

7. Has any instrumentation been modified or added to the protocol?

dY es

XX No

(If y e s , attach new instrumentation or indicate the modifications made.)
8.

Have there been any adverse even ts that need to be reported to the HSIRB?

dY es

XX No
(If y e s , provide details on an attached sheet.)
9.

Total number of subjects approved in original protocol: 3 0

10. Total number of subjects enrolled s o far . 3 0
If applicable: Number of subjects in experimental group:

Number in control group:

*

If this is a FINAL REPORT you may stop here and return the form electronically.

•

If this is an APPLICATION FOR CONTINUING REVIEW continue with numbers 11-13 below.

11. Estimated number o f subjects yet to be enrolled: N o n e
12. V erification o f C on sen t P roced ure: Provide copies of the consent docum ents signed by the last two
subjects enrolled in the project. Cover the signature in such a way that the nam e is not clear but there is
evid en ce of signature. If subjects are not required to sign the consent document, provide a copy o f the
m ost current consent document being used.
13. If y o u are c o n tin u in g to recruit s u b je c ts for th is project, p le a se rem em ber to in clu d e a clean
original o f th e c o n se n t d o c u m e n ts to receiv e a ren ew ed approval stam p.

Prindpal Investigator/Faculty Advisor Signature

Cp-Principal or Student Investigator Signature

Date

7

Date

Approved by the HSIRB:
fy j
HSIRB Chair/Signature

/

/

k T... I '1 ~
Date

Western Michigan University
Human Subject Institutional R eview Board - Mail Stop 5456
Revised 7/03
WMU HSIRB
All other copies obsolete.
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ARCOS: Automation o f Reports and Consolidated and Consolidated Orders system.
An automated, comprehensive drug reporting system which monitors the flow
o f DEA controlled substances from their point of manufacture to point of sale
at the retail level. Operated under the DEA.
Addiction: A chronic, relapsing disease, characterized by compulsive drug seeking
and use and by neurochemical and molecular changes in the brain. (NIDANIH) A primary chronic, neurobiologic disease, with genetic, psychosocial,
and environmental factors influencing its development and manifestation
(American Academy of Pain Medicine). It is characterized by behaviors that
include the following: impaired control over drug use, craving, compulsive
use, and continued use despite harm. Physical dependence and tolerance are
normal physiological consequences of extended opioid therapy for pain and
are not the same as addiction (Fed of State Medical Boards-2004 Policy
statement).
Pseudoaddiction: An iatrogenic syndrome characterized by a pattern of drug
seeking behavior in pain patients who are receiving inadequate pain
management. Pseudoaddiction can be mistaken for “drug-seeking”
behavior and addiction.
Physical Dependence: An adaptive physiological state that can occur with
regular drug use and results in withdrawal when drug use is
discontinued.
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Tolerance: A condition in which higher doses of a drug are required to
produce the same effect as experienced initially. A state o f adaptation
in which exposure to a drug induces changes that result in a diminution
of one or more of the drug’s effects over time.
Barbituate: A type o f central nervous system (CNS) depressant often prescribed to
promote sleep (also anxiety, tension, seizures).
Benzodiazephine: A chemical used in several types of CNS depressant prescribed to
relieve anxiety; among the most widely prescribed medications, includes
Valium, Librium, Vicodin and Lortab.
Chilling Effect: As used in this study, means the negative effect that public policies
have on prescribing patterns for controlled substances. The chilling effect is
present when a clinician prescribes differently due to concerns over regulatory
oversight.
CNS - Central Nervous System: The brain and spinal cord. (#1)
DAWN: Drug Abuse Warning Network, a national data system that collects
information on drug-related visits to emergency departments from a national
sample of hospitals. Operated through the Office of Applied Studies of
SAMHSA.
DEA: Drug Enforcement Administration, a division of the U.S. Department of
Justice.
Drug Diversion: As used in this study, drug diversion is defined as the use of legal,
controlled substance drugs for non-prescribed purposes.
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GAO: General Accounting Office.
MCO: Managed Care Organization.
Opioids: Controlled drugs or narcotics most often prescribed for the management of
pain; natural or synthetic chemicals based on opium’s active component—
morphine—that work by mimicking the actions of pain-relieving chemicals
produced in the body.
Opiate: Drugs whose origin is the opium poppy, including codeine and
morphine.
%

Policy: As used in this study, is a very broad term, and may be used to refer to laws,
regulations, or guidelines.
Statute: Law created by a legislative body.
Regulation: An official rule or order issues by agencies of the branches of
government. Regulations have the force of law and are intended to
implement a specific statute.
Guideline: An official policy statement, which does not have the force of
law. Although they do not have binding legal force, they often describe
accepted standards of practice for those regulated by an organization
or agency.
Pain: An unpleasant sensory and emotional experience associated with actual or
potential tissue damage or chronic pathologic process that causes continuous
or intermittent pain over months or years.
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Nociceptive pain: May be visceral or somatic and is most often derived from
stimulation of pain receptors. May arise from tissue inflammation,
mechanical deformation, ongoing injury, etc. Arthritis, broken leg, etc.
Usually responds well to standard analgesic treatments.
Neuropathic pain: Results from a pathophysiologic process that involves
injury to the peripheral or central nervous system. Neuralgia, etc. Does
not respond as well to conventional analgesic treatment.
Mixed or unspecified pain: Having unknown or mixed mechanisms.
Migraine headaches, vasculitic pain syndromes. May require treatment
trials.
Psychogenic pain: Pain caused by psychological factors, deemed to have a
major role in the onset, severity or persistence of pain. Needs
treatment with psychiatric interventions, does not respond to
traditional medical pain interventions.
PM P: Prescription Monitoring Program
Psychotherapeutics: Drugs that have an effect on the function of the brain and that
often are used to treat psychiatric disorders; can include opioids, CNS
depressants, and stimulants.
Substance Abuse: The use of any substance(s) for non-therapeutic purposes or use
of medication for purposes other than those for which it is prescribed.
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